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Summary 
The World Health Organization (WHO) states cancer to be a leading cause of death worldwide 
accounting for 7.6 million deaths (around 13% of all deaths) and is projected rising to over 11 
million in 2030. This is an alarming call to researchers for putting more effort into the analysis of 
the underlying patho-mechanisms. In a very simplified manner, cancer represents the destruction 
of healthy tissues and organs by uncontrolled cell proliferation and subsequent formation of a 
tumor. One key feature of solid tumors that marks the mostly deadly feature of the disease is the 
acquisition of the potential to invade into the surrounding tissue and form secondary tumors at 
distant sites, a process called ‘metastasis’. To gain migratory and invasive properties, cancer 
cells undergo epithelial to mesenchymal transition (EMT) where epithelial cells lose epithelial 
properties, e.g. their polarized organization and cell-cell junctions, and thus undergo changes in 
cytoskeleton organization and cell shape and acquire mesenchymal characteristics. Importantly, 
besides the formation of metastatic lesions, EMT is also involved during development as well as 
wound healing.  
To gain insights into the complex process of EMT and to identify new potential markers for 
ongoing metastasis, we established different in vitro EMT model systems. Global expression 
profiling during TGF-β-induced EMT revealed genome-wide transcriptome reprogramming 
during EMT and identified Krupple-like factor 4 (Klf4) and the SRY-Related HMG-Box Gene4 
(Sox4) as one of the key transcription factors that were modulated and may possibly contribute 
to transcriptional changes during EMT.  
We investigated the role of Klf4 and Sox4 during EMT by employing two different in vitro 
systems of EMT, using normal murine mammary gland (NMuMG) and Polyoma middle T- 
breast cancer (Py2T) cells, which undergo a progressive EMT upon transforming growth factor 
(TGF-β) treatment. We further validated the role of Sox4 in breast cancer carcinogenesis in vivo 
by orthotropic injection of Sox4-depleted cells into the mammary fat pad of nude mice. In 
addition, we also investigated whether such TGF-β-induced EMT accompanies epigenetic 
reprogramming and revealed how Polycomb group (PcG) complex-mediated H3K27me3 
modification modulates transcription of key genes underlying this process, thereby regulating 
EMT. 
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Klf4 is a zinc-finger protein, known to be abnormally expressed in various cancers. It can act as 
a tumor suppressor or as an oncogene in context dependent manner in different carcinomas. Klf4 
is downregulated during TGF-β-induced EMT. Our data reveal a tumor suppressor role for Klf4 
in breast carcinogenesis. Klf4 is essential for the maintenance of an epithelial phenotype during 
EMT, and forced expression of Klf4 leads to blockage of epithelial differentiation. Furthermore, 
Klf4 is inhibitory to EMT-driven cell migration and also behaves as a survival factor during 
TGF-β-induced EMT. Genome-wide location analysis by next generation ChIP-seq analysis 
revealed that Klf4 directly occupies the promoter of many key EMT genes such as N-cadherin, 
Vimentin, β-catenin and Mapk8. Moreover, one of these Klf4 targets, Mapk8, encoding Jnk1, is 
upregulated during EMT and a double-knockdown of Klf4 and Jnk1 is able to overcome Klf4 
knockdown-induced EMT, migration and apoptosis. These observations underscore a role of 
Klf4 during EMT by targeting and regulating crucial EMT genes. 
Sox4 is also known to be deregulated in many cancers. Sox4 is upregulated during TGF-β- 
induced EMT. We show that Sox4 is required for maintaining mesenchymal identity and 
depletion of Sox4 prevents TGF-β-induced EMT. Sox4 reduction further impairs the migratory 
capacity of cells. Moreover, Sox4 provides a survival advantage to cells during breast 
carcinogenesis. In addition, Sox4 contributes towards TGF-β-induced tumorigenicity and 
metastatic spread. Gene expression profiling after Sox4 depletion in complementation with 
Chromatin immunoprecipitation analysis revealed many key EMT genes such as Spred1, Edn1, 
Palld, Cyr61, Ereg, Areg and Yap1 which are directly targeted by Sox4 for transcriptional 
regulation. Furthermore, Sox4 also controls many genes which are shown to regulate various 
other features of EMT as well as cancer development such as angiogenesis, adhesion, migration, 
morphogenesis, cell cycle and cytoskeleton re-modeling. Ezh2, a catalytic subunit of the 
Polycomb Repressive Complex 2 (PRC2), has been also found to be transcriptionally regulated 
by Sox4. To delineate the role of Ezh2 during EMT, a loss of function approach has been used to 
demonstrate that Ezh2 is required for proper acquisition of EMT and EMT-driven processes such 
as migration and apoptosis. Taken together, our data provides a role of Sox4 during EMT via 
transcriptional regulation of key genes, including the Polycomb component, Ezh2. 
We also studied the role of two prominent epigenetic modifications- DNA methylation and 
histone 3 lysine 27 tri-methylation (H3K27me3) during TGF-β-induced EMT in a mammary 
epithelial cell line. Our data revealed no evidence of a reprogramming of DNA methylation 
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during this process. To assess the role of H3K27me3 during EMT, we performed chromatin 
immunoprecipitation using H3K27me3-specific antibodies followed by next-generation 
sequencing (ChIP-seq) on 6 different stages of EMT progression. This analysis revealed that 
many key EMT genes are regulated by H3K27me3 mark including Mcam, Pdgfrb and Itga5 
which are repressed by this mark in epithelial cells and loose it during EMT as they get activated 
conversely, Cdh1, Ocln and Cdx2 gain this mark during EMT and get repressed in mesenchymal 
cells. We further illustrated that the coordinated activities of Ezh1 and Ezh2 are required for 
H3K27me3-mediated repression of the gene expression and their co-depletion de-represses target 
genes and blocks EMT. This study provides novel insights into the important regulatory role of 
the Polycomb machinery during EMT. 
In summary, our findings demonstrate how transcription factors, such as Klf4 and Sox4 and the 
epigenetic machinery, such as PcG proteins, regulate EMT by directly contributing to the 
transcriptional reprogramming underlying this process.  
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1.0 Introduction 
1.1 Mechanism of carcinogenesis and acquired capabilities of cancer 
Cancer was first described by Greek Hippocrates (ca. 460 BC – ca. 370 BC) who used the Greek 
word carcinos (crab or crayfish) to describe it due to its crab-like tenacity. Cancer broadly refers 
to any one of a large number of diseases that are characterized by the development of abnormal 
cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue. 
Cancer is the one of leading cause of death worldwide. However, thanks to basic research- due to 
improvements in screening and treatment, the survival rates are improving. The major challenge 
in cancer therapy is the metastatic spread of malignant cells and existence of cancer stem cells 
that survive any therpay and later leads to recurrence of the disease (Figure 1).                                                                       
In 2000, Hanahan and Weinberg 
(Hanahan and Weinberg, 2000) 
described the following six 
essential physiological alterations 
which instruct malignant tumor 
growth: 
1. Sustaining proliferative 
signaling: Growth factors are 
required for the proper 
propagation of normal cells and 
are usually provided exogenously. 
However, this dependency is 
greatly reduced in tumor cells 
which produce their own growth 
factors/ligands to which they 
respond via the expression of 
xxxxx  
 
 
Figure 1: Systemic representation of cancer cell invasion. Normal cells become metastatic and spread to 
distant organs through blood stream and lymph-vessels. 
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cognate receptors. Alternatively, cancer cells may send signals to stimulate normal cells 
within the supporting tumor-associated stroma, which reciprocate by supplying the 
cancer cells with various growth factors by over-expressing them (Bhowmick et al., 
2004; Cheng et al., 2008). This liberation makes them free to grow in an uncontrolled 
manner. 
2. Evading growth suppressors: Within a normal tissue, multiple anti-proliferative signals 
operate to maintain cellular quiescence and tissue homeostasis. In tumors, this signaling 
is mainly blocked by attacking the anti-proliferative signaling cascades which are 
commonly regulated by E2F transcription factors. These are essential for the expression 
of banks of genes required for cell cycle progression and p53, tumor suppressor (Burkhart 
and Sage, 2008; Deshpande et al., 2005; Sherr and McCormick, 2002). Furthermore, Myc 
oncogene expression is also induced to override growth inhibition by these anti-growth 
molecules (Partanen et al., 2009). Recently, it has been shown that the Myc oncogene is 
regulated by another tumor suppressor, LKB1, whose expression is required for epithelial 
integrity (Shaw, 2009). The Myc oncogene only becomes active after suppression of 
LKB1 (Hezel and Bardeesy, 2008; Partanen et al., 2009). Another tumor suppressor 
protein Merlin, sequesters growth factor receptors and limits their ability to efficiently 
emit mitogenic signals and, thus, Merlin has to be repressed to provide a proliferative 
signal (Curto et al., 2007; Okada et al., 2005). 
3. Resisting cell death: Several intrinsic factors (e.g. genomic instability) as well as 
extrinsic factors (e.g. hypoxia) induce apoptosis of untransformed cells. Tumor cells 
evolve a variety of strategies to limit or circumvent apoptosis. Most common is the loss 
of p53 tumor suppressor function, which eliminates this critical damage sensor from the 
apoptosis-inducing circuitry. Alternatively, tumors may achieve similar ends by 
increasing expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or of survival signals 
(Igf1/2), by downregulating proapoptotic factors (Bax, Bim, Puma), or by short-circuiting 
the extrinsic ligand-induced death pathway (Adams and Cory, 2007; Junttila and Evan, 
2009; Willis and Adams, 2005).  
4. Enabling replicative immortality: Untransformed cells are limited in their replicative 
potential by the length of their telomeres. Telomere maintenance is evident in virtually all 
types of malignant cells (Blasco, 2005; Shay and Wright, 2000). 85%–90% of them 
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succeed in doing so by upregulating expression of the telomerase enzyme or by the 
mechanism called ALT where telomere is maintained by recombination-based 
interchromosomal exchanges of sequence information (Bryan et al., 1995). 
5. Sustained angiogenesis: The oxygen and nutrients supplied by the vasculature are 
crucial for cell function and survival. Tumors appear to activate the angiogenic switch by 
changing the balance of angiogenesis inducers such as VEGFs and FGFs (Baeriswyl and 
Christofori, 2009; Bergers and Benjamin, 2003) and countervailing inhibitors such as 
thrombospondin-1 or β-interferon (Singh et al., 1995).  
6. Tissue invasion and metastasis: Normal cells are usually tethered with each other by 
adherens and tight junction proteins. Tumor cells act on these proteins and subject them 
to degradation. Consequently, cell-cell contact is lost and they can migrate and 
metastasize to the distant organs. In addition, many proteases also become active which 
pave a way for these cells to migrate by degrading extracellular matrix (Berx and van 
Roy, 2009; Cavallaro and Christofori, 2004; Fidler, 2003; Talmadge and Fidler, 2010). 
In their recent review, they added two more hallmarks which are required for maintaining 
the malignancy (Hanahan and Weinberg, 2011). 
1. Reprogramming energy metabolism: Even in the presence of ample oxygen, cancer 
cells prefer to metabolize glucose by glycolysis, which is a less efficient pathway for 
producing ATP. This effect was first observed by Otto Warburg (Hsu and Sabatini, 
2008) and named after him as “Warburg effect”. To do so they upregulate GLUT1 
transporters, which substantially increases glucose import into the cytoplasm; 
glycolytic enzymes and inhibitors of mitochondrial metabolism. One compelling idea 
to explain the Warburg effect is that the altered metabolism of cancer cells confers a 
selective advantage for survival and proliferation in the unique tumor 
microenvironment such as hypoxia (Semenza, 2010). Moreover, glycolysis allows the 
diversion of glycolytic intermediates into various biosynthetic pathways, which are 
required for assembly of new cells (Vander Heiden et al., 2009). In addition, in some 
tumors, two sub-populations of cancer cells are present which differ in their energy 
generating pathway. One population consists of glucose dependent cells that secrete 
lactate and other population basically used the lactate produced by their neighboring 
cells as an energy source (Feron, 2009; Kennedy and Dewhirst, 2010; Semenza, 
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2008). In addition, increased glucose consumption, decreased oxidative 
phosphorylation, and accompanying lactate production are also distinguishing 
features of oncogene activation such as RAS and Myc (DeBerardinis et al., 2008) . 
2. Evading immune destructions: In general, cells and tissues are constantly 
monitored by an ever-alert immune system, and that such immune surveillance is 
responsible for recognizing and eliminating the vast majority of cancer cells. To 
propagate happily, tumor cells have to omit themselves from the immune 
surveillance. It has been shown that tumors grow/arise rapidly in immunodeficient 
mice in comparison to immunocompetent mice (Kim et al., 2007; Teng et al., 2008). 
In addition, transplantation experiments have shown that cancer cells that originally 
arise in immunodeficient mice are not capable of inducing secondary tumors in 
immunocompetent hosts while the tumors cells from immunocompetent mice can do 
so (Kim et al., 2007; Teng et al., 2008). Cancer cells may paralyze infiltrating 
cytotoxic CD8+ T-cells and NK cells by secreting TGF-β or other 
immunosuppressive factors (Shields et al., 2010; Yang et al., 2010a). Furthermore, 
they can recruit cells that are actively immunosuppressive, including regulatory T 
cells (Tregs) and myeloid-derived suppressor cells (Mougiakakos et al., 2010; 
Ostrand-Rosenberg and Sinha, 2009). TGF-β has been shown to inhibit the anti-
tumoral activity of cytotoxic CD8+ T cells, by inhibiting their ability to produce 
cytolytic factors such as pore-forming protein perforin, the caspase activating 
secreted factors granzyme A and B, and the pro-apoptotic cytokine Fas-ligand. In 
human glioma patients, TGF-β decreases the expression of the activating 
immunoreceptor NKG2D on CD8+ T cells and natural killer (NK) cells, which leads 
to reduced CD8+ T cell, mediated cancer-directed cytotoxic response. Knockdown of 
TGF-β synthesis in a glioma cell lines prevents NKG2D repression and enhanced 
glioma killing by cytotoxic T cells and NK cells (Thomas and Massague, 2005). 
1.2 Epithelial to mesenchymal transition (EMT) 
Epithelial-to-mesenchymal transition (EMT) is a basic cellular process in which epithelial 
cells lose epithelial properties, e.g. their polarized organization and cell-cell junctions, 
undergo changes in cytoskeleton and cell shape, acquire mesenchymal characteristics and 
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become migratory and invasive. EMT was first recognized as a distinct cell differentiation 
process in the late 70’s, and has received increasing attention, as it not only occurs in normal 
development but is also an integral component of various pathological conditions (Hay,et.al, 
1968). On the basis of its function, EMT can be classified into three different subtypes 
(Figure 2). Type 1 EMT is associated with implantation and embryonic gastrulation and 
gives rise to mesoderm and endoderm and to mobile neural crest cells. Type 2 EMT is 
involved in wound healing, tissue-regeneration, inflammation and fibrosis. Finally, Type 3 
EMT comprises the transformation of epithelium associated with organs into the cancer cells 
which later leads to invasion and metastasis (Kalluri and Weinberg, 2009). Although the fate 
determination of Type 1 and Type 3 EMT is different, they follow the same patho-
physiological pathway which involves the loss of epithelial marker E-cadherin and gain of 
mesenchymal marker N-cadherin.  Such EMT associated “cadherin switch” is always 
annotated as a hallmark of this process (Hazan et al., 2004a; Maeda et al., 2005a). 
 
 
Moreover, the classical cadherin switch is assisted by substitution of many more epithelial 
markers such as tight junction proteins, claudins and occludins; desomosomal proteins; α and β-
catenins localization and cytokeratins with mesenchymal markers such as vimentin; fibronectin 
and matrix metalloproteinase secretion;  integrin α V, integrin β 1 and smooth muscle actin 
Figure 2: Three different sub-
types of EMT. (A) EMT 
during embryonic development 
(Type 1). (B) EMT during 
wound healing and fibrosis 
(Type 2). (C) EMT during 
pathological conditions such as 
cancer (Type 3). Adapted from 
Kalluri and Weinberg, 2009. 
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(Yang and Weinberg, 2008). Furthermore, in case of many carcinomas, tumor-associated stroma 
produces many growth factors, mainly HGF (Savagner et al., 1997), EGF (Lo et al., 2007), 
PDGF (Yang et al., 2006), FGF2 (Strutz et al., 2002) and TGF-β (Zavadil and Bottinger, 2005), 
that result in induction of various transcription factors, notably Snail, Slug, zinc finger E-box 
binding homeobox 1 (ZEB1), Twist, Goosecoid, and FOXC2 (Jechlinger et al., 2002; Kokudo et 
al., 2008; Medici et al., 2008; Niessen et al., 2008; Shi and Massague, 2003; Thiery, 2002) which 
drive EMT. But the actual implementation is dependent on signal-transducing proteins, ERK, 
MAPK, PI3K, Akt, Smads, RhoB, β-catenin, lymphoid enhancer binding factor (LEF), Ras, and 
c-Fos as well as cell surface proteins such as β4 integrin, α5β1 integrin, and αVβ6 integrin [(Tse 
and Kalluri, 2007); Figure 3]. Recently, microRNAs were also implicated to have a role in 
EMT. Non-coding miRNA such as miR200 and miR205 modulate the function of  Zeb1 and 
Zeb2 transcription factors that are known to be repressors of E-cadherin gene expression 
(Gregory et al., 2008a; Gregory et al., 2008b; Korpal et al., 2008; Park et al., 2008; Paterson et 
al., 2008). In addition, the role of alternative splicing of transcripts in EMT is the most recent 
advancement in the field of cancer biology (see below 1.2.9).   
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1.2.1 EMT and E-cadherin 
In mammals, adhesion between epithelial cells is generally mediated by three types of junctions: 
tight junctions (TJs), adherens junctions (AJs), and desmosomes, which together constitute the 
Intercellular Junctional Complex (Perez-Moreno et al., 2003). The transmembrane core of AJs 
consists of cadherins. Cadherins were first discovered as cell surface glycoproteins responsible 
for Ca2+-dependent homophilic cell–cell adhesion during morula compaction in the 
preimplantation mouse embryo and during chick development (Gallin et al., 1983; Peyrieras et 
al., 1983; Yoshida and Takeichi, 1982). E-cadherin is the protype and well-characterized 
member of this family, is primarily expressed in epithelia and required for cell-cell adhesion 
between two cells. The highly conserved, cytoplasmic tail of classical cadherins possesses a 
binding site for either β-catenin or γ-catenin via which they are connected to actin cytoskeleton 
(Aberle et al., 1996). On the other hand, E-cadherin also binds to p120-catenin and regulates 
surface tracking, lysosomal degradation and localization of newly synthesized cadherins at the 
membrane (Ireton et al., 2002; Stehbens et al., 2006). Furthermore, p120-catenin has emerged as 
a major regulator and integrator of signaling by the Rho family of small GTPases (Anastasiadis, 
2007), and this is at least partially dependent on its interaction with the cadherin and repressing 
the activity of RhoA (Wildenberg et al., 2006). On the other hand, three closely related PDZ-
domain-containing proteins (ZO-1, ZO-2 and ZO-3) constitute the undercoat structure of TJs 
together with other peripheral membrane proteins such as cinglin, 7H6 antigen and symplekin. 
Occuldin and claudins are the main players in organization of TJs and thought to constitute the 
backbone of TJs strands (Tsukita et al., 1999). 
During EMT, cells lose their epithelial polarity and dissolve the adherent and tight junctions, 
favoring a more labile cell-cell adhesion and communicate with the extracellular matrix through 
focal adhesions. Thus, E-cadherin behaves as a tumor-suppressor, by keeping the cell-cell 
contacts intact and resisting their mobility (Egeblad and Werb, 2002; Friedl and Wolf, 2003; 
Figure 3: Overview of EMT process and its regulation. During EMT, cells lose their cell-cell junctions and re-
arrange the cytoskeleton so that they can migrate, invade the neighbouring tissues and metastasize to the distant 
organs. Many signaling molecules have been implicated in the induction of EMT such as BMP/TGF-β, Wt, HGF, 
FGF and EGF. Adapted from Derek C. Radisky, 2005. 
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Hood and Cheresh, 2002). It has been demonstrated that E-cadherin gene is silenced in many 
carcinomas and activation of E-cadherin is sufficient to reduce the aggressiveness of tumor cells 
(Vleminckx et al., 1991). Cadherins are generally regulated at both the mRNA and protein levels, 
by means of changes in subcellular distribution, translational or transcriptional events, and 
degradation. In various human carcinomas, functional loss of E-cadherin may result from the 
production of a defective protein, which could be a result of gene mutation, abnormal post-
translational modifications (phosphorylation or glycosylation) or protein degradation 
(proteolysis) (Kang and Massague, 2004; Thiery and Morgan, 2004). It can also be regulated at 
the transcriptional level by silencing through its promoter hypermethylation. Although E-
cadherin is downregulated during EMT, metastatic cells gain back E-cadherin, specifically 
during intravasation and seeding of metastatic cells (Kang and Massague, 2004; Thiery and 
Morgan, 2004). In addition to promoter hypermethylation, E-cadherin transcriptional repression 
may result from the activation of repressors, such as Snail, Slug, Zeb1, Zeb2 and Ets (Peinado et 
al., 2007).  
1.2.2 EMT and growth factors 
The oncogenic pathways involving recteptor tyrosine kinases (RTK) are shown to regulate 
adherent and tight junction proteins that are known to be involved in normal integrity of the 
epithelial cells such as E- cadherin, occludins, claudins and cytokeratins (Bos, 2005). It has been 
suggested that RTK activation participates in the EMT program by rendering the tight junction 
leaky and thus allowing access of TGF-β to its receptor, one subunit of which would otherwise 
remain segregated in the tight junction (Bos et al., 2003). Growth factors that activate RTKs 
were the first identified as potent inducers of EMT by activating Mitogen activated protein 
kinase (MAPK) signaling through Extracellular-regulated kinase (Erk). For instance, hepatocyte 
growth factor (HGF) signaling leads to induction of various matrix metalloproteinase (MMPs) 
and extracellular matrix proteins (ECMs) which alters the cell-ECM and cell-cell interaction 
through regulation of integrins and cadherin expression (Berrier et al., 2000). Constitutive 
activation of Erk is shown to be required for complete EMT in epithelial tumor metastasis 
models (Chen et al., 1997; Ingber et al., 1995; Lele et al., 2006; Parker and Ingber, 2007; Zhang 
et al., 1996). HGF also influences the EMT process by regulating the key EMT transcription 
factor, Snail (Chrzanowska-Wodnicka and Burridge, 1996). Another EMT inducer, FGF also 
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determines the fate of epithelial cells by triggering the MAPK signaling and possibly, TGF-β 
signaling (Bershadsky et al., 2006; Riveline et al., 2001). Recent studies in Xenopus showed that 
FGF signaling promotes mesodermal differentiation by enhancing embryonic TGF-β/nodal 
signaling (Bershadsky et al., 2006; Riveline et al., 2001). Binding of FGF ligand to its receptor 
elicts MAPK/FGFR signaling that induces phosphorylation of the N-terminal of p53 and further 
interaction of p53 with TGF-β-induced Smads in the nucleus.    
In addition to MAPK signaling, phosphatidylinositol 3' kinase (PI3K) signaling also plays a key 
role in inducing EMT. Cells producing a constitutively active form of Akt, a downstream 
effector of PI3K signaling, produce the transcription factor Snail, which is known to repress E-
cadherin transcription (Grille et al., 2003) and triggering EMT. Moreover, PI3K signaling can 
also be activated by integrins and small GTPases from Rho family, which controls cytoskeleton 
re-modeling, extended its necessity in EMT-driven processes (Xia et al., 2008; Zamir and 
Geiger, 2001). Furthermore, autocrine PDGFR signaling with oncogenic Ras, hyperactivates 
PI3K signaling that is required for survival during EMT (Jechlinger et al., 2002). 
Epidermal growth factor (EGF) is a potent stimulator of EMT in several cell types, and the 
EGFR has been shown to directly interact with β-catenin, leading to the tyrosine phosphorylation 
of β-catenin and disruption of cadherin-dependent junctions (Klymkowsky, 2005; Nelson and 
Nusse, 2004). Endocytosis of E-cadherin results in the release of β-catenin to act on the Wnt 
pathway, resulting in Snail gene transcription and consequently E-cadherin repression (Lu et al., 
2003).  On the other hand, engaged E-cadherin complexes in the intact adherens junction directly 
inhibit the activity of the EGFR by inhibiting transphosphorylation of Tyr845 (Perrais et al., 
2007). 
Similarly, insulin growth factor (IGF) can also induce EMT by affecting the distribution of E-
cadherin and internalization of E-cadherin in the vesicles located around the nucleus and 
degrading it. Similar to E-cadherin, IGF also redistributes β-catenin from the cell membrane to 
the nucleus, and induces the translocation of TCF3 from the cytoplasm to the nucleus (Morali et 
al., 2001). Thus, growth factors play a key role in initiating and maintaining EMT.       
1.2.3 EMT and transcription factors 
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It is well known fact that TGF-β induces many transcription factors which are essential for EMT. 
Transcription factors like Snail1/2, Slug, Zeb1/2, Twist and FoxC2 are potent repressor of genes 
which are important for keeping epithelial polarity and organization, particularly cell-cell 
interaction proteins such as E-cadherin, clauddin, occludins and ZO-family genes (Zhang et al., 
2008). Snail expression can be induced in a Smad-3 or MAPK dependent manner (Matsumoto et 
al., 2001; Xue et al., 2008). Snail1 binds to E-box element of the E-cadherin promoter and 
recruits a complex containing HDAC1, HDAC2 and mSin3A, and thus represses gene 
transcription (Batlle et al., 2000; Cano et al., 2000; Hajra et al., 2002). Snail2 also works in the 
same way as Snail1 but it recruits a different combination of co-repressors, i.e. HDAC1/3 and 
CTBP (Bolos et al., 2003; Hajra et al., 2002; Hemavathy et al., 2000). However, Snail proteins 
do not affect the PAR complex, another polarity complex (Whiteman et al., 2008). Some of the 
Snail target genes regulate tissue specific EMT processes such as HNF-1β (Boutet et al., 2006; 
Boutet et al., 2007). Similarly, Zeb1 and Zeb2 [also known as Smad-interacting protein1 and 2 
(SIP1 and 2)] also form repressive complexes with Smads and bind to the E-cadherin promoter 
to suppress it. The Zeb factors have been recently shown to be repressed by miRNA from miR-
200 family. These miRNAs are downregulated during EMT and their forced expression is 
sufficient to block TGF-β-induced EMT (Gregory et al., 2008a; Korpal et al., 2008; Park et al., 
2008). In addition, Zeb2 is subjected to post-translation regulation by Polycomb complex 2 
where sumoylation impairs its repressor activity (Long et al., 2005). Both Zeb proteins promote 
cell migration and induce invasion (Comijn et al., 2001; Spaderna et al., 2008; Vandewalle et al., 
2005). Helix-loop-Helix (HLH) proteins are a large family of transcription factors controlling a 
wide variety of developmental and biological processes. HLH family can be divided into seven 
categories on the basis of their tissue distribution, dimerization capabilities and DNA binding 
specifity (Massari and Murre, 2000).  E12 and E47 from class I, Twist1 and 2 from class II and 
Id1- 4 from class V had been elaborated in EMT. E12 and E47 are encoded by alternative 
splicing products of the E2A gene (Massari and Murre, 2000). They have been shown to repress 
E-cadherin by directly binding to its promoter. On the other hand, Ids are downregulated in 
response to TGF-β and act as antagonist for E-cadherin repression by binding to E2A protein 
(Kondo et al., 2004).  ID1 is usually suppressed during EMT by rapid activation of expression of 
the transcription repressor ATF3 by TGF-β and the subsequent binding of an 
ATF3/Smad3/Smad4 complex to the Id1 promoter (Kang et al., 2003; Kowanetz et al., 2004). 
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Loss of Id1 expression is co-relates with a decrease in E-cadherin expression, and ectopic 
expression of Id2 or Id3 dose-dependently blocks TGF-β-induced repression of E-cadherin 
expression, inhibits TGF-β-induced ZO-1 delocalization and represses TGF-β-induced smooth 
muscle actin expression (Kang et al., 2003; Kowanetz et al., 2004). Besides E-cadherin, E47 also 
represses desmoplakin expression and induces the expression of N-cadherin, Sparc and α5-
integrin (Moreno-Bueno et al., 2006). Twist1 and 2, other members of this family, are a major 
regulator of mesoderm formation (Chen and Behringer, 1995). Ectopic expression of both leads 
to EMT (Ansieau et al., 2008; Yang et al., 2004). Hmga2, a downstream molecule of Smad-3 
signaling, is also shown to be expressed in mesenchymal cells and induces the expression of 
Snail1/2, Twist, and represses Id2 expression (Thuault et al., 2006).  
1.2.4 EMT and metastasis 
Metastasis (from the Greek “change of place”) is a major cause of death among cancer patients. 
This process refers to the spread of cancer from its original site to other areas in the body. Cancer 
cells have the ability to invade the blood vessels and lymph-nodes and find their way into the 
bloodstream. Once in the blood, cancer cells can disseminate to virtually any part of the body 
and make a home for themselves. Metastasis is a multistage process. These stages have been 
defined as local invasion, intravasation into the circulation, survival and transport in the 
circulation, extravasation from the bloodstream, and growth in the metastatic site (Bogenrieder 
and Herlyn, 2003; Condeelis and Segall, 2003; Fidler and Balch, 1987; Fidler and Radinsky, 
1996; Gopalkrishnan et al., 2001; Kauffman et al., 2003). Progression through these stages 
requires changes in cellular phenotype such as cellular motility, antiapoptotic capability, 
adhesion molecule expression, expression of matrix metalloproteinases and other proteases and 
expression of angiogenic factors and other paracrine or autocrine factors. Several authors have 
emphasized that if even one requisite step of the multistep metastatic process could be blocked, it 
would result in the abrogation of clinically relevant metastasis (Fidler and Balch, 1987; Fidler 
and Radinsky, 1996; Gopalkrishnan et al., 2001; Kauffman et al., 2003). 
The tumor metastatic process has been compared to a marathon. Tumor cells have to invade the 
solid tissues around the primary tumor site. The tissue in which the tumor arose is complex, 
containing other cells such as fibroblasts, a protein filled matrix that provides a solid support and 
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immune cells and lymphatic drainage. Tumors have to invade past these barriers. To do so they 
develop the ability to move. Tumor cells do not float out of a tissue, they crawl. Basically, tumor 
cells react to factors in their environment; they put out a “finger” of the cell toward the attractant 
and ratchet the cell forward. To move, tumor cells must alter their adhesion to other cells and to 
the protein matrix in a very dynamic fashion. They may also have to create a pathway amongst 
the tissue, by degrading the protein matrix using enzymes (proteases). 
Tumor cells can spread around the body using one of two major “highways”. All tissues are 
served by blood vessels (which provide oxygen and nutrients) and also lymphatic vessels which 
drain excess fluid to nearby lymph glands. For many cancer cells, their first opportunity to 
escape is to use the lymphatic drainage system. This is why for many cancers lymph nodes are 
biopsied or removed at surgery to see if the cancer has spread and oncologists use the 
information to determine the “stage” of the cancer. Cancer cells can enter the bloodstream either 
indirectly via the lymphatics or directly from a vessel in the primary tumor. The bloodstream is a 
very harsh environment with a high velocity of flow and full of immune cells. Moreover, cancer 
cells are used to being attached to the proteinaceous matrix, many tumor cells die when detached 
from their support and have to swim (detachment mediated death is called anoikis, another Greek 
word describing the death of leaves from as they detach from trees in Fall). The majority of 
tumor cells get stuck (arrest) in the first capillary bed that they float into. To get out from the 
bloodstream, they attach to the endothelial cells lining the blood vessels and the endothelial cells 
retract, they move apart, to permit the tumor cells to enter the tissue. This may be a normal 
reaction of endothelial cells to immune cells, cells of our immune systems migrate in and out of 
the bloodstream all the time to maintain surveillance. In fact, tumor cells can disguise themselves 
as lymphocytes by expressing similar molecules on their surface that fools the endothelial cells. 
These molecules may also determine their apparent ability to “home” to specific organs 
preferentially, as they may respond to gradients of chemicals differentially expressed there. 
 
1.2.5 EMT and migration 
Migration is certainly a key step in metastasis and a universal process. Depending on the tumor 
type and the surrounding tissue, cell migration involves different cellular strategies to overcome 
the physical restrain provided by primary tissues and their epithelium. For most cells, including 
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epithelial, stromal, and neuronal cells, migration phases are confined to morphogenesis and cease 
with terminal differentiation toward intact tissue to become reactivated only for tissue 
regeneration or neoplastic processes. For other cell types, such as leukocytes, migration is 
integral to their function and maintained throughout their life span. Some cell types migrate only 
in the context of a defined substrate, such as epithelial cells moving along a basement membrane 
but not through interstitial tissues, whereas other cell types, including leukocytes, are versatile, 
as they interact with and migrate within virtually any substrate present in the body. These cell 
and tissue-type specific patterns of migration are acquired in various cancers can be subdivided 
into at least two main migration modes: single cell migration and collective cell migration 
(Figure 4). The essential molecules that control and specify these different types of migration 
include adhesion molecules of the β1 and β3 integrin families that mediate interaction with the 
extracellular matrix (ECM); matrix metalloproteinases (MMPs) and serine proteinases, such as 
uPA/uPAR, responsible for ECM degradation; cadherins and associated molecules that mediate 
stable intercellular adhesions; and signaling molecules that control the actin cytoskeleton, 
specifically the small GTPases RhoA, Rac and Cdc42 and their downstream effectors. Single cell 
migration is characterized by the presence of isolated and dispersed tumor cells in an adjacent 
tissue. This contrasts with what is observed during collective cell invasion, where the cancerous 
tissue pushes forward as a whole, thereby displacing the healthy surrounding cells (Friedl and 
Wolf, 2010; Ilina and Friedl, 2009; Matise et al., 2009; Pals et al., 2007; Yilmaz et al., 2007). 
1.2.5.1 Single cell migration 
Single cell migration can be further classified into two sub-groups: (a) Mesenchymal migration 
and (b) Amoeboid migration. Single cell mesenchymal migration has been identified in 
numerous cancers, including fibrosarcomas, glioblastomas and epithelial cancers. This kind of 
migration is also implanted in non-neoplastic neural crest cells (Jacques et al., 1998), myoblasts 
(El Fahime et al., 2000), infiltrating lobular or metaplastic breast carcinoma (Pitts et al., 1991), 
ovarian cancer (Sood et al., 2001) and melanoma of a vascular-type pattern (Seftor et al., 2002). 
However, single cell amoeboid migration is common in leukocytes and some tumor cells, such as 
in leukaemias, as well as in tumors occurring in organs lacking extensive cross-linked collagen 
network (Friedl and Wolf, 2003) .  
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(a) Mesenchymal Migration: In mesenchymal migration, which represents the archetype of 
cell migration, cells complete a migration sequence consisting of (1) cell polarization 
driven by localized actin polymerization causing formation of a leading pseudopod; (2) 
attachment of this pseudopod to ECM ligands via β1 and β3 integrin clusters called focal 
adhesions, interaction sites that recruit cytoplasmic adaptor, signaling, and cytoskeletal 
Figure 4: Diversity of tumor cell migration.  Tumor cells can migrate individually or collectively. 
Ameoboid migration involves the deattachment of individual cells for invasion into the surrounding tissue 
but here the interaction between cells and ECM matrix is weak. The mesenchymal migration also follows 
similar strategy but the cells become spindle-shaped and possess integrins for invading the ECM. During 
collective cell migration, cells form a cohort of 5-6 cells. In cluster migration, cells loss their contact with 
primary tumor while in sheet migration, contact with primary tumor remains intact. Adapted from Peter 
Friedl & Katarina Wolf, 2003. 
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proteins as well as cell surface proteases such as MMPs and the uPA/uPAR complex; (3) 
local proteolysis of the ECM, widening the space for forward movement of the cell; (4) 
activation of contractile proteins, such as myosin II, and consequent shortening of 
membrane-anchored actin filaments; (5) contraction of the cell, leading to retraction of its 
rear end and consequent forward movement. This 5-step migration program is typical for 
single-cell migration of fibroblasts and keratinocytes as well as for single epithelial 
(cancer) cells that have undergone epithelial to mesenchymal transition (EMT), and 
represents a relatively slow process with migration velocities of 0.1 to 2 μm/min. 
Furthermore, chain migration is also a part of mesenchymal migration where chains of 
single tumor cells aligned between stromal fibres, termed 'Indian files' and infiltrate the 
lobular or metastatic breast cancer, ovarian cancer and melanoma of vascular type-
pattern. 
 
(b) Amoeboid Migration: Interestingly, recent studies indicate that lymphocytes display a 
characteristic form of cell migration, which has been termed “amoeboid” migration, 
because it mimics that of the amoeba Dictyostelium discoideum (Friedl, 2004). In this 
migration type, integrin-mediated adhesion is partially dispensable and stable focal 
contacts are not formed, but cell movement is driven by short-lived relatively weak 
interactions with the stromal cell networks in the T- and B-cell areas of the lymphoid 
tissues (Bajenoff et al., 2006; Friedl, 2004; Mempel et al., 2006). The lack of focal 
contacts and high deformability of lymphocytes allow movement at high velocity (2-30 
μm/min) (Bajenoff et al., 2006; Friedl, 2004; Mempel et al., 2006; Miller et al., 2003; 
Miller et al., 2002). Moreover, the fast deformability of lymphocytes allows them to 
overcome matrix barriers by physical mechanisms, that is, adaptation of shape to 
preformed matrix structures (contact guidance), extension of lateral footholds (elbowing), 
and squeezing through narrow spaces (contraction rings). Thus, lymphocyte migration is 
shape-change driven and lymphocytes use protease-independent physical mechanisms 
that allow easy cell traffic toward and between structurally different tissue compartments. 
Among higher eukaryotes, this migration type is found only in lymphocytes and other 
leukocytes, hematopoietic stem cells, and certain tumor cells (Friedl, 2004). 
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1.2.5.2 Collective cell migration 
Collective movement, which relies on local proteolytic degradation of the extracellular 
matrix  can occur by two-dimensional (a) sheet migration or three-dimensional group 
(Lauffenburger and Horwitz, 1996), or (b) strand/ cohort migration (Adams, 2001). 
However, collective migration of cells is a well-described phenomenon that occurs during 
embryological development (Davidson and Keller, 1999), or during the development of 
glands and ducts of mammary tissue (termed 'branching morphogenesis') (Klinowska et 
al., 1999; Simian et al., 2001) and the sprouting of endothelial cells during the formation 
of new blood vessels (Collen et al., 2003; Hiraoka et al., 1998). 
(a) Multicellular strands/sheets migration: This kind of migration consists of cell sheets 
that extend into tissue, yet maintain contact with the primary tumor to generate local 
invasion. Cells present at the migrating front produce MMPs that generate a path for the 
cells to follow. This type of movement is observed in invasive epithelial cancer such as 
oral squamous cell carcinoma, basal cell carcinoma, melanoma, mammary carcinoma and 
colon carcinoma (Nabeshima et al., 2000). The precise molecular mechanisms underlying 
this coordinated invasion are still largely unknown, mainly due to the difficulties to 
model this complex type of migration in vitro. 
(b) Cluster/ Cohort migration: Collective cell migration, as seen during wound healing and 
during the invasion of epithelial cancer cell, uses the same integrin- and protease-
dependent migration cycle as single-cell migration, but in this migration type the cell 
junctions within the invasive collectives are stabilized by cadherins and gap-junctional 
cell-to-cell communication (Pals et al., 2007). Cellular cohorts are heterogeneous in 
nature with leading, and presumably more motile, cells serving as a guide for following 
cells (path-generating cells) which basically generates migratory traction via pseudopod 
activity and reducing apico-basal polarity. Moreover, cells at the leading edge cluster β1 
integrins in anterior protrusions towards the ECM substrate (Hegerfeldt et al., 2002; 
Klinowska et al., 1999), and show an increased expression and activity of MT1-MMP 
and MMP-2, leading to polarized ECM degradation (Nabeshima et al., 2000). The 
following cells maintain polarity and junctional proteins (Burridge and Chrzanowska-
Wodnicka, 1996). However, communication between cells in a cohort is necessary to 
induce collective rearrangement of their cytoskeletal structures, thereby facilitating 
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collective migration in response to extrinsic guidance cues. Collective cell migration is 
morphologically expressed as either a branch-like extension protruding out of the 
primary tumor mass or as a separate cohort of cells moving through the tumor stroma 
(Friedl and Brocker, 2000). Collective cell migration in vivo may be advantageous for 
cell survival, such as robust protection of the innermost cells in the cluster from 
immunological attack. Additionally, collectively moving cells probably have enhanced 
cell–cell communication in response to micro-environmental cues, due to the 
heterogeneity of leading and following cells. This is beneficial for effective movement 
and invasion beyond the primary tumor, as the less motile cells are influenced by highly 
motile cells (Burridge and Chrzanowska-Wodnicka, 1996; Friedl and Brocker, 2000). 
 
1.2.6 EMT and cancer stem cells 
The cells within a tumor display functional heterogeneity, with different morphology, 
differentiation grade, proliferation rate, and invasiveness (Heppner and Miller, 1983). Recent 
studies suggest that the ability of a tumor to proliferate and propagate relies on a small 
population of stem-like cells, called cancer stem cells (CSCs). CSCs share fundamental 
characteristics with normal adult stem cells: they divide asymmetrically producing one stem cell 
and one progenitor cell (self-renewal). In normal stem cells, this allows the continuation of the 
stem cell compartment and starts the production of cells that undergo multi-lineage 
differentiation. Similarly, CSCs have the ability to perpetually self-renew and to produce tumors 
comprised of cells with different phenotypes. Since their discovery in leukaemia (Bonnet and 
Dick, 1997), the existence of a subpopulation of CSCs has been corroborated in several solid 
tumors, including breast, brain, colon, pancreas, prostate, lung, and head and neck tumors 
(Eramo et al., 2008; Glinsky, 2007; Li et al., 2007; Prince et al., 2007). Several of the molecular 
signaling pathways associated with normal stem cell development, such as Wnt, Shh and Notch, 
are also active in cancer development. Stem cells are notable for the presence of ATP-binding 
cassette transporters, which remove drugs from the cell (Dean et al., 2005).  Cancer stem cells 
maintain this characteristic, which accounts for the ineffectiveness of chemotherapy to destroy 
these cells. Normal stem cells are under tight metabolic control and divide only under specific 
conditions. Cancer stem cells no longer have these controls. Furthermore, like cancer cells, they 
are also resistance to apoptosis. 
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While some studies suggest that CSC may arise from the transformation of their normal 
counterparts, recent observations rather suggest that they originate from fully differentiated cells 
through an adaptive trans-differentiation program such as EMT (Mani et al., 2008; Morel et al., 
2008; Vesuna et al., 2009). 
 
 
 
 
 
 
 
 
 
 
Cells that have undergone an EMT were thus found to form mammospheres in low adherent 
conditions and to be highly tumorigenic when orthotopically xenografted at limit dilution in nude 
mice. They additionally display a CD44high CD24low antigenic phenotype that was previously 
allotted to mammary CSCs (Al-Hajj et al., 2003). Several lines of evidence exist where it has 
been shown that these cells are resistant to chemotherapy and do not undergo apoptosis. EMT 
Figure 5: (A) The “cancer stem-cell theory” is based on the assumption that during tissue regeneration, the 
amplification of progenitor cells opens a window of time suitable for accumulating genetic alterations, leading to 
the emergence of cancer cell-stems (CSCs). CSCs would thus initiate and sustain tumour growth. (B) Alternatively, 
under stress conditions, fully differentiated cells reacquire stem-like properties, including self-renewal. This gain of 
function is influenced by cellular intrinsic properties as well as micro-environmental conditions. These cells could 
potentially be prone to transformation and give rise to CSCs. Both models are not exclusive. CSCs and cell 
dedifferentiation would thus constitute the initial and secondary tumour drivers, respectively. 
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being by definition a reversible process, these cells continuously generate CD44low CD24high 
epithelial cells that interestingly lack a tumorigenic potential (Mani et al., 2008; Morel et al., 
2008; Vesuna et al., 2009). In regards to the EMT-associated properties, the trans-differentiation 
process is thus considered as a biological process able to convert differentiated epithelial cells 
into CSCs. EMT being strongly impacted by micro environmental conditions, the balance 
between differentiated cells and CSCs was then proposed to be a highly dynamic process with 
important repercussions on therapeutic approaches, eradication of the entire primary tumor, 
including differentiated cells, being henceforth a requisite to prevent recurrence (Gupta et al., 
2009a). 
The key roles of CSCs in breast cancer biology suggest that new therapies must target these 
cells. The main objective of those therapies would be the eradication of the CSC compartment 
with no harm to other cell types. Eradication of breast CSCs may include different strategies as 
summarized in Table 1. 
 Different approaches have been used to overcome ABC transporter-mediated chemoresistance. 
The anthracycline-modified drug annamycin, which is not extruded by ABC transporters, is toxic 
to the resistant cell line MCF-7/VP (Perez-Soler et al., 1997). The plant alkaloid berberine 
decreases the expression of the ABCG2 transporter and reduces the “side population” of the 
MCF-7 cell line (Kim et al., 2008a; Kim et al., 2008b), suggesting that downregulation of ABC 
transporters may be useful for targeting breast CSCs. However, the ability to target drug 
transport in CSCs may be difficult since these cells express multiple ABC transporters (de 
Grouw et al., 2006). The use of inhibitors of ABC transporters simultaneously with anticancer 
drugs is an efficient approach to overcome resistance in vitro and in animal models (Ozben, 
2006). However, clinical trials with this kind of inhibitors have shown that they produce serious 
side effects (Ozben, 2006). High-throughput screening identified the ionophore salinomycin as 
toxic to breast CSCs (Gupta et al., 2009b). Salinomycin induces caspase-independent apoptosis 
in human cancer cells of different origins that display multiple mechanisms of drug resistance, at 
concentrations that do not affect normal cell viability (Fuchs et al., 2009). Subsequent studies 
have shown that salinomycin induces a conformational change of the ABC transporter 
MDR1/ABCB1 that reduces its activity (Riccioni et al., 2010). Therefore, salinomycin is 
particularly effective at inducing apoptosis in leukemia cells that display ABC transporter-
mediated drug-resistance (Fuchs et al., 2010). Targeting CSCs through their specific markers 
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was partially succesful in acute myeloid leukemia (AML) (Sperr et al., 2005; Tsimberidou et al., 
2006). Cytotoxic antibodies directed against CD33 (a common marker in leukemic stem cells) 
induced remission in some patients. However, the antibody produced cytopenia due to its effects 
on normal hematopoietic stem cells (Sperr et al., 2005; Tsimberidou et al., 2006). Similarly, a 
monoclonal antibody against CD44 induced terminal differentiation and apoptosis of AML cells 
in engrafted mice (Jin et al., 2006). Anti-CD44 antibodies conjugated with cytotoxic drugs or 
radiolabels have shown to reduce disease progression in breast cancer patients and animal 
models (Platt and Szoka, 2008). Other potential targets in breast CSC therapy include molecules 
that participate in self-renewal and cell fate. Inhibition of Hedgehog signaling in xenografts 
established from pancreatic cancer cell lines reduced the number of ALDH-overexpressing cells 
(Feldmann et al., 2008). The promoters of the MDR, hTERT, and Cox-2 genes are active in 
breast CSCs. Oncolytic adenoviruses driven by these promoters were effective in killing 
CD44+/CD24-/low cells in vitro, and reducing tumor growth in vivo (Bauerschmitz et al., 2008). 
Interruption of signals generated in the CSC microenvironment using antibodies or soluble 
ligands against adhesion receptors may be useful in CSC targeting. α6-integrin inactivation with 
antibodies or siRNA abrogated mammosphere-forming ability and tumorigenicity of breast 
cancer cells (Cariati et al., 2008). The IL-8 receptor CXCR1 inhibitor repertaxin reduced the 
breast CSC population, producing apotosis in the tumor population, and reduced metastasis 
(Ginestier et al., 2010). 
Metformin is an anti-diabetic drug that has found to reduce breast cancer incidence and improve 
survival of breast cancer patients with type 2 diabetics (Vazquez-Martin et al., 2010). Recent 
studies showed that the drug metformin selectively reduces the breast CSC population. In human 
breast cancer cell lines, metformin reduced the CD44+/CD24- population and their ability to 
form mammospheres (Hirsch et al., 2009). In a xenograft mice model, concurrent treatment with 
metformin and doxorubicin reduced tumor mass much more effectively than either drug alone 
(Hirsch et al., 2009). Metformin also targeted traztasumab-resistant CSCs that overexpressed 
HER-2 (Vazquez-Martin et al., 2011). The mechanism involved in the metformin effects on 
CSCs is unclear, but seems to be associated with its activator effect on AMP-activated kinase 
(AMPK) (Vazquez-Martin et al., 2010). AMPK phosphorylates and inhibits Acetyl CoA 
carboxylase (ACACA), the limiting enzyme of the fatty acid synthesis. Thus, metformin may be 
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affecting cancer cell metabolism and functioning on lipid raft platforms (Vazquez-Martin et al., 
2010). 
 
Table 1: Strategies for the eradication of CSCs. 
 
 
 
1.2.7 EMT and MicroRNAs 
miRNAs are highly conserved, small 17–25-nucleotide non-coding RNA molecules which are 
able to control gene expression at the post-transcriptional level by specifically interacting with a 
target mRNA. It is estimated that miRNAs regulate 30% of all proteins in humans (Lewis et al., 
2005). They play a pivotal role in regulation of key processes including cell differentiation, 
proliferation, apoptosis, angiogenesis, and the cell cycle (Esquela-Kerscher and Slack, 2006; 
Johnson et al., 2007; Wang and Olson, 2009).  
Beyond their roles in physiological processes, many miRNAs have been shown to be aberrantly 
expressed in various pathologies including cancer (Calin and Croce, 2006; Cho, 2010a; Cho, 
2010b; Shenouda and Alahari, 2009) and usually present in the chromosomal regions which are 
prone to deletion, amplification, or translocation, e.g., during the development of tumors (Calin 
et al., 2004). This has led to the identification of “miRNA signatures” that are characteristic for 
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certain tumors and allow their further classification (Calin and Croce, 2006; Lu et al., 2005). 
miRNAs can act as oncogenes or tumor-suppressors and influence the tumorigenesis process 
when down or upregulated, respectively. They can also affect the sensitivity of tumor cells to 
cytostatics or radiotherapy (Trang et al., 2008; Weidhaas et al., 2007).  For many miRNAs, target 
genes have been identified which are relevant in tumorigenesis, tumor growth, tumor 
angiogenesis and metastasis such as p53 (Le et al., 2009), p63  
 
Table 2: miRNAs relevant in tumor cell invasion and metastasis (Adapted from A. Aigner, 2011) 
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(Manni et al., 2009; Papagiannakopoulos et al., 2008; Scheel et al., 2009), Hmga2, Myc and Ras 
(Bussing et al., 2008) as well many of them are regulated by upstream regulators such as EGFR 
(Wang and Olson, 2009), Myc (Chang et al., 2008; Ma et al., 2010; Sampson et al., 2007) and 
NFκb (Zhang et al., 2009) which are also shown to affect tumorigenicity (Table 2). Furthermore, 
some of these molecules are involved in processing of miRNA by regulating the major 
components of the miRNA processing machinery including Drosha-DGCR8, Dicer-TRBP2, and 
Ago proteins (Boominathan, 2010). microRNA-like miR-31 has been shown to involved in 
regulation of three different steps of metastasis, i.e., invasion, extravasation, survival, and 
colonization by targeting three different molecules, integrin-α5 (ITGA5), radixin (RDX), and 
RhoA (Valastyan et al., 2010). Moreover, in some cases, auto-regulatory feedback loops have 
been observed, like for let-7 which inhibits metastasis by downregulating Myc, with Myc in turn 
transcriptionally and post-transcriptionally inhibiting let-7. A similar double-negative feedback 
loop is also observed for the miR-200 family, with ZEB1 and ZEB2 being a target of miR-200 
which, at the same time, are transcriptional repressors of both miR-200 gene clusters (Burk et al., 
2008; Wellner et al., 2009). Since ZEB1/ZEB2 are relevant in the EMT transition, this directly 
affects the epithelial vs. mesenchymal status of tumor cells and thus their migratory potential. 
However, other studies have demonstrated a miR-200-mediated increase in metastasis of 
mammary carcinoma cell lines (Dykxhoorn et al., 2009). An approach to reconcile those 
seemingly contradicting findings focuses on the different steps during metastasis. E-cadherin, a 
key molecule in EMT, is also regulated by several other miRNAs including miR-101 via Ezh2 
(Varambally et al., 2008) or miR-9 (Ma et al., 2010). Together, these data underscore the 
importance of miRNA in EMT and carcinogenesis. 
 
1.2.8 EMT and splicing factors 
Splicing aberrations have been associated with several diseases, including cancer, where altered 
splicing can lead to production of protein isoforms with oncogenic properties (Pajares et al., 
2007). 41 breast cancer-specific markers have been identified that can discriminate between 
normal breast tissue and ductal breast tumors (Venables et al., 2008). Furthermore, luminal and 
basal B cell lines could be distinguished based solely on their splicing patterns. Therefore, it 
appears likely that alternative splicing analysis will dramatically increase the pool of potential 
biomarkers for cancer diagnostics.  
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Since EMT is considered an early event in the metastatic process, splicing changes associated 
with EMT in particular have the potential to become useful prognostic and diagnostic markers 
for breast cancer metastasis. Fibroblast growth factor-2 (FGFR2) was the first gene to be 
associated with splicing and EMT (Savagner et al., 1994). Alternative splicing of the third Ig-like 
domain determines the ligand-binding specificity of the receptor and generates the IIIb or the IIIc 
isoform of the FGFRs. The IIIb isoforms are usually expressed in epithelial cells, whereas the 
IIIc isoforms are normally expressed in mesenchymal cells. In contrast, the ligands for the IIIb 
isoforms are usually expressed in mesenchymal cells and the ligands for the mesenchymal-
restricted IIIc isoforms in epithelial cells. In this way, FGFR signaling functions in a paracrine 
manner between the epithelial and mesenchymal cells. A switch from one isoform to another can 
thus lead to autocrine signaling. Exon switching in epithelial cells from the epithelial FGFR2 IIIb 
isoform to the mesenchymal FGFR2 IIIc isoform by alternative splicing has been described in rat 
models of prostate and bladder cancer (Oltean et al., 2006; Savagner et al., 1994). After the 
discovery of FGFR2, many other genes such as ENAH1 (also known as Mena) and CTNND1 
(also known as p120) are also shown to be regulated by alternative splicing. ENAH1 belongs to 
Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) family and regulates actin 
organization. Human Mena (hMena) is overexpressed in human breast tumors, and a splice 
variant termed hMena+11a was recently isolated from a breast cancer cell line with an epithelial 
phenotype (Pino et al., 2008). Similar to ENAH1, p120 can be spliced into isoform 1 and 3. 
Isoform 3 is expressed in epithelial cells while isoform 1 is expressed in mesenchymal cells 
(Keirsebilck et al., 1998).  Cell surface marker CD44 also undergoes splicing events and leads to 
the formation of CD44s and CD44v isoforms. The CD44s form is prominent in mesenchymal 
cells while CD44v in epithelial cells (Brown et al., 2011). Two recently described RNA binding 
proteins, ESRP1 and ESRP2 (epithelial splicing regulatory protein 1 and 2) have taken a central 
role in controlling splicing during EMT (Warzecha et al., 2010; Warzecha et al., 2009). In 
addition to the tight transcriptional regulatory control of EMT inducers, ESRP1 and ESRP2 exert 
an additional control to maintain epithelial homeostasis by promoting the splicing of epithelial-
specific forms of EMT-associated genes including MENA, CD44, FGFR2 and CTNND1 
(Warzecha et al., 2010; Warzecha et al., 2009). The RBFOX2 splicing factor has recently been 
demonstrated to regulate subtype-specific splicing in a panel of breast cancer cell lines (Lapuk et 
al., 2010). Shapiro and colleagues recently showed that EMT-associated splicing is likely to be 
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regulated by several splicing factors, including the ESRPs and members of the RBFOX, CELF, 
MBNL and hnRNP classes of splicing factors (Shapiro et al., 2011). These findings suggest that 
alternative splicing is an additional mechanism to control epithelial plasticity. 
 
1.3 TGF-β: its role in tissue homeostasis and cancer cell invasion 
 
1.3.1 Dual role of TGF-β 
TGF-β plays a central role in various biological processes including development, tissue 
homeostasis, immune system and cancer. In normal and premalignant cells, TGF-β enforces 
homeostasis and suppresses tumor progression directly through cell-autonomous tumor-
suppressive effects (cytostasis, differentiation, apoptosis) or indirectly through effects on the 
stroma (suppression of inflammation and stroma-derived mitogens) (Derynck et al., 2001; 
Massague, 2008; Siegel and Massague, 2003). However, when cancer cells lose TGF-β tumor-
suppressive responses, they can use TGF-β to their advantage to initiate immune evasion, growth 
factor production, differentiation into an invasive phenotype, and metastatic dissemination or to 
establish and expand metastatic colonies (Pardali and Moustakas, 2007; Thiery, 2002; Yang and 
Weinberg, 2008). 
 
1.3.2 TGF-β signaling 
The human TGF-β family can be sub-divided into two groups. Activin, nodal, lefty, myostatin 
and TGF-β belong to one group while bone morphogenetic proteins (BMPs), anti-muellerian 
hormone (AMH), and various growth factors and differentiated factors (GDFs) are belonging to 
the other. All these cytokines are well known to regulate various biological processes like cell 
proliferation, apoptosis, differentiation, angiogenesis and migration. Each ligand presents unique 
features of action, while they all share a common machinery to transmit intracellular signals, the 
TGF-β receptor complex. TGF-β can elicit its signaling either by using a canonical signaling 
pathway where it interacts with Smad proteins or via a non-canonical signaling where it interacts 
with non-smad proteins (Figure 6). These two modes of regulation result in immense complexity 
and variability of TGF-β signaling and its ability to control various cellular processes. 
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1.3.3. Canonical TGF-β signaling 
There are three variants of TGF-β: TGFβ1, TGFβ2 and TGFβ3 and all of them are synthesized as 
precursor molecules containing a propeptide region in addition to the TGF-β homodimer (Ulloa 
and Tabibzadeh, 2001). After it is synthesized, the TGF-β homodimer interacts with a Latency 
Associated Peptide (LAP) [a protein derived from the N-terminal region of the TGF-β gene 
product] forming a complex called Small Latent Complex (SLC). This complex remains in the 
cell until it is bound by another protein called Latent TGF-β-Binding Protein (LTBP), forming a 
larger complex called Large Latent Complex (LLC). It is LLC that gets secreted to the ECM 
(Laping et al., 2002). In most cases, before the LLC is secreted, the TGF-β precursor is cleaved 
from the propeptide but remains attached to it by noncovalent bonds (Blobe et al., 2001). After 
its secretion, it remains in the extracellular matrix as an inactivated complex containing both the 
Figure 6: Schematic diagram of TGF-β signaling from Cell membrane to the nucleus 
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LTBP and the LAP which needs to be further processed in order to release active TGF-β. The 
attachment of TGF-β to the LTBP is by disulfide bonds which allow it to remain inactive by 
preventing it from binding to its receptors. Because different cellular mechanisms require distinct 
levels of TGF-β signaling, the inactive complex of this cytokine gives an opportunity for a 
proper mediation of TGF-β signaling. 
Active TGF-β binds to two related receptors, namely TGFβRI and TGFβRII [(also known as 
activin receptor-like kinase 5 (ALK5)], which are serine/threonine kinases. Upon TGF-β binding, 
TGFβRI and TGFβRII form hetero-tetrameric complexes of two identical TGFβRI/TGFβRII 
receptors heterodimers. This binding causes the specific phosphorylation of serine and threonine 
residues of TGFβRI via TGFβRII, which further leads to rotation of the receptors so that their 
cytoplasmic kinase domains are arranged in a catalytically favorable orientation. Furthemore, 
TFGβRI phosphorylates effector proteins such as the receptor-associated Smad proteins 
(RSmads). Activated R-Smads subsequently interact with the common mediator Smad 4, 
translocate into the nucleus and control the transcriptional expression of various genes (Itoh et 
al., 2001). In addition, canonical TGF-β signaling is tightly regulated by specialized factors such 
as Smad6 and Smad7 which control the signaling by competing with Smad4 for binding to 
receptor-activated Smad1 or via recruiting the Smurf to TGF-β and BMP receptors for 
inactivation, respectively (Massague, 2008). 
 
1.3.3.1. Canonical TGF-β signaling mediated cell-cycle arrest 
In epithelial cells, TGF-β infers its cytostatic role via mobilization of cyclin-dependent kinase 
inhibitors (CDKI) such as p21CIP1 that targets cyclinE/A-cdk2 complexes for inhibition, or 
p15INK4B which inhibits cyclinD-cdk4/6 complexes. TGF-β may also suppress c-Myc and it is 
demonstrated that coordinated activity of Smad3/4, retinoblastoma-like 1 (p107) and the 
transcription factors E2F4/5 and C/ EBPβ may downregulate c-Myc (Chen et al., 2002; Gomis et 
al., 2006b). 
 
1.3.3.2. Canonical TGF-β signaling mediated apoptosis 
Many apoptotic genes such as GADD45β; Bim (Bcl-2 homolog domain-only factor); DAPK 
(death-associated protein kinase) and SHIP are regulated by TGF-β. All these factors, except 
SHIP are controlled by canonical mitochondrial cytochrome C release and consequent activation 
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of induction of caspase-mediated apoptosis. The lipid phosphatase SHIP promotes apoptosis by 
inhibiting PI3K activity, thereby blocking its survival promoting signaling (Pardali and 
Moustakas, 2007). 
 
1.3.4. Non-canonical TGF-β signaling 
The TGF-β receptor complex interacts with various non-Smad signaling proteins, including 
receptor tyrosine kinases (RTKs), cytoplasmic adapter proteins and G-protein-coupled receptors. 
Each of these interaction partners can be activated upon TGF-β binding to the TGF-β receptor 
complex and emit signals which can act independently or can interfere with canonical TGF-β 
signaling. Among well-known signaling pathways which are triggered by non-canonical TGF-β 
signaling are the MAPK, PI3K and Rho-like GTPase signaling pathways (Zhang, 2009). 
 
1.3.4.1. TGF-β-induced MAPK activation 
TGF-β can induce phosphorylation of tyrosine residues on both type I and type II receptors. The 
phosphorylated tyrosines are capable of recruiting the adapter proteins such as growth factor 
receptor binding protein 2 (Grb2) and Src homology domain 2 containing protein (Shc) which 
can further activate Erk through Ras, Raf and their downstream MAPK cascades. Erk activation 
is one of the non-smad pathways necessary for TGF-β mediated EMT (Davies et al., 2005; 
Zavadil et al., 2001). It is required for disassembly of cell adherens junctions, modulation of cell-
matrix interactions, increased motility and endocytosis (Zavadil et al., 2001). 
 
1.3.4.2. TGF-β-induced JNK/p38 activation 
Another interaction partner of the activated TGF-β-receptor complex is the adapter protein and 
E3 ligase TRAF6. Interaction of TRAF6 to the activated TGF-β receptors can induce the poly-
ubiquitination of TRAF6. Poly-ubiquitinated TRAF6 recruits TGF-β activated kinase 1 (TAK1) 
to activate the c-Jun N-terminal kinase (JNK) and MAPK p38 through induction of MAPKKs 
MKK4 and MKK3/6. The TRAF6-TAK1-JNK/p38 pathway is known to conjugate with 
canonical TGF-β signaling to induce TGF-β mediated apoptosis (Liao et al., 2001). 
Downregulation of TRAF6 and p38 prevent EMT and impair the EMT associated cytoskeleton 
re-modeling (Bakin et al., 2002; Yamashita et al., 2008; Yu et al., 2002). 
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1.3.4.3. Rho-like GTPases in TGF-β mediated EMT 
Par6, a scaffold protein regulating epithelial cell polarity, interacts with TGFβRI at tight 
junctions. TGF-β stimulation induces the assembly and accumulation of the TGF-β receptor 
complexes at tight junctions, where TGFβRII phosphorylates Par6. Upon phosphorylation, Par6 
recruits the E3 ubiquitin ligase Smurf1 to the activated receptor complex and mediates 
ubiquitination and turnover of RhoA, which finally enables TGF-β-dependent dissolution of tight 
junctions, a prerequisite for EMT (Ozdamar et al., 2005). TGF-β also induces the dissolution of 
tight junctions during EMT by recruiting Cdc42 to the receptor complex, and by triggering 
degradation of RhoA at cellular protrusions (Barrios-Rodiles et al., 2005; Wilkes et al., 2003). 
 
1.3.4.4. TGF-β-induced PI3K activation 
TGFβRII was found to be constitutively associated with p85, the regulatory subunit of PI3K. 
Upon TGF-β binding of the TGF-β receptor complex, PI3K becomes activated leading the 
activation of mammalian target of rapamycin (mTOR). mTOR is a key regulator of protein 
synthesis via phosphorylation of S6 kinase (S6K) and eukaryotic initiation factor 4E-binding 
protein (4E-BP1). The activation of S6K and 4E-BP1 by mTOR enhances translational capacity 
and protein synthesis, which is important for TGF-β-induced EMT (Lamouille and Derynck, 
2007). Furthermore, activation of PI3K protects cells from TGF-β-induced apoptosis and growth 
inhibition by regulating canonical TGF-β signaling or via inhibition of the transcription factor 
FoxO, which is essentially involved in TGF-β mediated cell-cycle arrest (Conery et al., 2004; 
Gomis et al., 2006a; Remy et al., 2004; Seoane et al., 2004). 
 
1.4 Epigenetic regulation of gene transcription  
Transcriptional regulation in higher eukaryotes occurs in the context of a chromatinized DNA 
template. While genetic information provides the basic information to encode cellular contents, 
the epigenetic information defines how, when and where this information has to be used. While 
histones were historically assumed to be simply a DNA packaging material, recent years have 
witnessed several molecular pathways that modify histones and DNA in a dynamic manner. 
Indeed several recent studies established that promoter sequences in eukaryotic genomes show 
characteristic patterns of histone modifications that associate with active or inactive state of the 
linked gene (Suganuma and Workman, 2011). Such modifications of DNA that are heritable, but 
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do not involve changes in the DNA sequence are referred to as ‘epigenetic’ modifications. 
Several studies conclude that one of the main functions of epigenetic modifications is to regulate 
the accessibility of DNA for regulatory factors (Suganuma and Workman, 2011). 
 
1.4.1 Epigenetic modifications of chromatin 
The fundamental building blocks of chromatin are the nucleosomes, which consist of globular 
histone protein cores around which the DNA is wrapped 1.65 times, corresponding to 147bp of 
DNA. These histone cores are composed of an octamer with two copies of each of the four 
highly conserved canonical histones H2A, H2B, H3 and H4 (Luger et al., 1997).The individual 
histones have a positively charged globular histone-fold domain which binds to the negatively 
charged DNA via electrostatic interactions. The unstructured C- and N-terminal histone tails, 
parts of which protrude outside of the nucleosomes, are subject to various post-translational 
modifications. These modifications affect the affinity of histones to DNA, the interaction with 
neighboring nucleosomes, chromatin higher order packaging and/or the recruitment of chromatin 
binding proteins. If not further compacted, the nucleosomes are arranged in a linear fashion 
along the DNA molecule, leading to a so-called “beads-on-a-string” structure with 10-60 bp of 
“free” linker DNA between the individual nucleosomes. This form of chromatin is generally 
found at active genes. Upon incorporation of histone H1 the chromatin structure can be further 
compacted. H1 binds to the linker DNA between the nucleosomes and leads to a transcriptionally 
inert higher order structure termed 30nm fiber (Robinson and Rhodes, 2006). 
Histones contain over 60 residues under post-translational modification (PTMs) such as  
acetylation, methylation, ubiquitination, phosphorylation, sumoylation and others (Kouzarides, 
2007). The N-terminal tails of histone H3 and H4 are the major substrates for such modifications 
as these protrude out of the nucleosomes cores. This further allows PTMs to be accessible to 
non-histone proteins that recognize these modifications and are recruited to chromatin. A second 
possible regulatory role of PTMs is direct interference with binding of DNA around nucleosomes 
via altering the electric charge of histones.  
Historically, chromatin modifications and the overall chromatin structure were thought to be 
stable and simply providing a structural scaffold. The discovery of the yeast transcriptional 
coactivator Gcn5 to mediate histone acetylation (Brownell et al., 1996) and of the corepressor 
Rpd3 to mediate histone deacetylation (Taunton et al., 1996) provided the one of the first 
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evidences directly linking transcriptional regulation to histone modifications. Soon, Suv39h, a 
previously identified transcriptional regulator and suppressor of variegation in Drosophila 
(Tschiersch et al., 1994), and its yeast homolog Clr4 were identified as methylases specific for 
lysine 9 at histone H3 [H3K9; (Rea et al., 2000)]. These findings led to a new era of research 
focusing on chromatin-mediated transcription regulatory mechanisms. Importantly, the recent 
years witnessed the discovery of histone demethylases, which argued for a dynamic nature of 
PTMs (Shi et al., 2004). Some of the well-studied PTMs are discussed below.  
 
1.4.1.1 Histone Acetylation: Lysines contribute largely to the overall positive charge of histone 
octamers and thus are crucial for binding the negatively charged phosphate backbone of DNA. 
The histone-DNA interactions need to be modified in order to facilitate DNA-template processes 
such as transcription, replication and DNA repair. All four core histones bear lysine residues 
which are subject to acetylation (Figure 7) and deacetylation by specific histone 
acetyltransferases (HAT) and deacetylases (HDAC)  respectively (Kouzarides, 2007). Generally, 
lysine acetylation of histones H2B, H3 and H4 are highly correlated with transcriptionally active 
state (Pokholok et al., 2005; Schubeler et al., 2004; Wang et al., 2008). It is thought that 
acetylation of lysine neutralizes the positive charge which lowers the electrostatic interactions 
with the negatively charged phosphate backbone of DNA and thus weakens the DNA-histone 
interaction. Indeed, acetylation was shown to increase DNA accessibility, destabilize 
nucleosomes and lead to an increase of non-histone protein binding to DNA in vitro (Lee et al., 
1993; Vettese-Dadey et al., 1996; Wolffe and Hayes, 1999). Thus, it is conceivable that 
acetylation of individual lysines conveys little specificity, but rather the cumulative effect of 
acetyl groups at multiple lysines would be important for regulating DNA accessibility. 
The acetylation of lysine 16 of histone H4 (H4K16) stands as an exception, since it has been 
shown to directly interfere with higher order chromatin structure formation via preventing 
interactions between neighboring nucleosomes (Robinson et al., 2008; Shogren-Knaak et al., 
2006). H4K16 acetylation has also been shown to play a specific role in Drosophila dosage 
compensation (Bell et al., 2008; Kind et al., 2008). A number of chromatin-associated proteins 
contain highly conserved Bromodomains which specifically bind to acetylated lysines, raising 
the possibility that acetylation may have much more regulatory potential than discovered so far 
(Taverna et al., 2007). 
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However, the data suggest that an “acetylation-code” (Kurdistani et al., 2004) may not exist. 
Genomewide data revealed that histone H3 and H4 lysine acetylation marks largely overlap and 
highly correlate with transcription (Wang et al., 2008). Furthermore, genetic substitution of 
individual lysines did not produce specific phenotypes in yeast (Dion et al., 2005). Together, 
these observations argue for a model where acetylation marks seems to have an additive 
function. Noteworthy, this does not hold true for certain specific functions for a few individual 
acetylated lysines such as H4K16ac in higher order chromatin compaction (Shogren-Knaak et 
al., 2006) and H3K56ac in nucleosome assembly during DNA repair (Das et al., 2009). 
 
Figure 7: A number of distinct post-translational modifications are known to occur at the N-terminus of canonical 
histones including acetylation (ac), phosphorylation (ph), methylation (me) and monoubiquitunation. Adapted from 
Bhaumik et.al 2007. 
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1.4.1.2 Histone Phosphorylation: In contrast to our knowledge about acetyltransferases and 
deacetylases, not so much is known about the enzymes involved in other histone modifications. 
Important progress has been made, however, towards understanding the role of histone 
phosphorylation in processes such as transcription, DNA repair, apoptosis and chromosome 
condensation (Cheung et al., 2000b). 
Phosphorylation of Histone 3 Serine 10 (H3S10) is a previously described hallmark of 
condensed mitotic chromosomes, which however in contrast, is also known to associate with 
relaxed chromatin and active transcription in interphase cells (Baek; Nowak and Corces, 2004; 
Prigent and Dimitrov, 2003; Thomson et al., 1999; Zhang et al., 2006). A number of other 
signaling kinases including PIM1, IKKa, MSK1/2, PKB/Akt, and Rsk2 have previously been 
reported to modify H3S10 (Anest et al., 2003; Cerutti and Casas-Mollano, 2009; Dyson et al., 
2005; Perez-Cadahia et al., 2009; Sassone-Corsi et al., 1999; Yamamoto et al., 2003; Zippo et 
al., 2007). Upon activation in response to upstream signals, these kinases were shown to 
phosphorylate H3S10 that accompanies proper gene expression responses (Anest et al., 2003; 
Cerutti and Casas-Mollano, 2009; Dyson et al., 2005; Perez-Cadahia et al., 2009; Sassone-Corsi 
et al., 1999; Yamamoto et al., 2003; Zippo et al., 2007) in a paradigm that further applies to a 
MAP kinase, JNK, that was recently shown to directly bind chromatin and phosphorylate H3S10 
for gene activation (Tiwari et al, Nature Genetics, in press). 
A number of mechanisms have been proposed by which such phosphorylation may result in 
transcriptional activation. The addition of negatively charged phosphate groups to histone tails 
was thought to neutralize their basic charge and thus reduce their affinity for DNA. Furthermore, 
several acetyltransferases have been shown to exert increased HAT activity on serine 10-
phosphorylated substrates and that mutation of serine 10 decreased activation of Gcn5-regulated 
genes (Cheung et al., 2000c; Lo et al., 2000). This suggests that phosphorylation may contribute 
to transcriptional activation through the stimulation of HAT activity on the same histone tail. 
This is supported by the observed phosphoacetylation of histone H3 on c-fos- and c-jun-
associated nucleosomes upon gene activation (Clayton et al., 2000). Importantly, high H3 Serine 
10 phosphorylation levels during M phase block binding of the heterochromatic protein 
HP1(Fischle et al., 2005), while reduced levels of the interphase histone H3S10 kinase, JIL-1, 
leads to spreading of the major heterochromatin markers H3K9me2 and HP1 to ectopic locations 
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(Zhang et al., 2006). These findings implied that H3S10 phosphorylation prevents ectopic 
recruitment or spreading of heterochromatic factors such as HP1 and thereby contributes to an 
active transcription state. 
Phosphorylation of H2A at Serine 10 has been correlated with mitotic chromosome condensation 
(Cheung et al., 2000b). For example, mutation of serine 10 in Tetrahymena histones causes 
abnormal chromosomal condensation and defective chromosome separation during anaphase. 
The Ipl1/aurora kinase in yeast and nematodes and the NIMA kinase in Aspergillus nidulans 
were shown to regulate H3 serine 10 phosphorylation and the expression of these enzymes 
correlated with mitosis (De Souza et al., 2000; Hsu et al., 2000). Disregulation of Ipl1 or NIMA 
results in disruption of chromosome condensation or segregation during mitosis. This mark was 
shown to be dephosphorylated by the protein phosphatase Glc7/PP1 after mitosis.  
The activation of DNA-damage signaling pathways was also show to result in phosphorylation 
of histone H3. A conserved motif (ASQE, in the single-letter amino-acid code) found in the 
carboxyl terminus of yeast H2A and the mammalian H2A variant H2A.X was shown to be 
rapidly phosphorylated upon exposure to DNA-damaging agents (Downs et al., 2000; Rogakou 
et al., 1999). In yeast, Mec1 phosphorylates Serine 10 in response to damage and this is required 
for efficient non-homologous end-joining repair of DNA. This suggests that phosphorylation 
mediates an alteration of chromatin structure, which in turn facilitates repair.  
1.4.1.3 Histone Methylation: Methylation of histones can either occur at lysine or arginine 
residues (Figure 7). In contrast to acetylation, mono- (me1), di- (me2) and tri-methylation (me3) 
states of the same residue are observed. These differential methylation states present another 
level of regulatory potential which indeed appears to be exploited. Several lysines display 
diverging functions and localization in the genome depending on their methylation state (Barski 
et al., 2007; Peters and Schubeler, 2005). Arginine methylation is performed by protein arginine 
methyltransferases (PRMTs) and is antagonized by PADI4 (Klose et al., 2006; Zhang and 
Reinberg, 2001). Lysine methylation is carried out by specific lysine methyltransferases (KTMs), 
which all contain a conserved SET-domain with the exception of Dot1/KTM4 (Zhang and 
Reinberg, 2001). Lysine methylation can be removed by two distinct classes of histone 
demethylases (KDMs): the LSD1 enzyme and the JmjC protein family (Klose et al., 2006). In 
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contrast to acetylation, methylation cannot neutralize the nucelosomal charge and has been 
proposed to function via recruiting chromatin modifying and regulatory proteins. Till date, three 
protein domains have been found to specifically recognize methylated lysines: tudor-domains, 
chromo-domains and PHD-finger domains. Each domain has characteristic affinities for different 
lysines and methylation states which further depend on other domains of the respective protein 
and its interaction partners (Martin and Zhang, 2005; Taverna et al., 2007). 
Genomewide location analysis experiments have revealed that active genes are enriched with 
methylation of lysine 4 of histone H3 (H3K4), H3K36 and H3K79 (Barski et al., 2007; Pokholok 
et al., 2005; Saunders et al., 2006; Schubeler et al., 2004). In yeast, Set1 and Set2 methylate 
H3K4 and H3K36 respectively which in turn directly interact with factors bound to the Pol II 
complex (Krogan et al., 2003a; Krogan et al., 2003b). Genetic evidence also predicts a 
recruitment of Dot1 (a H3K79 KMT) to chromatin via Pol II (van Leeuwen et al., 2002). 
H3K36me and H3K79me display a broader distribution within the gene body, starting just 
downstream of the H3K4me2/3 peak (Bell et al., 2007; Wirbelauer et al., 2005). Consistent with 
a role for H3K36me in transcription, data from yeast denote that H3K36me prevents cryptic 
initiation via recruiting a histone deacetylase to the body of genes, which presumably leads to a 
less accessible chromatin structure (Carrozza et al., 2005). 
H3K4 methylation is thought to function in transcriptional activation pathways since many 
chromatin remodeling and co-activator complexes contain H3K4me2/3 recognition modules. For 
example a PHD-domain in the NURF chromatin remodeling complex specifically recognizes 
H3K4me3 and might facilitate transcriptional activation via opening the chromatin structure 
around H3K4me2/3 modified promoters (Wysocka et al., 2006). 
Inactive loci display a different set of methylation marks mainly consisting of methylation of 
H3K9, H4K20, and H3K27. H3K9 and H4K20 di- and tri-methylation play essential roles in 
heterochromatin maintenance at pericentromeric repeat regions and are further present at 
repetitive, transposable and retroviral elements in mammalian genomes (Lehnertz et al., 2003; 
Mikkelsen et al., 2007; Peters et al., 2003). Very rarely, only certain regulatory regions have 
been identified to be methylated at H3K9 and/or H4K20 and are mostly CpG-poor promoters of 
large gene families such as the olfactory receptor clusters or zinc finger proteins (Mikkelsen et 
al., 2007; Vogel et al., 2006), suggesting that  this is likely resulting from the repetitive nature of 
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their genomic organization. H3K9 methylation is carried out by 5 known KMTs with distinct 
specificities: Suv39h1 and Suv39h2 largely contribute to the methylation in constitutive 
heterochromatin in pericentric and telomeric regions. G9a, GLP and Setdb1 rather localize to 
euchromatin and have roles in silencing of repetitive and retroviral elements (Kouzarides, 2007). 
H3K9me2/3 was also shown to recruit HP1 to chromatin, which is an integral component of 
heterochromatin and essential for repression (Lachner et al., 2001). Furthermore, direct 
interactions between DNMT1 and the H3K9 KMT G9a, and between DNMT3b and HP1 have 
been reported (Esteve et al., 2006; Lehnertz et al., 2003), suggesting that H3K9 methylation 
crosstalks to DNA methylation. The interaction between DNMT3b and HP1 was shown to be 
important for a correct establishment of pericentric heterochromatin (Lehnertz et al., 2003). 
According to a model by Feldman and coworkers, G9a complex methylates H3K9, which then 
recruits HP1. Subsequently, HP1 recruits DNMTs to mediate stable repression by DNA 
methylation (Cedar and Bergman, 2009; Feldman et al., 2006). Though attractive, this model 
needs further experimental validation. H3K27 di- and tri-methylation in turn is excluded from 
regions carrying H3K9 methylation and predominantly localizes to CpG-rich regions, which 
strongly implies different functions of these two repressive histone methylation marks.  
 
1.4.2 Polycomb-mediated repression 
The Polycomb Group (PcG) and trithorax Group (trxG) of proteins are involved in defining 
cellular memory and prevent changes in cell type specific transcription programs to maintain cell 
identity (Bantignies and Cavalli, 2006; Cao et al., 2005; Cao et al., 2002; Cao and Zhang, 2004a; 
Cao and Zhang, 2004b; Jacobs and van Lohuizen, 1999; Kuzmichev et al., 2004; Negishi et al., 
2007; Vire et al., 2006). The antagonistic trithorax-group (TrxG) and Polycomb-group (PcG) 
proteins were first identified as Hox gene regulators guiding embryonic patterning in Drosophila 
(Ringrose and Paro, 2007; Schuettengruber et al., 2007; Schwartz and Pirrotta, 2007; Sparmann 
and van Lohuizen, 2006a). Remarkably, PcG proteins underwent an expansion during evolution 
of vertebrates. Many paralogs arose, which has been suggested to contribute to cell type specific 
gene regulation; an essential requirement for the observed increase in organismal complexity 
(Whitcomb et al., 2007). 
Beyond their role in embryonic development, PcG proteins have been implicated in maintaining 
pluri-potency and cell identity via repression of key developmental regulators in embryos and 
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embryonic stem (ES) cells (Bernstein et al., 2006; Boyer et al., 2006; Lee et al., 2006). PcG 
proteins have further been shown to play a role in celluar differentiation, cell fate plasticity 
(Caretti et al., 2004; Ezhkova et al., 2009; Klebes et al., 2005; Lee et al., 2005) and proliferation 
(Martinez et al., 2006). In addition, their mis-regulation is show to correlate with neoplastic 
development (Sparmann and van Lohuizen, 2006a; van Leeuwen et al., 2002). Self-renewal of 
ES cell lacking Ezh2, Eed or Suz12 is unaffected in culture, arguing that Polycomb is not 
essential for their propagation. Importantly however, all of these cells show transcriptional 
upregulation of many differentiation genes that are otherwise normally repressed by Polycomb. 
Induction of differentiation of mutant ES cells results in either death or incomplete 
differentiation to term, which is in support of the early embryonic lethal phenotypes in vivo 
(Chamberlain et al., 2008; Erhardt et al., 2003; O'Carroll et al., 2001; Pasini et al., 2007). 
Biochemical purification experiments revealed that at least two separate multimeric PcG 
complexes or Polycomb repressive complexes (PRC) with distinct enzymatic activities exist 
(Schwartz and Pirrotta, 2007; Sparmann and van Lohuizen, 2006a). PRC2 contains Ezh2 which 
mediates di/tri-methylation of lysine 27 of Histone H3 [H3K27me2/3; (Czermin et al., 2002; 
Muller et al., 2002), the hallmark of Polycomb repressed genes. PRC1 on the other hand contains 
four conserved core components and mediates H2A lysine 119 mono-ubiquitination 
[H2AK119u1; (Wang et al., 2004a)]. PRC1 is thought to cooperate with PRC2 for binding at 
target genes enriched in H3K27me3, and to mediate repression by inhibiting chromatin 
remodeling, blocking transcription and/or by mediating chromatin compaction (Levine et al., 
2004; Margueron et al., 2008). It is unclear how PRC complexes regulate gene expression, but 
their overlapping genomic distributions suggest concerted actions (Boyer et al., 2006; Ku et al., 
2008). It was also shown that PcG-silenced genes may be clustered into sub-nuclear 
compartments termed PcG-bodies which may provide a means to coordinate repression of 
multiple genes (Grimaud et al., 2006; Lanzuolo et al., 2007; Terranova et al., 2008; Tiwari et al., 
2008). 
Interestingly, in mammals Polycomb-mediated repressive H3K27me3 was shown to very often 
coincide with activating H3K4me2/3 in close proximity and this was termed  as ‘bivalent 
chromatin’ (Azuara et al., 2006; Bernstein et al., 2006; Bracken et al., 2006; Mikkelsen et al., 
2007). Such bivalency was thought to “poise” genes for activation at a later time point (Bernstein 
et al., 2006; Spivakov and Fisher, 2007). However, no solid experimental evidence exists for 
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such proposal so far. In Drosophila, PcG proteins are recruited to regulatory elements called 
PREs (Polycomb Response Elements) to silence nearby genes and argues for a DNA sequence-
dependent recruitment of Polycomb (Ringrose and Paro, 2007). In mammals, despite large scale 
mapping efforts, no such DNA sequence elements for PcG recruitment could be identified so far. 
Furthermore, Drosophila PREs are very weakly conserved at the sequence level. Together this 
may reflect that many different sequence-specific transcription factors can recruit Polycomb and 
thus, PRE sequence identification in mammals will not be feasible. In support of this, the 
transcription factor Snail1 was shown to recruit Polycomb proteins to the E-cadherin promoter 
coinciding with its transcriptional silencing in cancer cells (Herranz et al., 2008). 
In addition to PcG targeting in mammals, the propagation of H3K27me3 and PcG complexes 
during replication is equally not understood. PRC2 was shown to directly bind to H3K27me3, 
thereby ensuring propagation of the mark during mitosis (Hansen et al., 2008). PRC1 was also 
show remain bound to the DNA during replication in an in vitro system (Francis et al., 2009). 
Despite these findings, the propagation of H3K27me3 and PcG complexes in vivo remains to be 
investigated in detail. A number of reports suggest interplay between the Polycomb pathway and 
DNA methylation. Ezh2 was show to recruit DNMT1 in cancer cell lines by a direct interaction 
(Vire et al., 2006), which however stays controversial due to non-reproducibility in non-
transformed cells. In addition, several recent studies suggested preferential aberrant DNA 
methylation in human cancer cell lines and primary cancers at promoters that are Polycomb 
targets in unrelated human ES cells in culture (Ohm et al., 2007; Schlesinger et al., 2007; 
Widschwendter et al., 2007). These studies suggest that a potential targeting pathway of DNMTs 
via Polycomb may exist, however no direct conclusive evidences exist so far. 
1.4.2.1 Polycomb and EMT 
The components of both Polycomb repressive complex1 and Polycomb repressive complex 2 are 
implicated in EMT. PRC1 complex comprises Bmi-1, Ring1, Hph1/2/3, and Hpc1/2/3 (Cao and 
Zhang, 2004a; Cao and Zhang, 2004b; Sparmann and van Lohuizen, 2006a) and PRC2 complex 
comprises Ezh2, Eed, Suz12, RbAp46/48 and Aebp2 (Cao and Zhang, 2004a; Cao and Zhang, 
2004b; Schuettengruber et al., 2007; Sparmann and van Lohuizen, 2006a). The PRC1 protein B 
lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) was the first reported PcG protein to 
be associated with cancer development and later on with EMT. Bmi-1 can inhibit c-Myc induced 
   Introduction 
 
 47  
 
apoptosis via Ink4a/Arf and regulate cell proliferation and senescence (Jacobs et al., 1999a; 
Jacobs et al., 1999b). Bmi-1 directly binds to Ink4a-Arf locus and represses it. Ink4a and Arf 
play a role to restrict cellular proliferation in response to aberrant mitogenic signaling. Ink4a is a 
cyclin-dependent kinase inhibitor and it can activate the Rb pathway. Arf can inhibit Mdm2 
function to induce p53. In many types of tumors, the Ink4a/Arf locus is found to be mutated, 
deleted or epigenetically silenced. Furthermore, Bmi-1 depletion leads to death of embryonic 
carcinoma stem cells as well as neuroblastoma cells (Cui et al., 2007). Recently, it has been 
demonstrated that over-expression of Bmi-1 leads to EMT, and its blockage prevents EMT 
driven-invasion. To elicit its function, Bmi-1 targets the tumor suppressor Pten and 
downregulates its expression. This all contributes toward the activation of the PI3K/Akt 
pathway, stabilization of Snail and downregulation of E-cadherin (Song et al., 2009). In addition, 
Bmi-1 is essential for Twist-1-induced EMT and both of them are cooperatively required for 
repression of E-cadherin and p16INK4a, which is a cyclin kinase inhibitor, in head and neck 
carcinoma. Thus, Twist1 and Bmi1 were needed together to promote EMT and tumor-initiating 
capabilities (Yang et al., 2010b). Another PRC1 protein, Ring1, was also shown to interact with 
Bmi-1, and overexpression of Ring1 represses Engrailed and increases expression of c-Jun and c-
Fos. Furthermore, Ring1 induces anchorage-independent growth of Rat1a and NIH3T3 cells, and 
overexpression of Ring1 can form tumors in nude mice (Ben-Saadon et al., 2006). 
Components of the PRC2 complex are extensively studied in cancer, especially Ezh2, which is a 
catalytic subunit of PRC2. Among tumors of epithelial origin, Ezh2 was first observed to be 
significantly associated with metastatic prostate cancer. It has been shown that Ezh2 is 
overexpressed with Bmi-1 in prostate metastatic precursor cells (Berezovska et al., 2006). 
Berezovska et al. demonstrated a marked enrichment of the population of circulating human 
prostate carcinoma metastasis precursor cells with dual-positive high-Bmi1/Ezh2-expressing 
cells. Importantly, depletion of Bmi1 or Ezh2 in prostate carcinoma metastasis precursor cells 
diminishes their tumorigenic, metastatic and proliferation potential when injected into mice 
(Berezovska et al., 2006). Adrb2, a target of Ezh2 and a G-protein-coupled receptor (GPCR) of 
the β-adrenergic signaling pathway, has been implicated in EMT (Yu et al., 2007). 
Overexpression of Ezh2 can repress Adrb2 at both the transcript and the protein levels and the 
recently discovered Ezh2 inhibitor, DZNep (Tan et al., 2007), can prevent Adrb2 repression by 
Ezh2. Downregulation of Adrb2 blocks EMT and prevents tumor growth in a xenograft model of 
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prostate cancer.  In addition, Ezh2 also targets E-cadherin for repression. This Ezh2-mediated 
repression could be inhibited by the HDAC inhibitor SAHA. Furthermore, co-expression of E-
cadherin can attenuate Ezh2-mediated invasion in prostate and breast epithelial cells, indicating 
that E-cadherin is an important target of Ezh2 in cancer progression (Rhodes et al., 2003). These 
results are similar to ES cell data where Ezh2 is required for ES cell pluripotency and 
differentiation by repressing E-cadherin. Moreover, Zeb2, another EMT inducer, is subjected to 
post-translation regulation by PRC2 where sumoylation impairs its repressor activity (Long et 
al., 2005). It is also shown that ZEB1 represses E-cadherin and induces EMT by recruiting the 
Swi/Snf chromatin-remodeling protein Brg1, the ATPase subunit of the Swi/Snf chromatin-
remodeling complex (Sanchez-Tillo et al., 2010). Recently, it has been reported that Snail1- 
mediated repression of E-cadherin is PRC2-dependent in ES cells and that depletion of Suz12, 
one of the components of PRC2, leads to partial de-represison of the E-cadherin promoter by 
Snail1. This study also showed that Snail1 interacts with Suz12 and Ezh2 and increases the 
binding of Suz12 at the E-cadherin promoter (Herranz et al., 2008).  
E-cadherin is not the only gene regulated by PRC2. Another EMT gene, β4 integrin has been 
shown to be controlled by Polycomb-mediated histone modifications. The expression of β4 
integrin is lost during EMT and this loss correlates with a decrease in active histone 
modifications H3K9Ac and H3K4me3 and an increase in the repressive histone modification 
H3K27me3. Furthermore, reversal of EMT leads to re-expression of β4 integrin and restoration 
of active marks. These results argue for a dynamic nature of epigenetic regulation during fate 
changes of epithelial cells (Yang et al., 2009). 
The most recent work by McDonald and colleagues studied the role of another repressive mark 
H3K9me2 and activating mark H3K4me3 during EMT. They showed a global reduction in 
heterochromatin, measured by the repressive mark H3K9me2, and increased levels of 
euchromatin, measured by the active mark H3K4me3, during EMT.  The authors further 
demonstrate that these changes are largely dependent on lysine-specific demethylase-1 (Lsd1) 
and depletion of Lsd1 prevents TGF-β-induced migration and chemoresistance.  Interestingly, all 
these chromatin changes are associated with so-called LOCKs, which is an acronym for ‘Large 
Organized Heterochromatic K9 modifications’ regions (McDonald et al., 2011a). 
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1.4.3. DNA methylation 
The best understood epigenetic modification of DNA in mammals is methylation of cytosine at 
position C5 in CpG dinucleotides. The mammalian DNA methylation machinery has two 
constituents, the DNA methyltransferases (DNMTs), which establish and maintain DNA 
methylation patterns, and the methyl-CpG binding proteins (MBDs), which ‘read’ these 
methylation marks (Goll and Bestor, 2005; Wade, 2001). 
Passive DNA demethylation has long been known to occur by a reduction in activity or absence 
of DNA methyltransferases (DNMTs). Recently, three enzyme families have been implicated in 
active DNA demethylation via DNA repair (Bhutani et al., 2011). First, 5-methylcytosine (5mC) 
can be hydroxylated by the ten-eleven translocation (TET) family of enzymes to form 5-
hydroxymethylcytosine (5hmC) or further oxidized to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). Second, 5mC (or 5hmC) can be deaminated by the AID/APOBEC 
family members to form 5-methyluracil (5mU) or 5-hydroxymethyluracil (5hmU). Third, 
replacement of these intermediates (i.e., 5mU, 5hmU, or 5caC) is initiated by the UDG family of 
base excision repair (BER) glycosylases like TDG or SMUG1, culminating in cytosine 
replacement and DNA demethylation. 
DNA methylation is crucially involved in regulating many cellular processes including 
embryonic development, transcription, chromatin structure, X chromosome inactivation, 
genomic imprinting and chromosome stability. In normal cells, DNA methylation occurs 
predominantly in repetitive genomic regions, including satellite DNA and parasitic elements 
(such as long interspersed transposable elements (LINES), short interspersed transposable 
elements (SINES) and endogenous retroviruses). Approximately 60-90% of all CpG sequences 
in the genome are methylated, while unmethylated CpG dinucleotides are mainly clustered in the 
CpG rich sequence termed ‘CpG islands’ which are mostly associated with promoter regions of 
active genes. CpG dinucleotides are under-represented in the mammalian genome due to the 
conversion of methylated cytosine to thymidine via spontaneous deamination, followed by 
stabilisation of the genome during replication in the germline. CpG islands, particularly those 
associated with (housekeeping mainly) promoters, are generally unmethylated, although an 
increasing number of exceptions are being identified. Specific cis-acting sequences seem to 
protect them from a global wave of de novo methylation occurring during reprogramming event 
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at the time of implantation. DNA methylation usually represses transcription directly, by 
inhibiting the binding of specific transcription factors. For example, the abnormal methylation 
that occurs on the fragile X mental retardation 1 (FMR1) promoter prevents binding of nuclear 
respiratory factor (NRF1; also known as α-PAL) and inhibits transcription of this gene, causing 
fragile X syndrome (Bardoni and Mandel, 2002). It could also cause transcriptional suppression 
indirectly, by recruiting methyl-CpG-binding proteins and their associated repressive chromatin 
remodeling activities such as histone deacetylases (HDACs) and histone methyl transferase 
(HMTs) that alters the local chromatin environment (Eden et al., 1998). Methylation can also 
affect nucleosomal positioning (Razin and Cedar, 1977). It could also lead to a general decrease 
in DNase I sensitivity and alteration in higher order structure (Eshet et.al, 1986) that makes these 
regions less accessible to the transcription machinery. Recently, it was shown that proximal 
sequence elements are both necessary and sufficient for regulating DNA methylation (Lienert et 
al., 2011). However, general principles of how DNMTs are targeted to specific regions are still 
not known; even though there are some observations suggesting that this may involve 
interactions between DNMTs and one or more chromatin-associated proteins. DNA methylation 
patterns are established by de novo DNMTs active on unmethylated DNA (de novo methylation) 
and then this pattern is maintained through replication by a semiconservative mechanism for 
copying the methylation residues from parental strands onto the newly synthesized nascent DNA 
by maintenance DNMTs specific for the hemi-methylated DNA resulting from replication 
(maintenance methylation). The phenotypes of some selected mouse mutants of epigenetic 
regulatory factors are listed below in Table 3. 
There are several indications that DNA methylation and histone methylation are intimately 
linked and may control each other, but it stays unclear which one comes first due to reports from 
both ways (Cedar and Bergman, 2009; Vaissiere et al., 2008). Aberrations in DNA methylation 
patterns such as promoter CpG island hypermethylation of tumor suppressor genes, which results 
in their silencing, are accepted as being a common feature of human cancer (Berdasco and 
Esteller, 2010). Such CpG island promoter hypermethylation affects genes from a wide range of 
cellular pathways, such as cell cycle, DNA repair, toxic catabolism, cell adherence (including 
Cdh1), apoptosis, and angiogenesis, among others (Esteller, 2008a), and may occur at various 
stages in the development of cancer. During the last few decades, an increasing number of drugs 
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Table 3. Key epigenetic regulatory proteins, their function and mutant phenotype [Adapted from 
Jaenisch R and Bird A 2003 (Jaenisch and Bird, 2003)]. 
Protein Function Mutant Phenotype 
Methyltransferases   
Dnmt1 Maintenance of methylation Embryonic lethal, loss of 
imprinting and X-linked gene 
expression, ES cells viable 
Dnmt1o Oocyte-specific isoform Loss of material imprint 
Dnmt2 Non-CpG methylation in 
Drosophila 
No phenotype 
Dnmt3a, Dnmt3b De novo methyltransferases, 
establishment of methylation 
Embryonic lethal, ICF 
syndrome 
Dnmt3L No catalytic activity, 
colocalizes with Dnmt3a and 
Dnmt3b 
Abnormal maternal imprinting 
Methyl binding proteins   
MeCP2 Methyl binding proteins, 
recruit HDACs 
RTT 
MBD1 Methyl binding proteins, 
recruit HDACs 
 
MBD2 Methyl binding proteins, 
recruit HDACs 
Behaviour abnormalities 
MBD3 Methyl binding proteins, 
recruit HDACs 
Lethal 
MBD4 Repair enzyme Increased mutation frequency 
Histone-modifying proteins   
HDAC1 Histone deacetylase Embryonic lethal 
Suvar39 Lys9 methylation in histone H3 Embryonic lethal, 
chromosomal instability, 
increased tumor risk 
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targeting DNA methylation have been developed for epigenetic therapy and a few are in clinical 
trials (Yang et al., 2010c). One example of this success is the earliest and the most successful 
epigenetic drug to date, 5-Azacytidine, which is currently, recommended as the first-line 
treatment of high-risk myelodysplastic syndromes (MDS). 
1.4.3.1 DNA methylation and EMT 
In recent years, it has become evident that genomic regulation is not the only mechanism that 
governs anomalous gene expression during tumor progression. Epigenetic modification, 
especially DNA methylation, seems to play a widespread role during carcinogenesis. Anomalous 
hypermethylation of promoter CpG islands is an important means of repressing tumor suppressor 
genes.  Initially, E-cadherin promoter methylation was observed in primary prostate cancers and 
breast cancer lesions where E-cadherin silencing can be de-repressed by treatment with the 
demethylating agent 5’-aza-2’-deoxycytidine (5’-aza) (Graff et al., 1995; Yoshiura et al., 1995). 
Following those primary studies, E-cadherin repression and DNA hypermethylation was 
observed in many different kinds of carcinomas. 
To define the mechanism underlying E-cadherin promoter methylation, two models were 
proposed. According to the first model, Snail expression is co-related with the silencing of E-
cadherin and the hypermethylation of its promoter, suggesting a role for Snail in the coordination 
of both processes (Cheng et al., 2001). On the other hand, the second model proposed that the 
silencing of E-cadherin is not always correlated with promoter hypermethylation, indicating the 
involvement of additional genetic and epigenetic modifications are required for E-cadherin 
downregulation. In addition, DNA methylation and histone deacetylation are correlated with 
transcriptional repression. Several co-repressor complexes have recently been described that can 
be recruited to the E-cadherin promoter by different repressors such as Snail-mediated 
recruitment of a mSin3a/Hdac1/2 complex (Peinado et al., 2004) or of δEf1/Sip1 (Shi et al., 
2003) with ctbp complex, containing several Hdacs and Dnmts. In addition, hypermethylation of 
8 tumor suppressor genes (APC, BIN1, BRCA1, CST6, GSTP1, P16, P21 and TIMP3) was 
observed in plasma of the breast cancer patients which allowed the development of blood based 
tests as a predictive and prognostic biomarkers for breast cancer (Radpour et al., 2011). 
 
1.5 MARA 
   Introduction 
 
 53  
 
MARA stands for “Motif Activity Response Analysis”. MARA models gene expression profiles 
across a set of samples in terms of the predicted transcription factor binding site (TFBS) and 
infers which transcription factors (TFs) are the key regulators that drive gene expression changes 
across the samples, how each regulator changes its activity across the samples, and what are the 
genome-wide targets of each regulator. It benefits from two key resources. First, MARA uses 
‘promoteromes’, i.e. genome-wide promoter annotations, in human and mouse constructed from 
genome-wide transcription start site data that was obtained using next-generation sequencing  
(Balwierz et al., 2009). Second, it uses Bayesian probabilistic methods for predicting functional 
TFBSs by integrating rigorous models of TFBS evolution with comparative genomic sequence 
analysis. The MotEvo algorithm (van Nimwegen, 2007) is used to predict functional TFBSs for 
all regulatory motifs across all promoters in human and mouse. The result of this analysis was, 
for both human and mouse, a large matrix N, where Npm is the predicted total number of 
functional binding sites in promoter p for motif m. 
1.5.1 Model 
The model follows the approach of Bussemaker et al. (Gao et al., 2004) of assuming that the 
expression at each promoter p can be modeled as a linear function of the binding sites Npm . 
Specifically, if we denote by Eps the log-expression of promoter p in sample s, we assume the 
following model where cp is a term reflecting the basal activity of promoter p, cs reflects the total 
expression in sample s, and Ams is the (unknown) activity of motif m in sample s. That is, using 
the predicted site-counts Npm and the measured expression levels Eps we use this approximation 
to infer the activities Ams of all motifs across all samples. 
1.5.2 MARA Outputs 
The results include an ordered list of regulatory motifs and corresponding TFs, sorted by a z-
value that quantifies the importance of the motif in explaining observed expression changes. For 
each motif, MARA also provides an activity-profile across all input samples which quantify how 
much the corresponding TFs are driving the expression of their targets in each sample. In 
addition, MARA predicts a list of target promoters for each motif, as well as the binding sites in 
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the promoters through which the corresponding the binding TFs are predicted to act. Finally, to 
functionally characterize the role of each regulatory motif, MARA reports the functional gene 
ontology categories that are enriched among the targets, and provides links to the String data-
base network representations of the predicted targets of each regulator.
Aims of the study 
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2.0 Aims of the study 
Epithelial-mesenchymal transition (EMT) is a critical process underlying the onset of cancer cell 
invasion and has been identified at the invasive front of murine and human tumors. Hence, the 
identification of reliable prognostic markers and the intervention with EMT driven invasion is of 
major interest in cancer diagnostics and therapy. To achieve these goals, we need to gain new 
and detailed insights into the molecular processes regulating EMT. For this purpose, we induced 
EMT in different in vitro model systems and followed changes in gene expression profile to 
investigate: 
• Master regulatory genes underlying EMT 
• Cell biological processes controlled by these master regulators 
• Requirement of these master genes in tumor progression and metastasis formation in vivo 
• Possibility of these master regulators to act as potential markers for invasion and 
metastasis in human tumors 
• If these master regulators are under control of epigenetic mechanisms 
Here, we studied two transcription factors, namely Klf4 and Sox4 for their role in EMT by 
investigating the cell biological functions they control and their contribution to tumor 
progression and metastasis formation in vivo. In the last part of the thesis, using genomewide 
approaches, we studied the contribution of the Polycomb machinery and DNA methylation to the 
transcriptional reprogramming that accompanies EMT.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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3.0 Results 
 
3.1 Klf4 directly regulates transcription of genes crucial for Epithelial to Mesenchymal 
transition 
Neha Tiwari, Phil Arnold, Erik Van Nimwegen and Gerhard Christofori 
Manuscript in preparation 
 
3.1.1 Abstract 
Krupple-like factor 4 (Klf4) is a zinc-finger transcription factor that is abnormally expressed in 
diseased state including cancer. However, its regulatory role during carcinogenesis remains 
unclear. Using a genome-wide expression profiling approach, we uncovered Klf4 among the 
transcription factors that were significantly downregulated during TGF-β-induced Epithelial to 
Mesenchymal Transition (EMT) in NMuMG cells. Although Klf4 expression is diminished 
during EMT, its activity, as predicted by MARA analysis, goes up arguing for the regulatory role 
of Klf4. Gain of function experiments demonstrate that Klf4 is not only inhibitory to EMT and 
migration but also acts as a survival factor during this process. To reveal how its DNA binding 
activity may be related to the phenotype, we performed chromatin immunoprecipitation followed 
by deep-sequencing (ChIP-seq) to identify promoters genomewide that are occupied by Klf4. 
Interestingly, this analysis revealed Klf4 binding to the promoter of key EMT genes, including 
N-cadherin, Vimentin, β-catenin and Mapk8 (encoding Jnk1). In line with these observations, the 
depletion of endogenous KLF4 deregulated a number of Klf4 target genes, suggesting a direct 
transcriptional control by Klf4. One such target gene, Jnk1, is transcriptionally upregulated upon 
Klf4 depletion as well as during TGF-β-induced EMT that also accompanies substantial decrease 
in Klf4 levels. Knockdown of Jnk1 not only counteracted TGF-β-induced EMT but also Klf4 
depletion-induced apoptosis and cell migration. These observations reveal a critical role of Klf4 
as a tumor suppressor by direct targeting key EMT gene promoters for transcriptional regulation.  
3.1.2 Introduction 
Solid tumors are epithelial in origin. A loss of epithelial-cell markers and gain of mesenchymal-
cell markers has been observed in patient tumor samples, particularly at the leading edge or 
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invasive front of solid tumors such as non-small cell (NSCLC), pancreatic, colorectal, and 
hepatocellular cancers and this process defined as ‘Epithelial to Mesenchymal Transition’ (EMT) 
constitutes a key step during carcinogenesis. Such changes in phenotypic epithelial-like and 
mesenchymal-like cellular markers have been associated with the degree of tumor progression 
(Brabletz et al., 2005; Christofori, 2006; Grunert et al., 2003; Huber et al., 2005; Thiery and 
Sleeman, 2006). The mechanism underlying EMT and contribution of critical transcription 
factors to this process remains elusive. 
Krupple-like factor 4 (Klf4) is a zinc-finger transcription factor which is usually expressed in 
growth arrested cells, colon, small intestine, testis and lung (Shields et al., 1996). Klf4 -/- mice 
die shortly after birth due to loss of skin barrier function, as measured by penetration of external 
dyes and rapid loss of body fluids (Segre et al., 1999). The defect was not corrected by grafting 
of Klf4 -/- skin onto nude mice (Segre et al., 1999).  This protein has been implicated to be an 
activator as well as repressor at the promoter of various genes in a context-dependent manner 
(Rowland et al., 2005). Various previous studies as well as Oncomine and Nextbio databases 
report Klf4 to be downregulated in cancers of different types (Dang et al., 2000; Katz et al., 
2005; Ohnishi et al., 2003; Shie et al., 2000; Ton-That et al., 1997; Wei et al., 2005; Zhao et al., 
2004). On the contrary, it is also been shown to be upregulated in a large fraction of mammary 
carcinoma and squamous-cell carcinomas of the oropharynx (Foster et al., 2000). Klf4 is 
proposed to execute its oncogenic activity by directly binding to and repressing the p53 
promoter. In contrast, it can also act as a tumor suppressor by binding to p21 promoter for its 
activation (Rowland et al., 2005). Klf4 is further implicated to play a role in EMT (Yori et al., 
2010), however the underlying mechanisms remain largely unclear. Interestingly, a number of 
recent studies have identified Klf4 as one of the crucial factors, in addition to Oct4, Sox2 and c-
Myc, for the derivation of induced pluripotent cells (Takahashi and Yamanaka, 2006). It was 
further shown that the transcription factors Oct4, Sox2, c-Myc, and Klf4 can induce epigenetic 
reprogramming of a somatic genome to an embryonic pluripotent state (Wernig et al., 2007).  
The mitogen-activated protein kinases (Mapks) are a family of serine-threonine protein kinases 
that participate in various signaling pathways and are crucial for cellular responses to 
extracellular stimuli. One such MAP kinase, Jnk, is activated primarily by cytokines and stress 
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such as UV. Exposure to UV light leads to Jnk1 phosphorylation at serine-63 and serine-73 
residues (Derijard et al., 1994). Such activation of Jnk is required for UV-induced apoptosis in 
primary murine embryonic fibroblasts and the absence of Jnk caused a defect in the 
mitochondrial death signaling pathway, including the failure to release cytochrome c (Tournier et 
al., 2000). NFκB-mediated signaling cascade can downregulate Jnk1 via Gadd45b and regulates 
TNFR-induced apoptosis (De Smaele et al., 2001). Not only this, Jnk1 has also been previously 
implicated in EMT (Alcorn et al., 2008; Santibanez, 2006a; van der Velden et al., 2010). In line 
with these observations, Jnk1 can phosphorylates paxillin , a focal adhesion adaptor, required for 
maintaining the labile adhesions required for rapid cell migration (Huang et al., 2003). Jnk1-null 
mice exhibited progressive loss of microtubules within axons and dendrites due to 
hypophosphorylation of Map2, which reduced the ability of Map2 to bind microtubules and 
promote tubulin polymerization (Chang et al., 2003). 
Using a genomewide transcription profiling approach, we identified a comprehensive list of 
genes at six consecutive morphological states (1 day, 4 days, 7 days, 10 days and 20 days) during 
TGF-β-induced EMT in normal mammary epithelial cells [NMuMG; (Lehembre et al., 2008)]. 
The resulting datasets were computationally analysed to identify differentially regulated genes at 
each stage. We next searched for motifs for various transcription factors at the promoter of 
regulated genes (http://test.swissregulon.unibas.ch/cgi-bin/mara) and predicted a number of 
transcription factors that may possibly regulate a subset of genes in the early, intermediate and 
later stages (data not shown). Klf4 was discovered as one of such factor that might contribute to 
transcriptional regulation of certain genes during TGF-β-induced EMT in NMuMG cells.  This 
was especially interesting given the previous suggestions for an involvement of Klf4 in cellular 
transformation and motivated us to investigate the role of this transcription factor in EMT.  
Here we show that Klf4 not only blocks epithelial differentiation but also provides a survival 
advantage to the cells. Moreover, Klf4 functions inhibitory to cell migration. A combinatorial 
approach of genomewide transcription profiling after Klf4 depletion in the presence or absence 
of TGF-β, and identification of genomewide target promoters of Klf4 occupancy using ChIP-seq 
analysis, revealed many key EMT genes that are under direct transcriptional control by Klf4, 
such as N-cadherin, Vimentin and β-Catenin. Furthermore, we also show how through one of 
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such targets, Jnk1, Klf4 regulates EMT. Along with this, we also found Klf4 to be regulated by 
canonical TGF-β signaling via Smad4.  
3.1.3 Results 
3.1.3.1 Identification of Klf4 as a repressor during EMT 
To decipher gene regulatory mechanisms underlying epithelial to mesenchymal transition during 
the early, intermediate and later stages of breast carcinogenesis, we employed an established 
model of EMT in the untransformed normal murine mammary gland cell line NMuMG 
(Lehembre et al., 2008; Miettinen et al., 1994), which undergoes progressive EMT upon TGF-β 
treatment and acquires a complete mesenchymal morphology by the end point, usually involving 
10 days for this full morphological transition (Figure 1)  (Lehembre et al., 2008; Piek et al., 
1999b). We performed a genome wide expression analysis of non-treated cells as well as those 
treated with TGF-β for 1, 4, 7, 10 and 20 days to identify differentially expressed genes at the 
respective stages. We then employed the MARA tool (http://test.swissregulon.unibas.ch/cgi-
bin/mara) on the resulting gene list to search for transcription factor motifs for various 
regulatory factors at the promoters of modulated genes. This analysis revealed a set of 
transcription factors that possibly regulate the transcription of a subset of genes in the early, 
intermediate and later stages by a direct control of their promoter activity (data not shown). Klf4 
was identified as one of such factors whose motif was found enriched at a number of genes that 
were modulated in transcription during TGF-β-induced EMT. MARA analysis predicted an 
increase in Klf4 activity during EMT (Figure 1a). Since quantitative RT-PCR revealed that Klf4 
itself is downregulated during EMT (Figure 1b), we speculated for a repressive function of Klf4 
during this transition. Western blot analysis further confirmed RNA level analysis that Klf4 
levels are severely downregulated during EMT (Supplemental Figure S1). We further validated  
these observations in a murine breast cancer line, Py2T cell line, which is also responsive to 
TGF-β and undergoes EMT similar to NMuMG cells (Waldmeier et. al, unpublished) and in a 
human breast cancer line, MCF7, which undergoes EMT upon stable depletion of E-Cadherin 
[(Lehembre et al., 2008); Figure 1c and 1d]. Together these findings suggested a suppressive role 
of Klf4 during EMT. 
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3.1.3.2 KLF4 blocks epithelial differentiation  
To directly assess the role of Klf4 in EMT, we first performed loss of function studies. We 
knocked down Klf4 efficiently both in the absence and presence of TGF-β using a pool of two 
Klf4 siRNAs (Figure 2a). Depletion of Klf4 in the absence of TGF-β did not lead to any 
noticeable changes in cell morphology other than a slight increase in cell size accompanied with 
 
Figure 1: Klf4 acts as repressor during TGF-β-induced EMT. (a) MARA analysis predicts Klf4 activity during 
EMT in NMuMG cells. (b) RT-qPCR analysis for quantification of Klf4 expression levels in NMuMG cells during 
TGF-β mediated EMT. (c) RT-qPCR for quantification of Klf4 levels upon EMT induction in Py2T cells. (d) 
- 
- 
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Expression levels of Klf4 as quantified by RT-qPCR in control and E-cadherin-specific shRNA treated MCF7 cells. 
Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 
0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
minor flattening (Figure 2a). Although no major morphological changes were apparent after Klf4 
knockdown in the absence of TGF-β, immunoflourescence analysis revealed an increase in the 
expression of mesenchymal markers like N-cadherin and Vimentin (Figure 2b). In addition, focal 
adhesion formation was greatly increased with the induction in stress fibers formation. On the 
other hand, epithelial markers such as adherent junction protein E-cadherin were slightly 
downregulated and distorted from the membrane. Interestingly, Klf4 knockdown in the presence 
of TGF-β, sped up the EMT process and the cells became more elongated, spindle-shaped and 
fibroblast-like even after 2 days of TGF-β treatment and gave morphological appearance similar 
to wild type NMuMG cells treated with TGF-β for 10 days (Figure 2a). This accompanied 
appropriate changes in key EMT markers such as increase in vimentin  and N-cadherin 
expression and complete loss of E-cadherin from the membrane within 2 days of TGF-β 
treatment in Klf4 knockdown cells, in line with the classical cadherin switch observed during 
EMT (Hazan et al., 2004; Maeda et al., 2005). Furthermore, phalloidin staining revealed an 
increased stress fiber formation upon Klf4 knockdown (Figure 2b). Notably, Klf4 depletion in 
NMuMG cells treated with TGF-β for 15 days had similar effect and led to acceleration of EMT 
process, demonstrating that Klf4 is not only inhibitory to initiation but also for the maintenance 
of EMT (Figure 2a). All of these results were further confirmed in a different breast cancer 
model of Py2T cells (Supplemental Figure S2a, Supplemental Figure S2b). Together, these 
results argue for a role of KLF4 in maintaining epithelial morphology and an inhibitory action in 
EMT. 
3.1.3.3 Klf4 prevents cell migration and provides survival advantage to the cells during 
EMT  
Tumor cells dissolve their cell-cell contacts and undergo EMT so as to leave the primary tumor 
and invade into the surrounding tissue. This process furthers facilitate the migration of tumor  
                                                                                 Klf4 directly regulates transcription of genes crucial for  
                                                                                                                  Epithelial to Mesenchymal transition 
 
 62  
 
 
Figure 2: Depletion of KLF4 induces epithelial differentiation. (a) qRT-PCR was performed after siRNA 
mediated knockdown of Klf4 in the absence and presence of TGF-β to assess the knockdown efficiency. Cells were 
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treated with TGF-β for 2 days and 15 days. Morphology of NMuMG cells transfected with either control or Klf4-
specific siRNA in the absence as well as presence of TGF-β, as evaluated by phase contrast microscope. Original 
magnification was 10X. (b) Immunoflorescence stainings for adherent junction protein, E-cadherin and N-cadherin, 
tight junction protein ZO-1, intermediate filamentous protein vimentin, focal adhesion protein paxillin and actin 
cytoskeleton protein phalloidin were performed after Klf4 knockdown in the absence and presence of TGF-β. 
Original magnification was 40X. Cells were treated with TGF-β for 2 days. Statistical values were calculated by 
using an unpaired, two-tailed t-test.  p-value ≤ 0.001 indicated with (***). 
 
 
cells to neighboring blood vasculature and the distant organs to form metastasis (Brabletz et al., 
2005; Christofori, 2006; Grunert et al., 2003; Huber et al., 2005; Thiery and Sleeman, 2006; 
Yilmaz and Christofori, 2010).  Since migration constitutes such a key step in forming metastasis 
via EMT, we assessed the migratory capacity of Klf4 knockdown cells. Wound healing assay 
revealed that Klf4-depleted NMuMG cells migrated significantly faster than control counterpart 
even in the absence of TGF-β (Figure 3a). We further validated these results by performing a 
scratch wound healing assay in cells stably knocked down for Klf4 and found similar results 
(Figure 3b). Moreover, transwell migration assays with these cells revealed a significantly higher 
chemo-tactic migration of Klf4 knockdown cells compared to control cells both in the absence 
and presence of TGF-β (Figure 3c and 3d). These studies were repeated in Py2T cells which 
further confirmed and validated the above findings (data not shown). 
Klf4 has been shown to inhibit proliferation and promote differentiation of skin and colonic 
epithelium (Segre et al., 1999; Shie et al., 2000).  Thus, we next investigated whether Klf4 
depletion can affect the proliferation and survival during EMT in NMuMG cells. It was 
surprising that the loss of Klf4 led to a decrease in growth of NMuMG cells after treatment with 
TGF-β. On the other hand, we didn’t observe any changes after Klf4 knockdown in the absence 
of TGF-β. To determine whether this effect was due to alterations in proliferation, or changes in 
apoptosis profile, we performed a proliferation assay using propidium iodide staining as well as 
an apoptosis assay using Annexin V staining. In comparison to control siRNA treated cells, a 
significant G0/G1 blockade was observed upon Klf4 depletion in the presence of TGF-β for 
2days and 4 days (Figure 3e). We observed a similar effect in proliferation assay (Figure 3f). In 
addition, there was increased apoptosis upon Klf4 depletion after treatment with TGF-β for 2  
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Figure 3: KLF4 inhibits migration and provides a survival advantage during TGF-β-induced EMT. (a) 
Following siRNA-mediated ablation of Klf4 in the absence of TGF-β, wound healing assays were performed after 
19 hours of wound creation. (b) Wound healing assay was performed in stably transfected Klf4-ablated cells. 
Pictures were taken at 0 hour and 19 hours after wound creation. (c) shRNA-mediated Klf4 depleted cells were 
subjected to Boyden chamber migration assays for 20 hours using 20% FBS as a chemoattractant in the absence of 
TGF-β. (d) Boyden chamber migration assays were carried out in stably transfected Klf4 depleted cells in the 
presence of TGF-β. 20% FBS was used as a chemoattractant. (e) Cell cycle analysis was done after transient 
knockdown of Klf4 during EMT for 0, 1 and 4 days by FACS. Propidium Iodide (PI) was used for the staining. (f)  
Proliferation assays were performed after siRNA-mediated knockdown of Klf4 during a TGF-β time-course. Cells 
were counted by using a Neubauer counting chamber. (g) Annexin V staining was performed by FACS to quantify 
cell death in Klf4 knockdown cells during TGF-β-induced EMT for 0, 2 and 15 days. Statistical values were 
calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with 
(**), p-value ≤ 0.001 indicated with (***). 
 
days or 15 days (Figure 3g). Thus, the TGF-β sensitive growth of Klf4 knockdown cells depends 
on both decreased proliferation and increased apoptosis during EMT. We further extended our 
studies to Py2T cells and found that unlike NMuMG cells, these cells do not undergo apoptosis 
during TGF-β treatment suggesting that the apoptotic phenotype is biased toward untransformed 
cells. We did observe a significant increase in apoptosis after Klf4 knockdown in Py2T cells, 
however, the fractions were not as substantial as NMuMG cells (Supplemental figure S3a). 
Furthermore, we could not notice any significant difference in cell cycle profiling after Klf4 
depletion during TGF-β time-course (Supplemental figure S3b). 
Together, these results reveal an inhibitory role for Klf4 in migration as well as supporting role 
for Klf4 in proliferation and G1/S phase progression of non-transformed mammary epithelial 
cells and in cell survival during TGF-β-induced EMT. 
3.1.3.4 Klf4 over-expression prevents EMT 
Given the above findings, we next asked whether the forced expression of Klf4 could have an 
inhibitory effect on EMT.  We generated NMuMG cells expressing a Klf4-ER fusion protein 
(Foster et al., 2005) where the Klf4-ER fusion protein translocates to the nucleus upon treatment  
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Figure 4: Over-expression of KLF4 prevents EMT and migration and supports cell survival during EMT. (a) 
Immunoflorescence staining by using a myc antibody to visualize the localization of Klf4 after 4-OHT treatment in 
the absence as well as presence of TGF-β (2 days) in NMuMG cells stably transfected with a myc-Klf4-ER 
construct. Cells were treated with 1uM OHT for 2 days and compared with non-treated cells. (b) Morphological 
changes are observed in non-treated and 1uM 4-OHT treated myc-Klf4-ER transfected cells during TGF-β time-
course for 0, 1, 4 and 7 days. Original magnification was 10X. (c) Immunoblot to assess the expression of adherent 
junction proteins E-cadherin and N-cadherin and tight junction protein ZO-1 during TGF-β-induced EMT in 
NMuMG and Klf4-ER transfected cells in the presence and absence of 4-OHT. Actin is used as loading control. (d) 
Wound healing assay to assess the migratory capacity after Klf4 over-expression. Cells were either treated with 1uM 
4-OHT or not. Experiment was done for 19 hours. (e) Trans-well migration assay was carried out in the absence and 
presence of 1uM 4-OHT by using 20% FBS as a chemoattractant for 20 hours. (f) Annexin-V staining was 
performed by FACS to determine the percentage of dead cells during TGF-β-induced EMT in Klf4-ER transfected 
cells in the presence and absence of 1uM 4-OHT. (g) Proliferation assays were performed during TGF-β time-course 
to assess the growth rate in Klf4-ER transfected cells in the absence and presence of TGF-β. Cells were counted by 
using a Neubauer counting chamber. Statistical values were calculated by using an unpaired, two-tailed t-test. p-
value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
with the Tamoxifen derivative, 4- hydoxy tamoxifen (4-OHT) (Figure 4a). We induced Klf4 
over-expression and followed morphological changes in the presence and absence of TGF-β. 
Interestingly, despite the presence of TGF-β, Klf4 overexpressing cells retained their epithelial 
phenotype (Figure 4b) which further accompanied gain in the epithelial markers like E-cadherin 
and ZO-1 and loss of mesenchymal markers such as N-cadherin as shown by immunoblot 
analysis (Figure 4c). Scratch wound healing assay and transwell migration assay in Klf4 
overexpressing cells suggested that Klf4 functions inhibited cell migration (Figure 4d and 4e). In 
addition, Klf4 over-expression also blocked TGF-β-induced apoptosis (Figure 4f) and cells grew 
better than control counterpart as shown by the proliferation assay (Figure 4g). These findings 
were further validated in Py2T cells and the results were compatible with the above findings 
(Supplemental figure S4a and S4b). These results suggested that, being a transcription factor, 
Klf4 probably elicited a transcriptional program that helped maintain epithelial phenotype and 
acted inhibitory to EMT.  
3.1.3.5 KLF4 regulates the expression of crucial EMT genes by directly binding to their 
promoters  
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Our observations and the previous established role of Klf4 as a transcriptional regulator led us to 
attempt identifying genes that are regulated by Klf4 through which it acts in maintaining 
epithelial phenotype and in repressing EMT. Towards this, we carried out siRNA mediated 
knockdown of Klf4 in NMuMG cells in the absence and presence of TGF-β (2 days) and 
performed a global transcription profiling. This led to the identification of a number of genes that 
were significantly up and downregulated in Klf4-deficient cells (Figure 5a and Supplemental 
figure S5a-d). However, we speculated that this list may also contain genes which are indirect 
target. In order to reveal the transcriptional changes that are directly linked to Klf4 occupancy at 
their promoters we attempted to identify the genome-wide targets of Klf4. This was achieved by 
Chromatin Immunoprecipitation (ChIP) using a Klf4-specific antibody followed by next 
generation sequencing (ChIP-seq) in NMuMG cells. Computational analysis led to the 
identification of gene promoters directly bound by Klf4 in these cells. We next compared this list 
with the transcription profile for all the stages from the EMT time-course generated earlier 
(Figure 5a and 5b & Supplemental figure S5a-d). Interestingly, among the direct targets of Klf4 
that are regulated during EMT, we identified N-cadherin .Quantitative real time RT-PCR showed 
that N-cadherin is significantly upregulated upon Klf4 depletion (data not shown). ChIP-qPCR 
using N-cadherin (Cdh2) promoter-specific primers confirmed its promoter to be bound by Klf4 
(Figure 5c). In addition, Klf4 occupies promoters of many other crucial EMT genes like vimentin 
(Vim), β-catenin (Ctnnb1), Inhibitor of differentiation 1(Id1), Inhibitor of differentiation 2 (Id2), 
Vascular endothelial growth factor A (VEGFA) and Endothelin1 (Edn1) (Figure 5c and 5d). 
These results strongly suggest that Klf4 regulates transcription of key EMT genes by directly 
binding to their promoters. ChIP-qPCR data is further validated in Py2T cells, where also Klf4 
binds at the promoter of key EMT genes such as N-cadherin, vimentin and β-catenin 
(Supplemental figure S5e). 
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Figure 5: Klf4 directly targets promoters of crucial EMT genes for transcriptional regulation. (a) Venn-
diagram showing the commonly regulated genes in Klf4 ChIP-Seq data, EMT time-course affymetrix array 
expression profile and Klf4 knockdown expression array. Left panel is for genes upregulated during EMT and right 
panel is for genes downregulated during EMT. All the analysis were done in NMuMG cells. (b) List of commonly 
regulated genes as mentioned above. (c) ChIP-PCR to see the occupancy of Klf4 at N-cadherin (Cdh2), vimentin 
(Vim) and β-catenin (Ctnnb1) promoters.  ChIP-PCR was followed by Klf4 chromatin immunoprecipitation by 
using a Klf4 specific antibody in NMuMG cells. Data is normalized to an intergenic region, which supposed to be 
transcription factors free. (d) Wiggle-tracks to show the binding of Klf4 at N-cadherin (Cdh2), Vimentin (Vim), β-
Catenin (Ctnnb1), Jnk1 (Mapk8), Inhibitor of differentiation 1 (Id1), Inhibitor of differentiation 2 (Id2), Vascular 
growth factor A (VEGFA) and endothelin1 (Edn1) promoters. These files were collected after Klf4 ChIP-Seq on 
Klf4 ChIP material. Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 
indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
3.1.3.6 Klf4 is regulated by canonical TGF-β signaling but regulates non-canonical TGF-β 
signaling during EMT 
It has been shown before that Klf4 directly binds to p53 promoter, and Klf4 depletion in breast 
cancer cells restores p53 levels and causes p53-dependent apoptosis (Rowland et al., 2005). 
Recently, p53 was also shown to be involved in EMT and modulate stem cell properties via miR-
200 (Chang et al., 2011). Jnk, a group of mitogen-activated protein kinases that are activated by 
cytokines or environmental stress, participate in various signaling pathways, including apoptotic 
pathways. Activated Jnk1 can modify p53 post-translationally by phosphorylation and can 
activate it (Hu et al., 1997). We found Jnk1 to be transcriptionally significantly upregulated in 
Klf4-depleted NMuMG and Py2T cells (Figure 6a and Supplemental Figure S6a) and 
downregulated in Klf4 over-expressing NMuMG and Py2T cells (Supplemental Figure S6b and 
S6c). Given the central role of Jnk1 in p53-dependent apoptosis, we next investigated whether 
this could be involved in EMT.  To assess whether Jnk1 is a direct target of Klf4, Chromatin 
Immunoprecipitation (ChIP) assay was performed using a Klf4-specific antibodies followed by 
ChIP-qPCR revealed Jnk1 promoter to be directly bound by Klf4 (Figure 6b and Supplemental 
figure S6d) in both cell lines. Transient knockdown of Jnk1 using a pool of two siRNA led to a 
significant reduction in Jnk1 levels (Supplemental Figure S6e). Interestingly, similar to Klf4 
over-expressing cells, Jnk1 depletion blocked epithelial differentiation and leads to retention of x 
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Figure 6: KLF4 directly binds Jnk1 promoter for its transcriptional regulation and depletion of Jnk1 
phenocopies the over-expression of KLF4 during TGF-β-induced EMT. (a) RT-qPCR for measurement of Jnk1 
expression levels upon Klf4 knockdown. The cells were treated with TGF-β for 2 days. (b) Following Chromatin 
Immunoprecipitation (ChIP) assay using Klf4-specific antibodies in NMuMG cells. Realtime PCR was performed 
using Jnk1 promoter-specific primers to test Klf4 occupancy at this region. (c) Phase contrast microscopy was 
performed for studying morphology of NMuMG cells transfected with siControl and siJnk1 is monitored before and 
after TGF-β treatment. Cells were treated with TGF-β for 2 days. (d) Expression levels of the epithelial markers, E-
cadherin and ZO-1 and the mesenchymal marker N-cadherin were measured by immunoblot analysis in cells treated 
with either control of Jnk1-specific siRNA during a TGF-β time-course. Actin was used as a loading control. Jnk1 
siRNA knockdown efficiency was checked by using Jnk1 antibody. (e) The localization and expression levels of 
indicated EMT markers after 7 days of TGF-β treatment in siControl and siJnk1 transfected cells was assessed by 
immunofluorescence. (f) Wound healing assays were performed to check the migratory capacity after single 
knockdown of Klf4 and Jnk1 and double-knockdown of Klf4 and Jnk1. Assays were done for 19 hours. (g) 
Apoptosis was measured by Annexin V staining in combination with FACS analysis in control (siControl) and Klf4-
depleted (siKlf4), Jnk1-depleted (siJnk1) and siKlf4 with siJnk1 in NMuMG cells treated with TGF-β for days for 2 
days. Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-
value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
epithelial morphology even in the presence of TGF-β in NMuMG cells (Figure 6c). These 
morphological changes also accompanied corresponding changes in the expression of epithelial 
markers such as E-cadherin and ZO-1 and loss of mesenchymal markers like N-cadherin during 
TGF-β-induced EMT (Figure 6d). These data were further validated by immunofluorescence 
analysis after TGF-β treatment for 7 days for various EMT markers and showing that Jnk1 
depletion led to a retention of the adherence junction and tight junction proteins E-cadherin and 
ZO-1, respectively at the membrane. This was also accompanied by a reduction in the 
mesenchymal marker N-cadherin. We did not observe any differences in the intermediate 
filamentous mesenchymal marker vimentin, although, TGF-β mediated cytoskeleton re-modeling 
is highly prevented as shown by reduced phalloidin staining for stress fibers visualization (Figure 
6e). Furthermore, double-knockdown of Klf4 and Jnk1 revealed that Klf4 knockdown-induced 
EMT could be rescued by Jnk1 depletion and all markers reverted back to normal levels (data not 
shown). Furthermore, the double-knockdown of Klf4 and Jnk1 not only prevented Klf4 
knockdown-induced migration (Figure 6f) but also Klf4 knockdown-induced apoptosis (Figure 
6g). These experiments strongly argue for a role of Klf4 in regulating EMT by a direct 
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transcriptional control of Jnk1. 
To gain insight whether Klf4 is regulated by canonical or non-canonical TGF-β signaling, we 
analyzed the expression of Klf4 in NMuMG cells stably knocked-down for Smad4 and found 
Klf4 to be significantly upregulated in Smad4 depleted cells upon TGF-β treatment. This 
implicated that Klf4 is a target of canonical TGF-β-signaling, while Klf4 is a downstream target 
of Smad4 (Supplemental figure S6f).  
In summary, these results strongly argue that Klf4 regulates non-canonical TGF-β signaling by 
targeting Jnk1 but itself is regulated by canonical TGF-β signaling.  
 
3.1.4 Discussion 
EMT is an orchestrated series of events in which cell-cell and cell-extracellular matrix (ECM) 
interactions are altered to release epithelial cells from the surrounding tissue, the cytoskeleton is 
reorganized to confer the ability to move through a three-dimensional ECM, and a new 
transcriptional program is induced to maintain the mesenchymal phenotype. Essential for 
embryonic development, EMT is nevertheless potentially destructive if deregulated, and it is 
becoming increasingly clear that inappropriate utilization of EMT mechanisms is an integral 
component of the progression of many tumors of epithelial tissues. 
In this study, using genome-wide expression profiling during ongoing EMT process, we were 
able to predict transcription factors which may regulate EMT by modulating the expression of 
their target genes. Klf4 was identified as one of such factors whose targets were over-represented 
among genes that were transcriptionally modulated during the EMT process in our system. Our 
data revealed an inhibitory role of Klf4 during EMT as the absence of Klf4 in breast cancer cell 
lines lead to an acceleration of EMT and higher migration potential. In addition, in contrast to a 
study in colon cancer where Klf4 inhibits proliferation by blocking G1/S progression of cell 
cycle (Chen et al., 2001), we found that a part of the phenotypic effect of Klf4 could also be 
attributed to its property to infer a survival advantage to cells undergoing EMT. It is also 
possible that the decrease in proliferation observed after Klf4 depletion result from E-cadherin 
silencing. E-cadherin also has both growth inhibitory (Perrais et al., 2007; St Croix et al., 1998) 
and growth promoting roles similar to Klf4 (Fournier et al., 2008; Liu et al., 2006b) and this 
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function is suggested to mainly depend on E-cadherin expression levels. Blocking E-cadherin 
engagement abrogated the elevated proliferation levels at intermediate seeding densities, but no 
inhibition of proliferation was observed when cells were confluent, which again points to the fact 
that similar to E-cadherin, low expression of Klf4 in mesenchymal state is required for 
maintaining the basal level of proliferation. Moreover, genome-wide ChIP-seq analysis also 
demonstrated that Klf4 directly occupies the promoters of crucial EMT genes, including N-
cadherin, vimentin, β-catenin, Jnk1, Id1, Id2, Edn1 and VEGFA, a number of which are 
deregulated upon Klf4 depletion.  Since, Klf4 directly binds to the β-catenin promoter and 
ablation of Klf4 leads to a decrease in its expression levels (data not shown), it is possible that 
increased migration observed after Klf4 depletion is due to a decrease in the expression of β-
catenin which further contributes to low levels of E-cadherin and liberates cells for the 
migration. In addition, the mesenchymal-specific isoform of p120 is also increased after Klf4 
knockdown during EMT (data not shown), resulting in increased migratory capacity of these 
cells. Increased expression of the mesenchymal-specific isoform of p120 is has been shown to be 
responsible for increased migration (Mo and Reynolds, 1996; Yanagisawa et al., 2008). We 
further show that one of the Klf4 genomic targets, Jnk1, can not only counteract Klf4 
knockdown-induced EMT but also migration and apoptosis.  
Klf4 is known for its dual role as a transcriptional activator and repressor. Our study emphasizes 
that Klf4 acts as a repressor in breast carcinogenesis. High Klf4 expression is correlated with 
metastasis free survival in the Uppsala breast cancer database (Bergh et al., 1995) and 
TRANSBIG database [(Desmedt et al., 2007); data not shown]. Certain studies have suggested 
an involvement of Klf4 (Yori et al., 2010) and Jnk1 (Alcorn et al., 2008; Santibanez, 2006b; 
Velden et al., 2011) in EMT, however, the underlying mechanisms and the relationship between 
these two remained unknown. In contrast to a previous report (Yori et al., 2010), our unbiased 
genomewide binding assay as well as single gene analysis did not reveal any Klf4 binding at the 
E-cadherin promoter. Importantly however, our genome-wide ChIP-Seq data analysis identified 
the promoters of N-cadherin as well as many other key EMT genes such as vimentin and β-
catenin to be a direct target of Klf4 for transcriptional regulation. Moreover, Klf4 also regulates 
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many genes required for angiogenesis, including VEGFA and Edn1, further implicating it in the 
angiogenic switch during tumor formation and metastasis.  
Together, these data reveal fundamental principles of how transcription factors like Klf4 regulate 
cell-fate changes such as during EMT by directly modulating transcription of underlying genes. 
These findings have potential to provide fundamental knowledge that has relevance for a broad 
range of research disciplines encompassing basic to translational research and will possibly pave 
the way for the development of therapeutic approaches involving such factors as targets in the 
long-term. 
3.1.5 Supplemental figures 
 
 
Figure S1: Klf4 is downregulated 
during EMT. Immunoblot for Klf4 during 
TGF-β-induced EMT in NMuMG cells. 
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Figure S2: Klf4 depletion accelerates EMT in Py2T cells. (a) Western blot analysis for the epithelial protein E-
cadherin and the mesenchymal proteins N-cadherin and fibronectin during TGF-β-mediated EMT in Py2T cells after 
Klf4 reduction. Actin is used as a loading control. (b) Morphological changes were monitored after Klf4 ablation 
during a TGF-β time-course in Py2T cells. Original magnification was 10X. 
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Figure S3: Klf4 provides survival advantage to the cells during EMT in Py2T cells: (a) Annexin V staining was 
performed to assess the percentage of dead cell during TGF-β conducted EMT after Klf4 ablation. Cells were treated 
with TGF-β for 0, 1, 4 and 7 days. (b) Propidium iodide staining was carried out to assess the changes in cell cycle 
phases during TGF-β time-course in Py2T cells after Klf4 reduction. Statistical values were calculated by using an 
unpaired, two-tailed t-test. p-value ≤ 0.001 indicated with (***). 
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Figure S4: Klf4 over-expression prevents epithelial differentiation in Py2T cells: (a) Morphological changes 
were observed after Klf4 induction by using 1uM 4-OHT during TGF-β-induced EMT in Py2T cells. Original 
magnification was 10X. (b) Expression levels of various EMT markers were assessed by doing an immunoblotting 
analysis after Klf4 induction with 1uM 4-OHT. Cells were treated with TGF-β for 0, 1, 4 and 7 days. The epithelial 
marker E-cadherin and the mesenchymal markers N-cadherin and fibronectin were analyzed for their expression 
levels. 
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Figure S5: Klf4 directly binds at the promoters of key EMT genes: (a-d) Detailed comparison between ChIP-seq 
data after performing Klf4 ChIP,  affymetrix array data after conducting chip in Klf4 knockdown cells  in the 
absence and presence of TGF-β (2days) and affymetrix array data after carrying  out chip  during TGF-β mediated 
EMT (Day 0, 1, 4, 7 and 10). Lists generated after Klf4 knockdown array analysis, both in the presence and absence 
of TGF-β, were merged together for upregulated and downregulated genes. Panel (a) and (b) comprise the genes 
which were upregulated during EMT as well as upregulated in Klf4 knockdown array. Panel (c) and (d) comprise 
the genes which were downregualted during EMT as well as downregulated in Klf4 knockdown array.All 
experiments were carried out in NMuMG cells (e) Klf4 ChIP was performed in Py2T cells, followed by 
quantitative-PCR to test the occupancy of Klf4 at Cdh2 (N-Cadherin), Vim (Vimentin) and Ctnnb1 (β-Catenin) 
promoters. Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with 
(*). 
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Figure S6: Klf4 regulates non-canonical TGF-β signaling via Jnk1 but itself is regulated by canonical TGF-β 
signaling: (a) Immunoblot analysis of the expression of Jnk1 during TGF-β-induced EMT in Py2T cells after Klf4 
depletion. (b-c) Immunoblot was performed to check the Jnk1 expression after Klf4 induction with 1uM 4-OHT in 
NMuMG (b) and Py2T (c) cells after treating them with TGF-β for 0, 1, 4 and 7 days. (d) Quantitative-RT-PCR was 
carried out after Klf4 chromatin immunoprecipitation in Py2T cells to check the occupancy of Klf4 at Mapk8 
promoter which encode for Jnk1. (e) Quantitative-RT-PCR was performed to assess the knockdown efficiency of 
Jnk1 siRNAs pool in the absence and presence of TGF-β in NMuMG cells. Cells were treated with TGF-β for 2 
days. (f) Q-PCR was conducted after stable knockdown of Smad4 to monitor the expression level of Klf4 during 
TGF-β mediated EMT in NMuMG cells. Statistical values were calculated by using an unpaired, two-tailed t-test. p-
value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
3.1.6 Methods and Materials 
Reagents and antibodies 
Reagents: TGF-β (240-B, R&D systems). DMEM (D5671, Sigma-Aldrich), PBS (D8537, 
Sigma-Aldrich), trypsin (T4174, Sigma-Aldrich), Opti-MEM (11058, Gibco), FBS (F7524, 
Sigma-Aldrich), Glutamine (G7513, Sigma-Aldrich), Pencillin/streptomycin (P4333, Sigma-
Aldrich), Lipofectamine RNAiMax (11668-019, Invitrogen), Alexa Fluor-488, 568, 633 
(Invitrogen),  Polybrene (AL-118, Sigma-Aldrich), Puromycin (P7255, Sigma-Aldrich), Fugene 
HD ( 12998300, Roche), Trizol (T9424, Sigma-Aldrich), M-MLV reverse transcriptase (M314C 
28692233, Promega),  SYBR-green PCR MasterMix (Eurogentec) and  Bradford reagent (500-
0006, Biorad), Protease inhibitor cocktail (P2714, Sigma-Aldrich). Antibodies: Western Blot: 
E-Cadherin (610182, Transduction Laboratories), N-Cadherin (M142, Takara), ZO-1 (617300, 
Zymed), Fibronectin (F-3648, Sigma-Aldrich), Actin (SC-1616, Sanata Cruz Biotechnology). 
Immunofluorescence: E-Cadherin (13-1900, Zymed), N-Cadherin (610921, Transduction 
Laboratories), ZO-1 (617300, Zymed), Phalloidin (A12380, Invitrogen), Paxillin (13520, 
Transduction Laboratories), Vimentin (V2258, Sigma). Apoptosis and Cell cycle: Annexin-V 
(559934, BD Biosciences) and PI (P4170, Sigma-Aldrich), Small interfering RNAs:  siControl 
(Stealth RNAi™ siRNA Negative Controls, 12935-100, Invitrogen), siKlf4 
(SASI_Mm01_00114972 and SASI_Mm01_00114974, Sigma-Aldrich) and siJnk1 
(SASI_Mm01_00061987 & SASI_Mm01_00061988, Sigma-Aldrich). Small hairpin RNA: 
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shControl (Mission Non-target shRNA control vector, SHC002) and shKlf4 (SHCLNG-
NM_010637 Mouse, TRCN0000095370; TRCN0000095371 and TRCN0000095372).  
Cell lines and cell culture 
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has been 
previously described (Maeda et al., 2005). MCF7 shControl and MCF7-shEcad have been 
described before (Lehembre et al., 2008). Py2T cells were derived from Polyoma middle T 
breast cancer tumor model (unpublished data, Waldameir et.al). NMuMG, MCF7shControl, 
MCF7-shEcad, Py2T, 293T and PLAT-E cells were cultured in DMEM supplemented with 10% 
FBS, 2mM glutamine, 100U penicillin and 0.2mg/ml streptomycin. All the cells were cultured at 
370c with 5% CO2 in humid incubator. For TGF-β time-course experiments, cells were treated 
with 2ng/ml TGF-β for indicated time point and it was replaced every 2 days. For siRNA 
transfections, Lipofectamine RNAiMax was used according to the manufacturer's instructions.  
Quantitative RT-PCR 
Total RNA was prepared by using a Tri Reagent according to the manufacturer’s instructions. 
RNA was further reverse transcribed with ImProm-II Reverse Transcriptase, and transcripts were 
quantified by PCR using SYBR-green PCR Mastermix in a real time PCR system (Step One 
Plus, Applied Biosystems). Human or mouse ribosomal L19 primers were used for 
normalization. PCR assays were performed in duplicates, and fold induction was calculated 
against control-treated cell lines using the comparative Ct method (ΔΔ Ct). Following primers 
were used:  
Primer name Sequences 
mRpl19 Forward primer ctcgttgccggaaaaaca 
mRpl19 Reverse primer tcatccaggtcaccttctca 
mKlf4 Forward primer cctcgctctcctcgtcct 
mKlf4 Reverse primer tcgtcttcgaactcgtcgt 
hRpl19 Forward primer gatgccggaaaaacaccttg 
hRpl19 Reverse primer tggctgtacccttccgctt 
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hKlf4 Forward primer ccaaatcttttggggactttt 
hKlf4 Reverse primer ctggcccctcaactcctc 
mE-cadherin Forward primer cgaccctgcctctgaatcc 
mE-cadherin Reverse primer tacacgctgggaaacatgagc 
mN-Cadherin Forward primer caatgacgtccaccctgttct 
mN-Cadherin Reverse primer ctgccatgactttctacggaga 
mFibronectin1 Forward primer cccagacttatggtggcaatt 
mFibronectin1 Reverse primer atattccgactcgagtctga 
mJnk1 Forward primer aactgttccccgatgtgct 
mJnk1 Reverse primer tctcttgcctgactggcttt 
 
Immunoblot 
Cells were lysed for 1 hour on ice in RIPA-Plus buffer (50mM Tris-HCl, pH8.0), 150mM NaCl, 
10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 2mM 
CaCl2, 1mM dithiothreitol, 1mM sodium fluoride, 0.2mM sodium orthovanadate, 1x protease 
inhibitor cocktail and further quantified by using Bradford reagent. 50 μg of cleared protein 
lysates were separated by SDS-PAGE and electroblotted on PDVF membranes, and proteins 
were visualized with the appropriate primary and secondary antibodies and ECL on superRX 
films. Depending on the species origin of antibodies, immunoblots were either probed 
sequentially or on multiple membranes. Adobe Photoshop has been used to excise the relevant 
portion of the immunoblots from the original scans of X-ray films exposed to 
chemoluminescence visualization of specific proteins. 
Immunofluorescence 
siControl, siKlf4 and siJnk1 cells were plated on coverslips and treated with TGF-β for 
mentioned time. The cells were fixed with 4% paraformaldehyde in HBSS and further 
permeablized with 0.2% Triton for 5 minutes at room temperature. These cells were blocked by 
using 3.5% goat serum for 15 minutes and incubated with primary antibodies against E-cadherin, 
N-cadherin, Fibronectin, ZO-1, vimentin, Paxillin and Phalloidin for 1 hour and then incubated 
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with flurochrome-labeled secondary antibody for 1 hour at room temperature. The coverslips 
were counterstained with DAPI and imaged with a confocal laser-scanning microscope. Data 
were processed with Adobe Photoshop 7.0 software. 
Production of lentivirus for knockdown studies  
Murine Klf4 shRNAs and control shRNA were purchased from Sigma-Aldrich as described 
above. For lenti-virus production, 293T cells were transfected with the shRNA expressing lenti-
viral vector in combination with the packaging vectors including envelope protein; HDM-
pVSV/G,  codon-optimized HIV gag-pol; HDM-Hpgm2, transactivator of transcription; HDM-
Tat1b and  pRC-CMV-RaII by Fugene HD. After 48 hours of transfection, viral supernatant was 
harvested, filtered (0.46 µm), supplemented with polybrene (8ng/ml) and used to infect target 
cells. Infections were performed once a day for two consecutive days. Infected cells were 
positively selected using Puromycin (5ug/ml). 
Production of retrovirus for over-expression studies  
Klf4-ER (kindly provided by Prof. J.M. Ruppert) cloned into the retroviral expression vector 
pbabe. Retroviral particles were produced by transfecting PLAT-E cells with the retroviral 
expression vectors using Fugene HD. After two days of virus production, retroviral-containing 
supernatants were harvested, filtered (0.45 µm) and added to target cells in presence of 
polybrene (8 ng/ml). Infections were performed once a day for two days, and later on selection 
was performed by using puromycin. Single clones were picked for the experiments. 
Wound healing assay 
In vitro wound healing assays were done on confluent siControl, siKlf4, siJnk1 and siKlf4 + 
siJnk1 cells. The media on the confluent cells was replaced with DMEM with 2% fetal bovine 
serum media, and an area of cells was scraped off using a 200ul pipette tips. Light microscopic 
images were taken at time 0 and at 20 hours. The data was further analyzed by using an ImageJ 
program. 
Migration assay 
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Cell migration was assessed in shControl and shKlf4 cells in a transwell migration assay (pore 
size: 8 μm; Falcon BD). 104 cells were seeded in 2% FBS/DMEM (Sigma) in the upper chamber 
and the lower chamber was filled with 20% FBS/DMEM. After 20 hours of incubation at 37°C, 
cells in the upper chamber were carefully removed with a cotton swap, and the cells that had 
traversed the membrane were fixed in 4% paraformaldehyde/PBS, stained with DAPI. Pictures 
of the membrane were taken at a 10x magnification using a fluorescent microscope (Nikon 
Diaphot 300). Quantification was done using the software ImageJ. 
Apoptosis assay (Annexin assay) 
Cells were washed twice with cold PBS and resuspended in 1X Annexin V binding buffer at a 
concentration of 1 x 106 cells/ml. 5 µl of Cy5 Annexin V was added to the 100 µl of cells (1 x 
105) and incubated for 15 min on ice in the dark. Stained cells were filtered through 40µm mesh 
and analyzed on a FACSCanto II using DIVA software. 
Cell growth curve 
1x104 cells were seeded in each well of 24-well plate, and cell numbers were assessed for 
mentioned days by using a Neubauer counting chamber. 
PI Staining 
Cells were trypsinized and fixed in 70% ice-cold Ethanol for overnight.  Washed twice with PBS 
and resuspended in sodium citrate buffer with 5μg/ml PI for overnight. Stained cells were 
analyzed by FACSCanto II using DIVA software. 
Microarray processing and data analysis 
RNA was isolated from NMuMG cells transfected with control siRNA or Klf4 siRNA and 
treated with TGF-β for 0 and 2 days using Tri Reagent (Sigma-Aldrich). RNA quality and 
quantity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies). The 
manufacturer’s protocols for the GeneChip platform by Affimetrix were followed. Methods 
included synthesis of the first- and second-strand cDNA followed by synthesis of cRNA by in 
vitro transcription, subsequent synthesis of single-stranded cDNA, biotin labeling and 
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fragmentation of cDNA and hybridization with the microarray slide (GeneChip® Mouse Gene 
1.0 ST array), posthybridization washings and detection of the hybridized cDNAs using a 
streptavidin-coupled fluorescent dye. Hybridized Affimetrix GeneChips were scanned using an 
Affimetrix GeneChip 3000 scanner. Image generation and feature extraction were performed 
using Affimetrix GCOS Software and quality control was performed using Affimetrix 
Expression Console Software. Raw microarray data were normalized with Robust Multi-Array 
(RMA) and analyzed using Partek® Genomics Suite Software (Partek Inc.). One-way analysis of 
variance (ANOVA) and asymptotic analysis were used to identify significantly differentially 
expressed genes. The gene ontology (GO) tool from Partek® Genomics Suite Software as well as 
the David gene ontology software were used for further analysis. 
Chromatin Immunoprecipitation 
ChIP experiments were performed as previously described (Weber et al, 2007). In brief, 
crosslinked chromatin was sonicated to achieve an average fragment size of 500 bp. Starting 
with 100 μg of chromatin and 5 μg of anti-HA antibody, 1 μl of ChIP material and 1 μl of input 
material were used for quantitative real-time PCR using specific primers covering the motif of 
Klf4 in the promoter of target genes. Primers covering an intergenic region are used as a control. 
The efficiencies of PCR amplification were normalized for between the primer pairs. Following 
primers were used for ChIP –PCR.  
Name Sequences 
Cdh2 FP ggtttgctggtagccatgtt 
Cdh2 RP cattcccttttcctgctttg 
p53 FP ggtcaagtggagaagggtga 
p53 RP gcacctcgagagaaggacac 
Junb FP tttccttccttgctaactcctg 
Junb RP agatcaccctacttttccacca 
Vim FP gttttgcattgagttccatttg 
Vim RP gtcacgaacagcagagagaaga 
Ctnnb1 FP agtctcaaagtgttgggaccat 
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Ctnnb1 RP ttatgctgacctttccacactg 
Interg FP attctcctgcaaaggaaacaaa 
Interg RP ggggctcagagtaggttatgtg 
 
Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad 
Software Inc, San Diego, CA). All statistical analysis was done by unpaired, two-sided t-test. 
Normality testing was performed using the Kolmogorov-Smirnov test with Dallal-Wilkinso- 
Lillie for p-values.
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3.2.1 Abstract 
Epithelial-to-mesenchymal transition (EMT) is a key process during organismal development 
and in the progression of solid epithelial tumors to invasive and metastatic cancers. It involves 
loss of various epithelial markers, which are required for normal integrity of cells and at the 
same time gain of various mesenchymal markers which make the cells more migratory and 
invasive. Using a genome-wide expression profiling approach, we uncovered Sox4 among the 
transcription factors that were significantly upregulated during TGF-β-induced EMT in NMuMG 
cells. Sox4 depletion during TGF-β-induced EMT leads to a retention of epithelial morphology 
and decrease in cell migration properties. In addition, Sox4 provides a survival advantage to cells 
during EMT. Importantly, Sox4 is also required for breast cancer metastasis and tumorigenesis in 
vivo. Interestingly, Chromatin Immunoprecipitation experiments reveal that Sox4 directly binds 
to the promoter and regulates expression of Ezh2, a Polycomb Group (PcG) Complex gene that 
encodes for the enzyme that trimethylates H3K27 for gene repression. This results in the 
activation of EMT, ultimately leading to enhanced invasiveness of epithelial cells. Taken 
together, our results provide a novel mechanism of EMT regulation by transcription factor Sox4, 
where in addition to controlling the expression of crucial EMT genes including Spred1, Edn1, 
Palld, Cyr61, Ereg, Areg and Yap1, it also contributes to EMT by regulating transcription of the 
epigenetic machinery component Ezh2. 
3.2.2 Introduction 
Epithelial–mesenchymal transition (EMT) is a cellular mechanism long known to constitute the 
core of normal embryonic development. Several critical development events, including 
gastrulation, neural crest formation and heart morphogenesis, rely on the plastic transition 
between epithelium and mesenchyme (Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and 
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Weinberg, 2009; Nieto, 2010; Polyak and Weinberg, 2009; Thiery and Sleeman, 2006). In the 
last few years it has been uncovered that similar but physio-pathological transitions occur during 
the progression of epithelial tumors, endowing cancer cells with increased motility and 
invasiveness (Hanahan and Weinberg, 2011; Nieto, 2010; Polyak and Weinberg, 2009; Thiery 
and Sleeman, 2006). Multiple oncogenic pathways mediated by peptide growth factors, TGF-β, 
Src, Ras, Ets, integrin, Wnt/β-catenin and Notch signaling, are implicated in induction of EMT 
(Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and Weinberg, 2009; Nieto, 2010; Polyak 
and Weinberg, 2009; Thiery and Sleeman, 2006) .  
Sox4 ( SRY-Related HMG-Box Gene 4) is a member of the Sox (SRY-related HMG-box) family 
of transcription factors and it has been shown to have a role in embryonic development and in 
cell-fate determination during organogenesis including heart (Restivo et al., 2006; Schilham et 
al., 1996), pancreas (Lioubinski et al., 2003; Wilson et al., 2005) and brain (Cheung et al., 2000a; 
Hong and Saint-Jeannet, 2005). Sox4 has been shown to be a lymphocyte specific-transcriptional 
activator (van de Wetering et al., 1993) and facilitates B and T cell differentiation (Cheung et al., 
2000a; Hong and Saint-Jeannet, 2005; Lioubinski et al., 2003; Schilham et al., 1997; Schilham et 
al., 1996; van de Wetering et al., 1993; Wilson et al., 2005). Moreover, Sox4 gene expression is 
up-regulated in many tumor types, with experimental evidence suggesting that this contributes to 
cellular transformation (Liu et al., 2006a; Shin et al., 2004), control of apoptosis (Aaboe et al., 
2006; Ahn et al., 2002; Liu et al., 2006a; Pramoonjago et al., 2006) and/or a metastatic 
phenotype (Liao et al., 2008; Tavazoie et al., 2008). Restoration of miR335 expression in 
malignant cells suppressed lung and bone metastasis in human cancer cells through targeting the 
progenitor cell transcription factor Sox4 and extracellular matrix component tenascin C 
(Tavazoie et al., 2008).  Sox4 has also been shown to directly regulate key cellular regulators 
like EGFR, TNC, HSP70, FZD5, DLL1, PTCH1, various transcription factors like MLL, 
FOXA1, ZNF281 and NKX3-1 and components of the RNAi machinery including Dicer, 
Argonaute 1, and RNA Helicase A in prostate cancer (Scharer et al., 2009). Moreover, Sox4 has 
been shown to regulate Wnt signaling by directly binding to β-catenin and interacting with 
various Tcf family members (Sinner et al., 2007). Recently, organogenesis has been suggested to 
rely on SoxC transcription factors, which comprise Sox4, Sox11 and Sox12, for the survival of 
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neural and mesenchymal progenitors and in part by activating Tead2, which is a mediator of 
Hippo signaling (Bhattaram et al., 2010). 
Ezh2 (Enhancer of Zeste, Drosophila, Homolog 2) is a histone methyltransferase that belongs to 
the polycomb group (PcG) complex 2 and is known to be involved in epigenetic regulation of 
genes involved in cell fate decisions. It specifically trimethylates nucleosomal histone H3 at 
lysine 27 (H3K27me3), an epigenetic mark associated with gene silencing (Cao et al., 2002; 
Ernst et al., 2010).  Ezh2 has also been shown to be phosphorylated by Akt which further 
suppress its methyltransferase activity and de-represses the silenced genes (Cha et al., 2005). 
Ezh2 also has been shown to be upregulated in various cancers (Varambally et al., 2002). 
Furthermore, the expression and function of Ezh2 in cancer cell lines are inhibited by microRNA 
101(Varambally et al., 2008). It has been proposed that the genomic loss of MIRN101 in cancer 
leads to the overexpression of Ezh2 and concomitant deregulation of epigenetic pathways, 
resulting in prostate cancer progression (Varambally et al., 2008). Furthermore, Ezh2 can induce 
EMT by downregulation of DAB2IP, which is a Ras GTPase activating protein that acts as a 
tumor suppressor, and increases the metastatic potential of prostate cancer (Chen et al., 2005; 
Min et al., 2010). Ezh2 knockout mice suffer from early embryonic death (O'Carroll et al., 2001). 
Interestingly, a conditional knockout of Ezh2 in basal keratinocytes resulted in thickened stratum 
corneum and granular layer and precocious acquisition of epidermal barrier function in the 
embryo (Ezhkova et al., 2009) while a conditional knockout of Ezh2 in B-cells led to improper 
IGH re-arrangement in B-cell (Su et al., 2003), suggesting a  possible role for Ezh2 in the 
determination of cell-type identity.  
Using global gene expression profiling, we identified a comprehensive list of genes at six 
consecutive different morphological states (1 day, 4 days, 7 days, 10 days and 20 days) during 
TGF-β-induced EMT in normal mammary epithelial cells, NMuMG (Lehembre et al., 2008). 
This data was further subjected to computational analysis and based on motif search for various 
transcription factors at the promoter of regulated genes (http://test.swissregulon.unibas.ch/cgi-
bin/mara), we predicted a number of transcription factors that might regulate transcription of a 
subset of genes in the early, intermediate and later stages of EMT (data not shown).  
Interestingly, Sox4 was discovered as one of such factor that might possibly regulate expression 
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of certain crucial genes during TGF-β-induced EMT in NMuMG cells. Given the findings for 
Sox4 in cell-fate decision during development as well as its implicated role in cellular 
transformation during carcinogenesis (Liu et al., 2006a; Shin et al., 2004), the above findings 
motivated us to investigate the role of this transcription factor during Epithelial to Mesenchymal 
transition.  
Our data reveal that not only Sox4 induces EMT, but also acts as a survival factor during this 
process. Sox4 knockdown inhibits cell migration.  We also show that loss of Sox4 function in 
Py2T cells, derived from the MMTV-mouse PyMT model of breast cancer, significantly impairs 
their ability to form primary tumors and metastatic lesions in the lungs, lymph-nodes and liver of 
transplanted nude mice. Furthermore, Sox4 loss in B16-F10 metastatic model also leads to a 
decrease in metastasis. Expression profiling analysis upon Sox4 depletion in the absence and 
presence of TGF-β revealed many Sox4 target genes, including Ezh2.  Interestingly, Sox4 
directly binds to the Ezh2 promoter controlling its transcriptional regulation. Along these lines, 
we show that Ezh2 induces EMT and act as a survival factor, thus revealing Ezh2 as one of the 
Sox4-target gene, critical for EMT. 
3.2.3 Results 
3.2.3.1 Identification of Sox4 as a transcription factor upregulated in EMT  
To identify the crucial genes underlying EMT during early, intermediate and later stages, we 
used the established untransformed normal murine mammary gland cell line NMuMG 
(Lehembre et al., 2008; Miettinen et al., 1994). We treated NMuMG cells with TGF-β for 1, 4, 7, 
10 and 20 days and consequently these cells underwent progressive EMT and acquired a 
complete mesenchymal morphology by the end point, as shown previously (Lehembre et al., 
2008). These morphological changes were accompanied by a “cadherin switch”, a hallmark of 
EMT, as well as with the gain of other mesenchymal markers and loss of epithelial markers 
(Hazan et al., 2004; Maeda et al., 2005). We next performed a genome-wide expression profiling 
of the above stages and identified genes that were differentially expressed at early, intermediate 
and later stages of the EMT process. We then employed MARA (Motif Activity Response 
Analysis) to identify crucial transcription factors whose targets are transcriptionally modulated 
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during EMT based on their motif occurrence at target promoters. This analysis revealed a 
number of interesting transcription factors that may possibly regulate EMT via transcriptional 
regulation of underlying genes (data not shown), and Sox4 was identified as one of the top  
 
Figure 1: Sox4 expression and activity is upregulated during TGF-β-induced EMT. (A) MARA analysis 
predicts Sox4 activity during EMT in NMuMG cells. (B) RT-qPCR analysis for quantification of Sox4 expression 
levels in NMuMG cells during TGF-β mediated EMT.  (C) Expression levels of Sox4 as quantified by RT-qPCR in 
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control and E-cadherin-specific shRNA treated MCF7 cells. (D) RT-qPCR for quantification of Sox4 levels upon 
EMT induction in Py2T cells. Statistical values were calculated by using a paired, two-tailed t-test. p-value ≤ 0.05 
indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
scoring factor in this analysis. Sox4 has AACAA/TG/A binding motif (Figure 1A) and according 
to MARA analysis, its activity is increased during EMT (Figure 1A). Very interestingly, 
quantitative RT-PCR experiments revealed that not only the activity, but also Sox4 expression is 
up-regulated during such TGF-β-induced EMT in NMuMG cells (Figure 1B). We further 
confirmed Sox4 upregulation in a human breast cancer cell line that undergoes EMT upon E-
cadherin knockdown (MCF7) (Lehembre et al., 2008) (Figure 1C). In addition, this was also seen 
in another cell line from PyMT model system of breast cancer that also undergoes EMT in 
response to TGF-β treatment (Waldameier et.al. unpublished data) (Figure 1D). These results 
suggested a potential oncogenic role for Sox4 during EMT.  
3.2.3.2 Sox4 depletion prevents EMT 
To directly assess the role of Sox4 in EMT, we used two different siRNAs and pooled them 
together to knockdown Sox4 in the absence and presence of TGF-β in NMuMG cells. This 
siRNA pool efficiently downregulated Sox4 levels (Figure 2A). Sox4-ablated NMuMG cells 
were not able to undergo EMT and retained an epithelial phenotype during TGF-β treatment 
(Figure 2B). Immunoflorescence studies revealed that Sox4 depletion in the absence of TGF-β 
led to a retention of all tested epithelial markers similar to control cells while mesenchymal 
markers like N-cadherin and paxillin were decreased (Figure 2C). On the other hand, in the 
presence of TGF-β, cells were able to maintained E-cadherin and ZO-1 at the membrane while 
the mesenchymal marker N-cadherin was decreased. Along with these observations, TGF-β- 
mediated cytoskeleton re-modeling was also prevented and stress fibers were reduced. 
Fibronectin and paxillin staining revealed a significant failure to form focal adhesion after Sox4 
reduction (Figure 2C). These observations were further confirmed by immunoblot analysis 
(Figure 2D). Notably, Sox4 depletion in NMuMG cells treated with TGF-β for 15 days (LT) 
exhibited epithelial cell morphology, demonstrating that Sox4 is not only required for the 
initiation but also for the maintenance of EMT in NMuMG cells (Figure 2E). We further  
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Figure 2: Depletion of Sox4 blocks epithelial differentiation. (A) qRT-PCR was performed after siRNA-mediated 
knockdown of Sox4 in the absence and presence of TGF-β. Cells were treated with TGF-β for 2 days. (B) 
Morphology of NMuMG cells transfected with either control or Sox4-specific siRNA during TGF-β mediated EMT, 
as evaluated by phase contrast microscopy. Original magnification was 10X. (C) Immunoflorescence stainings for 
adherent junction protein, E-cadherin and N-cadherin, tight junction protein ZO-1, the actin cytoskeleton by 
phalloidin and focal adhesion protein paxillin were performed after Sox4 knockdown in the absence and presence of 
TGF-β. Cells were treated with TGF-β for 2 days. Original magnification was 40X. (D) Expression of the epithelial 
proteins E-cadherin, ZO-1 and β-catenin and the mesenchymal proteins N-cadherin, fibronectin and p120 as 
detected by immunoblot analysis after siRNA mediated knockdown of Sox4 during the TGF-β time-course. Actin 
was used as a loading control.  (E) Morphology of long term TGF- β treated NMuMG cells transfected with either 
control or Sox4-specific siRNA, as evaluated by phase contrast microscopy. Original magnification was 10X. 
Statistical values were calculated by using a paired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 
0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
extended these studies to the Py2T murine breast cancer model. Similar to NMuMG cells, upon a 
lentiviral mediated stable knockdown of Sox4 Py2T cells failed to undergo EMT at later stages 
and recovered the epithelial marker E-cadherin (Supplemental figure S1 A) while the 
mesenchymal marker fibronectin was decreased (Supplemental figure S1 B). We did not observe 
any change in N-Cadherin expression as well as in morphology after TGF-β treatment in Sox4- 
depleted cells (data not shown). Together, these results strongly argue that Sox4 is required for 
TGF-β induced EMT.  
 
3.2.3.3 Sox4 provides a survival advantage during TGF-β-induced EMT and supports 
migration 
Sox4 has been implicated in cell survival in various cancers (Hur et al., 2010; Pramoonjago et 
al., 2006; Shen et al., 2010). Thus, we next investigated whether Sox4 has a similar function 
during TGF-β-induced EMT in NMuMG cells. Sox4-depleted NMuMG cells showed a 
significant reduction in cell growth in comparison to control cells and displayed high sensitivity 
towards TGF-β-mediated growth inhibition (Figure 3A). To determine whether this effect was 
due to alterations in proliferation ability or changes in apoptosis levels, we used propidium 
iodide staining to perform FACS-based analysis of the cell cycle and further performed Annexin 
V staining to quantify apoptosis. In comparison to control siRNA-treated cells, a statistically  
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Figure 3: Sox4 supports migration and provides survival advantage to the cells during TGF-β-induced EMT. 
(A) Proliferation assays were performed after siRNA-mediated knockdown of Sox4 during a TGF-β time-course. 
Cells were counted using a Neubauer counting chamber.  (B) Cell cycle analysis was done after transient 
knockdown of Sox4 during EMT for 0, 1 and 4 days. Propidium Iodide (PI) was used for the staining. (C) Annexin 
V staining was performed to quantify cell death in Sox4 knockdown cells during TGF-β-induced EMT for 0, 1, 4 
and 7 days. (D) Following siRNA-mediated ablation of Sox4 in the absence of TGF-β, a wound healing assay was 
performed after 19 hours of wound creation. (E) Sox4 depleted cells were subjected to a Boyden chamber migration 
assay for 20 hours using 20% FBS as a chemoattractant. Statistical values were calculated by using an 
unpaired/paired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 
0.001 indicated with (***). 
 
significant G0/G1 block was observed after Sox4 depletion (Figure 3B). In addition, increased 
apoptosis occurred in Sox4 knockdown cells in the presence of TGF-β (Figure 3C). Thus, TGF-
β-sensitive growth of Sox4-depleted NMuMG cells relies on both increased proliferation and 
decreased apoptosis during TGF-β-induced EMT. These observation led us conclude that Sox4 is 
required for cell survival and proliferation during TGF-β-induced EMT. 
We next extended our study in Py2T cells carrying a stable knockdown of Sox4 and performed a 
similar series of experiments as described above. Unlike NMuMG cells, these cells did not show 
any apoptotic phenotype (data not shown), although they exhibited a slower growth rate 
(Supplemental figure S2 A) and G0/G1 arrest (Supplemental figure S2 B). These results suggest 
that the apoptotic phenotype is most likely prominent in untransformed cells. 
Since an increased migration potential is a characteristic feature of the EMT process (Brabletz et 
al., 2005; Christofori, 2006; Grunert et al., 2003; Huber et al., 2005; Thiery and Sleeman, 2006), 
we measured the migratory capacity of Sox4-depleted NMuMG cells. Wound healing assays 
revealed a significant reduction in migration of cells depleted of Sox4 compared to control cells 
(Figure 3D). Similar results were obtained in trans-well migration assays (Figure 3E) and in 
Sox4 depleted Py2T cells treated with TGF-β for 15 days (Supplemental figure S2 C). 
3.2.3.4 Sox4 is required for TGF-β-induced tumorigenesis and metastatic spread 
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We next asked whether increased expression of Sox4 correlate with the ability of tumors to 
grow, progress and metastasize. Analysis of the Schmidt breast cancer database (Schmidt et al., 
2008) revealed a correlation between Sox4 expression and metastasis free survival (Figure 4A). 
This database contains 200 lymph node-negative breast cancer patients that were either treated 
with modified radical mastectomy or breast-conserving surgeries followed by irradiation and 
were not exposed to any systemic therapy after surgery. This led us to further investigate whether 
depletion of Sox4 in Py2T cells could impair the ability of these cells to form tumors and to seed 
metastasis. In order to address this question, we performed orthotropic mammary fat-pad 
injections of Sox4-depleted Py2T cells that were also tagged by luciferase expression into nude 
mice and quantified tumor growth and metastasis in lymph nodes, lungs and liver. To quantitate 
the knockdown efficiency of these cells before injection, Q-PCR was performed, showing a 
significant reduction in Sox4 levels (Figure 4B). Immunostaining experiments in tumor sections 
revealed that an efficient depletion of Sox4 was achieved in the tumors as well (Figure 4C). As 
shown in Figure 4D, the knockdown of Sox4 in Py2T cells led to a significant reduction in tumor 
growth, suggesting a crucial role for Sox4 expression in primary tumor growth. H&E staining of 
tumor sections did not show any morphological differences compared to the control counterpart 
(Figure 4E). We also performed luciferase assays in the organs known to be target of breast 
cancer metastasis and found that luciferase levels were decreased in axillary and inguinal lymph 
nodes as well as in lung and liver upon Sox4 depletion (Supplemental Figure S3). These results 
argue in favor of the hypothesis that Sox4 is required for breast cancer metastasis. It has recently 
been shown that tumor size can be correlated with metastasis (Minn et al., 2007). Therefore, we 
calculated the metastatic index by dividing the average luciferase levels in each organ with 
average tumor weight (metastatic index), and the results further supported our findings that Sox4 
depletion is associated with a decreased metastatic potential (Figure 4F). We further validated 
our data by performing sub-cutaneous injections of Sox4-depleted Py2T cells and found a similar 
reduction in tumor growth (Figure 4G).  
We next investigated whether knockdown of Sox4 expression in B16-F10 melanomas cells 
impairs their ability to metastasize. An initial analysis of Sox4 expression upon TGF-β treatment 
for 1, 4, 7 and 10 days in B16-F10 melanoma cells upregulated Sox4 mRNA levels similar to 
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Figure 4: Sox4 is necessary for breast cancer tumorigenesis and metastasis. (A) Correlation of Sox4 expression 
in human breast cancer array data set. Kaplan-Meier survival curve for the patient samples classified for having high 
Sox4 expression and low Sox4 expression to assess the metastasis free survival. (B) RT-qPCR quantification of 
Sox4 knockdown efficiency in Py2T cells stably transfected with control (shControl) and Sox4-specfic (ShSox4) 
shRNA. (C) Immunohistochemistry for Sox4 was performed on tumor sections to validate the Sox4 knockdown 
efficiency. (D) Tumor growth was measured following fat-pad injection of shControl and shSox4 cells into 7 weeks 
old female nude mice. Tumor weight was assessed after sacrificing the nude mice 23 days post-injection. (E) H&E 
staining on tumor sections derived from mice injected with shControl and shSox4 cells. (F) Metastatic spread was 
quantified by measuring the relative luciferase levels in lymph nodes, lung and liver of nude mice injected with 
shControl and shSox4 cells and further by dividing the relative luciferase levels with tumor weight in various 
organs. (G) Tumor growth was measured following sub-cutaneous injection of shControl and shSox4 cells into the 7 
weeks old female nude mice. Tumor weight was assessed after sacrificing the nude mice 27 days of post-injection. 
Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 
0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
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Figure 5: Sox4 is required for metastasis in B16-F10 melanoma cells.  (A) qRT-PCR to determine the expression 
of Sox4 during TGF-β-induced EMT in B16-F10 melanoma cell line. (B) RT-qPCR to assess the knockdown 
efficiency after stable transfection of shSox4 in B16-F10 melanoma cells. (C) Lung metastasis was measured after 
the intravenous injection of shControl and shSox4 melanoma cells into the tail-vein of C57 black 6 mice. Mice were 
sacrificed after 18 days of post-injection. (D) Pictures of lungs after sacrificing mice injected intravenously with 
shControl and shSox4 melanoma cells. Statistical values were calculated by using an unpaired/paired, two-tailed t-
test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
NMuMG cells (Figure 5A). We then performed intravenous injection of stable Sox4 knockdown 
B16-F10 melanoma cells (shSox4-B16-F10) into the tail-veins of C57BL/6 mice and quantified 
metastasis to the lung. The results show that Sox4 depleted B16-F10 melanomas cells were 
significantly impaired in colonizing the lungs (5B, 5C and 5D). Taken together, these 
observations led us to conclude that Sox4 was an important player in the metastatic process. 
3.2.3.5 Ezh2 is a transcriptionally regulated by Sox4  
Given the established role for Sox4 as a transcriptional regulator, we next attempted to identify 
genes that are possibly regulated by Sox4 and through which it may contribute to EMT. We 
performed a global transcription profiling in control and Sox4 siRNA-treated NMuMG in the 
absence and presence of TGF-β for 2 days in order to reveal the direct targets of Sox4. The 
differentially expressed genes were analyzed for Sox4 binding motif within 1 Kb of their 
transcription start site. The resulting gene list of 198 genes was further compared with the EMT 
time-course expression analysis we performed earlier to reveal that 99 EMT relevant genes were 
in common. This list was further subjected to gene ontology analysis and we could identify 35 
targets that have been implicated in angiogenesis, cell morphogenesis, apoptosis, migration, 
adhesion, MAPK signaling, cell cycle, cytoskeleton remodeling, EGFR signaling and EMT. In 
order to strengthen our observation, we assess the direct occupancy of Sox4 at the promoters of 
these genes. Chromatin Immunoprecipitation (ChIP) assay in NMuMG cells transiently 
transfected with HA-Sox4 construct using HA-specific antibodies revealed that out of these 35 
genes, the promoters of 23 genes are directly bound by Sox4 (including key EMT genes such as 
Spred1, Edn1, Palld, Cyr61, Ereg, Areg and Yap1) (Supplemental Figure S4 A-I). These Chips 
experiments further helped us to better define the Sox4 binding motif as A A C A A G/A for the 
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target promoters analyzed. It has been shown previously that Sox4 directly regulates Mll, a 
DNA-binding protein that methylates histone H3 lys4 (H3K4) and positively regulates 
expression of target genes, in prostate cancer (Scharer et al., 2009). Given emerging evidences of 
Polycomb group (PcG) proteins, especially the H3K27 methyltransferase Ezh2, in 
carcinogenesis, we investigated whether Sox4 may have possible regulatory influence on the  
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Figure 6: Sox4 directly binds the Ezh2 promoter. (A-B) RT-qPCR for measurement of Ezh2 expression levels 
upon Sox4 knockdown in NMuMG (A) and Py2T (B). Immunoblot for the repressive mark H3K27me3 after 
siRNA- mediated Sox4 ablation in NMuMG (A) and Py2T (B) cells. The cells were treated with TGF-β for 2 days. 
(C-D) Following Chromatin Immunoprecipitation (ChIP) using HA-specific antibody in NMuMG (C) and Py2T (D) 
cells transiently transfected with HA-Sox4 construct, realtime PCR was performed using Ezh2-promoter specific 
primers to determine the  Sox4 occupancy at this region. Statistical values were calculated by using an 
unpaired/paired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 
0.001 indicated with (***). 
 
 
transcriptional regulation of Ezh2. Interestingly, expression array results and further validation 
by quantitative RT-PCR showed that Ezh2 is significantly dowregulated upon Sox4 depletion in 
presence of TGF-β in NMuMG (Fig 6A) and Py2T (Figure 6B). Sox4 knockdown also led to a 
global reduction in H3K27me3 levels in NMuMG and Py2T cells (Figure 6A and 6B). 
Interestingly, Chromatin Immunoprecipitation assays revealed that Sox4 directly bound the Ezh2 
promoter in NMuMG (Figure 6C) and Py2T cells (Figure 6D). These data suggest that Sox4 
directly binds to promoters of key EMT genes, including Ezh2, for their transcriptional 
activation during TGF-β induced EMT. 
 
3.2.3.6 Ezh2 knockdown phenocopies Sox4 depletion 
We next speculated whether some aspect of EMT regulation by Sox4 are mediated via its 
regulation of Ezh2 and assessed whether knockdown of Ezh2 phenocopies Sox4 depletion. 
Interestingly, siRNA-mediated depletion of Ezh2 in NMuMG cells led to a retention of an 
epithelial phenotype even in the presence of TGF-β (Figure 7A). Furthermore, these 
morphological changes were also accompanied with retention of the epithelial markers like E-
cadherin and ZO-1 as well as the loss of the mesenchymal marker N-cadherin (Figure 7B). These 
results were further supported by immunoflorescence staining for epithelial and mesenchymal 
markers in Ezh2-depleted NMuMG cells (Figure 7C).  
We next investigated whether Ezh2 also exerted a survival effect during EMT similar to that 
observed for Sox4. Annexin V staining in Ezh2 depleted NMuMG cells during TGF-β treatment 
revealed that apoptosis was significantly increased upon Ezh2 depletion during EMT (Figure  
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Figure 7: Depletion of Ezh2 phenocopies the absence of Sox4 during TGF-β-induced EMT. (A) Phase contrast 
microscopy was performed to study the morphology of NMuMG cells transfected with siControl and siEzh2 is 
monitored after TGF-β treatment for the indicated period. (B) Expression levels of the epithelial markers, E-cadherin 
and ZO-1 and mesenchymal marker, N-cadherin were measured by immunoblot analysis in cells treated with either 
control or Ezh2-specific siRNA during a TGF-β time-course. Actin was used as a loading control. (C) Confocal 
microscopy analysis of NMuMG cells to assess the localization and expression levels of EMT markers after 7 days 
of TGF-β treatment. (D) Apoptosis was measured by Annexin V staining in combination with FACS analysis in 
control (siControl) and Ezh2-depleted (siEzh2) NMuMG cells treated with TGF-β for the days indicated. (E) 
Propidium iodide staining to quantitate the cell cycle phases after Ezh2 knockdown during TGF-β-induced EMT for 
0, 1 and 4 days. (F) NMuMG cells transfected with siControl and siEzh2 were treated with TGF-β for the days 
indicated and counted using a Neubauer chamber to assess the proliferation rate during TGF-β EMT. (G) Ezh2 
depleted cells were subjected to Boyden chamber migration assays using 20% FBS as a chemoattractant. Statistical 
values were calculated by using an unpaired/paired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 
0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
7D). In addition, similar to Sox4 knockdown cells, Ezh2-depleted NMuMG cells were also 
blocked in the G0/G1 phase of the cell cycle and were not able to proliferate (Figure 7E and 7F). 
These results suggest that, in line with Sox4 depletion phenotype, decreased and TGF-β sensitive 
growth of Ezh2 depleted NMuMG cells relies on both increased proliferation and decreased 
apoptosis during TGF-β-induced EMT. We also tested whether Ezh2 had an impact on the 
migration capacity of cell during EMT by performing a trans-well migration assay in Ezh2- 
depleted NMuMG cells in the absence of TGF-β. As expected, these cells were not able to 
migrate more than the control counterpart (Figure 7G). Together, these observations have led us 
to conclude that Ezh2 is an downstream effector of Sox4 regulatory network and functions to 
regulate TGF-β-induced EMT in a fashion similar to Sox4. 
 
3.2.4 Discussion 
Most solid tumors are epithelial in nature and increasing evidences suggest that tumor 
progression accompanies EMT to enable tumor cells to acquire the capacity to be motile and 
infiltrate surrounding tissues, thus licensing them to metastasize to distant sites. 
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Transcription factors play a range of crucial regulatory roles in diverse aspects of cellular 
function such as cell proliferation, differentiation and survival by regulating transcription of 
genes underlying the process. Such regulation has to be tightly regulated and is crucial for proper 
execution of the gene-expression program that defines cellular identity. Misregulation in the 
expression and function of transcription factors involved in cellular pathways has been linked to 
various diseases including cancer. 
Sox4 is a one of such key transcription factors that has been linked to certain cancers. However, 
no detailed investigation has been performed to assess its direct relation with EMT. Our study 
revealed that Sox4 is an inducer of EMT and the absence of Sox4 in breast cancer cells leads to 
suppression of EMT. Moreover, Sox4 is required for EMT-driven cell migration and provides a 
survival advantage to cells undergoing EMT by attenuating TGF-β-induced apoptosis. More 
importantly, we also demonstrated that Sox4 is not only required for EMT but also for metastatic 
spread during breast carcinogenesis. Orthotropic fat-pad injection of Sox4 depleted Py2T cells 
into nude mice has revealed that metastasis lesions are decreased in different breast cancer 
metastasis sites including lymph-nodes (axillary and inguinal), lungs and liver. In addition, after 
surveying the gene expression profiles of human cancer biopsies using the NextBio.com 
database, we found a significant positive correlation between increased Sox4 expression and 
metastatic potential of melanoma cancer. Moreover, a positive and significant correlation of 
increased Sox4 expression with tumorigenicity and advances in tumor stage was also observed. 
Interestingly, in melanomas it is well known that the resistance towards TGF-β-mediated growth 
inhibition and EMT plays an essential role for their metastatic spread, supporting our findings 
that Sox4 depletion has a protective function during tumor-progression and metastasis (Poser et 
al., 2001; Silye et al., 1998; Teicher, 2001). Intravenous injection of Sox4-depleted B16-F10 
melanoma cells into the tail-veins of C57/Bl6 mice revealed that Sox4 also plays a key role in 
metastasis formation in a melanoma cell model.  
To identify genes that are possibly under direct transcriptional control of Sox4, genomewide 
expression profiling was performed after Sox4 depletion in the absence and presence of TGF-β 
which identified a number of genes that were deregulated in Sox4 knockdown cells. To reveal 
the possible direct targets of Sox4, we screened for genes that had a Sox4 binding motif within 
1Kb of their transcription start site. In addition, the resulting list was further compared with the 
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genome-wide expression data of a EMT time-course to identify the EMT relevant genes. This 
analysis has revealed that Sox4 regulates many key EMT genes, such as Spred1, Edn1, Palld, 
Cyr61, Ereg, Areg and Yap1 by directly acting on their promoters. In addition, Sox4 also 
targeted many genes involved in other EMT relevant processes such as angiogenesis, adhesion, 
migration, morphogenesis, cell cycle regulation and cytoskeleton re-modeling. We further 
identified the Ezh2 promoter to be bound by Sox4 for transcriptional modulation. Ezh2 is a 
histone H3K27 methytransferase that has been shown to repress E-cadherin (Cao et al., 2008) 
and is therefore implicated in EMT. In line with being a downstream effector of Sox4, Ezh2 
contributes to TGF-β-induced EMT in a fashion similar to Sox4 with respect to being required 
for transition from epithelial to mesenchymal identity and cell migration and cell survival events 
that accompany this process.  
Taken together, our findings reveal mechanistic insight into how Sox4 regulates EMT by 
targeting and controlling the expression of crucial EMT genes, thereby directly contributing to 
the transcriptional reprogramming underlying this process. Keeping the versatile function of this 
factor in view, our data are certainly of key importance in the EMT field and will possibly pave 
the way for a therapeutic value in the long-term. 
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3.2.5 Supplemental figures
 
Figure S1: Sox4 ablation delays EMT in Py2T cells. (A-B) RT-qPCR quantification of the epithelial marker E-
cadherin (A) and themesenchymal marker fibronectin (B) in Py2T cells stably transfected with control (shControl) 
and Sox4-specfic (ShSox4) shRNA. (C) RT-qPCR to assess the knockdown efficiency after stable transfection of 
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shSox4 in Py2T cells. Statistical values were calculated by using an unpaired/paired, two-tailed t-test. p-value ≤ 0.05 
indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
Figure S2: Sox4 is required for cell proliferation and migration in Py2T cells. (A) Py2T cells transfected with 
shControl and shSox4 were treated with TGF-β for 2, 4, 7 and 10 days and counted using a Neubauer chamber to 
assess the proliferation rate during TGF-β-induced EMT. (B)  Cell cycle analysis was performed by using FACS 
Diva software after Propidium Iodide staining. (C) Boyden chamber migration assays were performed in Sox4-
depleted cells after 15 days of TGF-β treatment. 20% FBS was used as chemoattractant and assays were performed 
for 20 hours. Statistical values were calculated by using an unpaired/paired, two-tailed t-test. p-value ≤ 0.05 
indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
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Figure S3: Absence of Sox4 impairs breast cancer metastasis. (A) Metastatic spread was quantified by measuring 
relative luciferase levels in lymph nodes, lung and liver of nude mice injected with shControl and shSox4. Statistical 
values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 
indicated with (**), p-value ≤ 0.001 indicated with (***). 
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Figure S4: Sox4 directly binds to promoters of crucial EMT genes (a-i) Chromatin Immunoprecipitation (ChIP) 
assay is performed using HA-specific antibodies in NMuMG cells transiently transfected with HA-Sox4 construct. 
Following this, qPCRs were performed to test the occupancy by Sox4 at the promoters of various genes implicated 
in angiogenesis and development (A), adhesion (B), migration (C), morphogenesis (D), cell cycle (E), cytoskeleton 
(F), EGF-related (G), Mitogen activated protein kinases related (H) and some other genes (I). 
3.2.6 Methods and Materials 
Reagents and antibodies 
Reagents: TGF-β (240-B, R&D systems). DMEM (D5671, Sigma-Aldrich), RPMI-1640 
(R0883, Sigma-Aldrich), PBS (D8537, Sigma-Aldrich), trypsin (T4174, Sigma-Aldrich), Opti-
MEM (11058, Gibco), FBS (F7524, Sigma-Aldrich), Glutamine (G7513, Sigma-Aldrich), 
Pencillin/streptomycin (P4333, Sigma-Aldrich), Lipofectamine RNAiMax (11668-019, 
Invitrogen), Alexa Fluor-488, 568, 633 (Invitrogen),  Polybrene (AL-118, Sigma-Aldrich), 
Puromycin (P7255, Sigma-Aldrich), Fugene HD ( 12998300, Roche), Trizol (T9424, Sigma-
Aldrich), M-MLV reverse transcriptase (M314C 28692233, Promega),  SYBR-green PCR 
MasterMix (Eurogentec) and  Bradford reagent (500-0006, Biorad), Protease inhibitor cocktail 
(P2714, Sigma-Aldrich). Antibodies: Western Blot: E-Cadherin (610182, Transduction 
Laboratories), N-Cadherin (M142, Takara), ZO-1 (617300, Zymed), Fibronectin (F-3648, 
Sigma-Aldrich), β-Catenin (C 2206, Sigma-Aldrich), p120 (P1870, Sigma-Aldrich), Actin (SC-
1616, Sanata Cruz Biotechnology). Immunofluorescence: E-Cadherin (13-1900, Zymed), N-
Cadherin (610921, Transduction Laboratories), ZO-1 (617300, Zymed), Fibronectin (F-3648, 
Sigma-Aldrich), Phalloidin (A12380, Invitrogen), Paxillin (13520, Transduction Laboratories), 
Vimentin (V2258, Sigma). IHC: Sox4 (ab52043, Abcam), ChIP: HA (ab9110, Abcam). 
Apoptosis and Cell cycle: Annexin-V (559934, BD Biosciences) and PI (P4170, Sigma-Aldrich), 
Small interfering RNAs:  siControl (Stealth RNAi™ siRNA Negative Controls, 12935-100, 
Invitrogen), siSox4 (SASI_Mm01_00114972 and SASI_Mm01_00114974, Sigma-Aldrich) and 
siEzh2 (SASI_Mm01_00061985, SASI_Mm01_00061987 & SASI_Mm01_00061988, Sigma-
Aldrich). Small hairpin RNA: shControl (Mission Non-target shRNA control vector, SHC002) 
and shSox4 (SHCLNG-NM_009238 Mouse, TRCN0000012081).  
Cell lines and cell culture 
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A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has been 
previously described (Maeda et al., 2005). MCF7 shControl and MCF7-shEcad have been 
described before (Lehembre et al., 2008). Py2T cells were derived from Polyoma middle T 
breast cancer tumor model (unpublished data, Waldmeires et.al). B16-F10 melanoma cells also 
have been described earlier (Briles and Kornfeld, 1978; Fidler, 1975; Fidler and Bucana, 1977; 
Fidler et al., 1976; Fidler and Kripke, 1977). NMuMG, MCF7shControl, MCF7-shEcad, Py2T, 
293T and PLAT-E cells were cultured in DMEM supplemented with 10% FBS, 2mM glutamine, 
100U penicillin and 0.2mg/ml streptomycin. B16-F10 cells were cultured in RPMI-1640 
supplemented with 10% FBS, 2mM glutamine, 100U penicillin and 0.2mg/ml streptomycin. All 
the cells were cultured at 370c with 5% CO2 in humid incubator. For TGF-β time-course 
experiments, cells were treated with 2ng/ml TGF-β for indicated time point and it was replaced 
every 2 days. For siRNA transfections, Lipofectamine RNAiMax was used according to the 
manufacturer's instructions.  
Quantitative RT-PCR 
Total RNA was prepared by using a Tri Reagent according to the manufacturer’s instructions. 
RNA was further reverse transcribed with ImProm-II Reverse Transcriptase, and transcripts were 
quantified by PCR using SYBR-green PCR Mastermix in a real time PCR system (Step One 
Plus, Applied Biosystems). Human or mouse ribosomal L19 primers were used for 
normalization. PCR assays were performed in duplicates, and fold induction was calculated 
against control-treated cell lines using the comparative Ct method (ΔΔ Ct). Following primers 
were used:  
Primer name Sequences 
mRpl19 Forward primer ctcgttgccggaaaaaca 
mRpl19 Reverse primer tcatccaggtcaccttctca 
mSox4 Forward primer cctcgctctcctcgtcct 
mSox4 Reverse primer tcgtcttcgaactcgtcgt 
hRpl19 Forward primer gatgccggaaaaacaccttg 
hRpl19 Reverse primer cagggcagtgatctccttctg 
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hSox4 Forward primer ccaaatcttttggggactttt 
hSox4 Reverse primer ctggcccctcaactcctc 
mE-cadherin Forward primer cgaccctgcctctgaatcc 
mE-cadherin Reverse primer tacacgctgggaaacatgagc 
mN-Cadherin Forward primer caatgacgtccaccctgttct 
mN-Cadherin Reverse primer ctgccatgactttctacggaga 
mFibronectin1 Forward primer cccagacttatggtggcaatt 
mFibronectin1 Reverse primer atattccgactcgagtctga 
mEzh2 Forward primer caggctggggcatctttatc 
mEzh2 Reverse primer acgaattttgttgccctttc 
 
Immunoblot 
Cells were lysed for 1 hour on ice in RIPA-Plus buffer (50mM Tris-HCl, pH8.0), 150mM NaCl, 
10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 2mM 
CaCl2, 1mM dithiothreitol, 1mM sodium fluoride, 0.2mM sodium orthovanadate, 1x protease 
inhibitor cocktail and further quantified by using Bradford reagent. 50 μg of cleared protein 
lysates were separated by SDS-PAGE and electroblotted on PDVF membranes, and proteins 
were visualized with the appropriate primary and secondary antibodies and ECL on superRX 
films. Depending on the species origin of antibodies, immunoblots were either probed 
sequentially or on multiple membranes. Adobe Photoshop has been used to excise the relevant 
portion of the immunoblots from the original scans of X-ray films exposed to 
chemoluminescence visualization of specific proteins. 
Immunofluorescence 
siControl, siSox4 and siEzh2 cells were plated on coverslips and treated with TGF-β for 
mentioned time. The cells were fixed with 4% paraformaldehyde in HBSS and further 
permeablized with 0.2% Triton for 5 minutes at room temperature. These cells were blocked by 
using 3.5% goat serum for 15 minutes and incubated with primary antibodies against E-cadherin, 
N-cadherin, fibronectin, Zo-1, β-catenin, p120 and Ezh2 for 1 hour and then incubated with 
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flurochrome-labeled secondary antibody for 1 hour at room temperature. The coverslips were 
counterstained with DAPI and imaged with a confocal laser-scanning microscope. Data were 
processed with Adobe Photoshop 7.0 software. 
Production of lentivirus for in-vivo and in-vito knockdown studies  
Murine Sox4 shRNAs and control shRNA were purchased from Sigma-Aldrich as described 
above. For lenti-virus production, 293T cells were transfected with the shRNA expressing lenti-
viral vector in combination with the packaging vectors including envelope protein; HDM-
pVSV/G,  codon-optimized HIV gag-pol; HDM-Hpgm2, transactivator of transcription; HDM-
Tat1b and  pRC-CMV-RaII by Fugene HD. After 48 hours of transfection, viral supernatant was 
harvested, filtered (0.46 µm), supplemented with polybrene (8ng/ml) and used to infect target 
cells. Infections were performed once a day for two consecutive days. Infected cells were 
positively selected using Puromycin (5ug/ml). 
Production of retrovirus for over-expression studies  
HA-Sox4 (kindly provided by Prof. Dr.A-P Tsou) cloned into the retroviral expression vector 
pBabe. Retroviral particles were produced by transfecting PLAT-E cells with the retroviral 
expression vectors using Fugene HD. After two days of virus production, retroviral-containing 
supernatants were harvested, filtered (0.45 µm) and added to target cells in presence of 
polybrene (8 ng/ml). Infections were performed once a day for two days and later on selection 
was performed by using puromycin. Single clones were picked for the experiments. 
Wound healing assay 
In vitro wound healing assays were done on confluent siControl and siSox4 cells. The media on 
the confluent cells was replaced with DMEM with 2% fetal bovine serum media and an area of 
cells was scraped off using a 200ul pipette tips. Light microscopic images were taken at time 0 
and at 20 hours. The data was further analyzed by using a ImageJ software. 
Migration assay 
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Cell migration was assessed in siControl and siSox4 cells in a transwell migration assay (pore 
size: 8 μm; Falcon BD). 104 cells were seeded in 2% FBS/DMEM (Sigma) in the upper chamber 
and the lower chamber was filled with 20% FBS/DMEM. After 20 hours of incubation at 37°C, 
cells in the upper chamber were carefully removed with a cotton swap and the cells that had 
traversed the membrane were fixed in 4% paraformaldehyde/PBS, stained with DAPI. Pictures 
of the membrane were taken at a 10x magnification using a fluorescent microscope (Nikon 
Diaphot 300). Quantification was done using the software ImageJ. 
Apoptosis assay (Annexin assay) 
Following supernatant collection to get the floating cells for the assay, cells were trypsinized and 
mixed with supernatant. Furtheron, cells were washed twice with cold PBS and resuspended in 
1X Annexin V binding buffer (10mM Hepes (pH 7.4), 0.14 M NaCl, 0. 25 mM CaCl2) at a 
concentration of 1 x 106 cells/ml. 5 µl of Cy5 Annexin V was added to the 100 µl of cells (1 x 
105) and incubated for 15 min on ice in the dark. Stained cells were filtered with a 40um mesh 
and analyzed on a FACSCanto II using DIVA software. 
Cell growth curve 
1x104 cells were seeded in each well of 24-well plate and cell numbers were assessed for 
mentioned days by using a Neubauer counting chamber. 
PI Staining 
siControl, siSox4 and siEzh2 cells were trypsinized  and fixed in 70% ice-cold Ethanol for 
overnight.  Washed twice with PBS and resuspended in sodium citrate buffer with 5μg/ml PI for 
overnight. Stained cells were analyzed by FACSCanto II using DIVA software. 
Fat-pad injection, Subcutaneous injection and Intravenous injection 
7 weeks old female nude mice were injected orthotopically into the fat-pad with 1x106 shControl 
and shSox4 Py2T cells in 100ul of PBS. After 23 days of treatment, mice were sacrificed and 
tumor, lymph-nodes, lungs and liver were isolated, weighted and prepared as described in 
histological analysis. 
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shControl and shSox4 B16-F10 melanoma cells were harvested by trypsinization and 
resuspended in PBS to a final concentration of 1x105 cells/200μl. 8 weeks old C57/Bl6 mice 
were injected intravenously through tail-vein with 200 μl of each cell line, and waited for 18 
days before sacrificing the mice. After sacrifying the mice, lung metastasis were counted. 
shControl and shSox4 cells were harvested by trypsinization and resuspended in PBS to a final 
concentration of 1x106 cells/100μl. 8 weeks old C57/Bl6 mice were injected into the right flank 
with each cell line, and tumors were allowed to form for 27 days. Mice were sacrificed when the 
tumors reached a diameter of 1.5 cm and lymph-nodes, lungs and liver were isolated and 
processed for histological analysis. 
Histological analysis  
The preparation of immunohistochemical analysis was performed as described previously (Perl 
et al., 1998). Briefly, for the paraffin section preparation, tumors, lungs and livers from above 
mouse experiment were removed and fixed in HBS-Ca2+ (HEPES-buffered saline, 1 mM 
CaCl2) containing 4% paraformaldehyde for overnight and processed further for H&E staining.  
For OCT frozen sections, organs were removed and fixed in HBS-Ca2+ (HEPES-buffered saline, 
1 mM CaCl2) containing 4% paraformaldehyde for 2 h at 4 °C. Tissues were incubated 
overnight at 4 °C in HBS-Ca2+/20% sucrose, embedded in O.C.T. compound (Tissue Tek), and 
frozen in liquid nitrogen. H & E Staining was performed as described before (Perl et al., 1998) 
and evaluated on an AxioVert microscope. 
Immunohistochemistry 
shControl and shSox4 Py2T tumor sections deparaffined in xylene and rehydrated. Sox4 
antigenic recovery was carried out with a pressure cooker for 15 min in 10mM sodium citrate 
buffer with 0.05% Tween 20, pH 6.0. Slides were washed with TBS with 0.025% Triton X-100 
and blocked with 10% goat serum with 1% BSA in TBS for 1 hour at room temperature. After 
blocking, the sections were incubated with Sox4 antibody in TBS with 1% BSA for overnight. 
Sections were washed again in TBS with 0.025% Triton X-100 and incubated with 0.3 %H2O2 
to block the endogenous peroxidase. Sections were washed again with TBS and bound antibodies 
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were detected using the ABC vector-horseradish peroxidase kit according to the manufacturer's 
instructions. 
Microarray processing and data analysis 
RNA was isolated from NMuMG cells transfected with control siRNA or Sox4 siRNA and 
treated with TGF-β for 0 and 2 days using Tri Reagent (Sigma-Aldrich). RNA quality and 
quantity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies). The 
manufacturer’s protocols for the GeneChip platform by Affimetrix were followed. Methods 
included synthesis of the first- and second-strand cDNA followed by synthesis of cRNA by in 
vitro transcription, subsequent synthesis of single-stranded cDNA, biotin labeling and 
fragmentation of cDNA and hybridization with the microarray slide (GeneChip® Mouse Gene 
1.0 ST array), posthybridization washings and detection of the hybridized cDNAs using a 
streptavidin-coupled fluorescent dye. Hybridized Affimetrix GeneChips were scanned using an 
Affimetrix GeneChip 3000 scanner. Image generation and feature extraction were performed 
using Affimetrix GCOS Software and quality control was performed using Affimetrix 
Expression Console Software. Raw microarray data were normalized with Robust Multi-Array 
(RMA) and analyzed using Partek® Genomics Suite Software (Partek Inc.). One-way analysis of 
variance (ANOVA) and asymptotic analysis were used to identify significantly differentially 
expressed genes. The gene ontology (GO) tool from Partek® Genomics Suite Software as well as 
the David gene ontology software were used for further analysis. 
Chromatin Immunoprecipitation 
ChIP experiments were performed as previously described (Weber et al, 2007). In brief, 
crosslinked chromatin was sonicated to achieve an average fragment size of 500 bp. Starting 
with 100 μg of chromatin and 5 μg of anti-HA antibody, 1 μl of ChIP material and 1 μl of input 
material were used for quantitative real-time PCR using specific primers covering the motif of 
Sox4 in the promoter of target genes. Primers covering an intergenic region are used as a control. 
The efficiencies of PCR amplification were normalized for between the primer pairs. Following 
primers were used for ChIP –PCR.  
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Name Sequences 
Aldh1a1 FP ggtttgctggtagccatgtt 
Aldh1a1 RP cattcccttttcctgctttg 
Cyr61 FP ggtcaagtggagaagggtga 
Cyr61 RP gcacctcgagagaaggacac 
Edn_1 FP tttccttccttgctaactcctg 
Edn1_1 RP agatcaccctacttttccacca 
Edn_2 FP gttttgcattgagttccatttg 
Edn_2 RP gtcacgaacagcagagagaaga 
Sema3c FP agtctcaaagtgttgggaccat 
Sema3c RP ttatgctgacctttccacactg 
Serpina1b FP attctcctgcaaaggaaacaaa 
Serpina1b RP ggggctcagagtaggttatgtg 
Vcam1 FP tctgcatcaacgtcctttca 
Vcam 1 RP cccattatcatgagtcactctttt 
Vnn1 FP gttcaagtgacagctgagtgct 
Vnn1 RP ccctggggttttctttaaattc 
Fgd4 FP cttcagaatgagcctgtttcaa 
Fgd4 RP tgcatgcatgaaaactacacac 
Ptgs1 FP aaaacaactcccctcaccttt 
Ptgs1 Rp gggcagtgagtgggatgtaa 
Cfb FP tccttggacggagatacagg 
Cfb RP ggaagagacaacagggtgga 
Dusp1 FP cagcttctgttcagtggagatg 
Dusp1 RP ttgctgtgtagctctggctagt 
Ereg FP gcatttgagacaggcacaga 
Ereg RP ccctcagcttccaatgtgat 
Csrp1_1 FP gttcaaggccattctggtctac 
Csrp1_1 RP gctatgggtgggagtgttagag 
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Csrp1_2 FP tgacttctctttgcaccctatg 
Csrp1_2 RP ctcacagttaggtctccgcttt 
Palld FP gaagaactgaccacatggctaa 
Palld RP aattacctcccagccttttctc 
Areg FP cattatgcagctgctttgga 
Areg RP tttcgcttatggtggaaacc 
Mep1a1 FP gagtcaccacgagacaagca 
Mep1a1 RP ggggctttgttacacaggaa 
Spred1 FP actcatgccagttccattcttt 
Spred1 RP acgctcaagtccccgttact 
Ccl20 FP gttgagactggtgttttccaca 
Ccl20 RP ccagtcctagaggggaaagatt 
Ctnnbp2nl FP aattaagccaccacaaggtgtt 
Ctnnbp2nl RP gaggaagtaccctcctctggtc 
Gss FP taggttgccagaggatgagg 
Gss RP tgtgagatggggacactcaa 
Yap1 FP agcttcaaaaaccccgttct 
Yap1 RP ggctaaagcagcacaggaac 
Ypel1 FP gctgggctacgggtccaaaaca 
Ypel RP gcgcccatccggcccaggct 
Ezh2 FP gtcacacgccttcctttcagt 
Ezh2 RP gcctgagccaagtttgaaatagt 
 
Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad 
Software Inc, San Diego, CA). All statistical analysis was done by unpaired, two-sided t-test. 
Normality testing was performed using the Kolmogorov-Smirnov test with Dallal-Wilkinson-
Lillie for p-values. 
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3.3.1 Abstract 
Epithelial-to-mesenchymal transition (EMT) represents a key example of cell plasticity that 
underlies crucial steps during development, would healing and carcinogenesis. Despite emerging 
evidences that genes involved in EMT are altered in tumors via both genetic and epigenetic 
changes, the later remains largely unknown. In the current study, we comprehensively 
investigated the role of two prominent epigenetic modifications – Histone 3 Lysine 27 tri-
methylation (H3K27me3) and DNA methylation during TGF-β-induced EMT of mammary 
epithelial cells. A genome-wide ChIP-seq analysis for the H3K27me3 mark during six 
consecutive stages of EMT progression uncovered a number of key EMT genes that are 
transcriptionally regulated by the Polycomb-mediated H3K27me3 during this process. Genes 
such as Mcam, Pdgfrb and Itga5 are enriched with H3K27me3 and repressed in epithelial cells 
and treatment with TGF-β leads to a progressive loss of this mark that accompanies their 
transcriptional activation and acquisition of EMT. Another set of genes such as Cdh1, Ocln and 
Cdx2, gain this mark and become repressed during TGF-β-induced EMT. We further show that 
the coordinated activities of both Ezh1 and Ezh2 are responsible for H3K27me3-mediated 
repression in these cells as co-depletion of these two enzymes not only removes the H3K27me3 
mark from the target promoters and de-represses them but also prevents EMT. A genomewide 
analysis of promoter methylation using Methylated DNA Immunoprecipitation (MeDIP) in 
combination with tiling arrays revealed no major changes during EMT. Taken together, our data 
provides evidence that Polycomb machinery-mediated epigenetic reprogramming underlies 
transcriptional changes driving EMT.  
3.3.2 Introduction 
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TGF-β belongs to most potent inducers of the epithelial-mesenchymal transition (EMT). Cancer 
cells which undergo EMT are able to detach from the primary tumor by breaking their cell-cell 
contact and follow the chemoattractive path through extracellular matrix to invade into the 
surrounding tissue and form metastatic lesions at distant sites (Grunert et al., 2003; Polyak and 
Weinberg, 2009; Thiery and Sleeman, 2006). Interestingly, besides promoting invasiveness, 
TGF-β-induced EMT was shown to induce the transition of transformed and immortalized 
human mammary epithelial cells into mesenchymal cancer cells with stem cell traits, thus linking 
EMT to tumor cell plasticity (Cao et al., 2008; Shipitsin et al., 2007). It is established that such 
TGF-β-mediated cellular transformation involves activation of downstream signaling cascades 
and subsequent transcriptional reprogramming. In addition to the remarkable variety of 
transcription factors and co-regulators, the role of chromatin-mediated transcription control in 
transcriptional regulation has been increasingly appreciated. However, there is no solid evidence 
that EMT involves epigenetic reprogramming events to initiate transcriptional changes. 
The Polycomb Group (PcG) and trithorax Group (trxG) of proteins are involved in defining 
cellular memory and prevent changes in cell type-specific transcription programs to maintain cell 
identity (Bantignies and Cavalli, 2006; Cao et al., 2005; Cao et al., 2002; Cao and Zhang, 2004a; 
Cao and Zhang, 2004b; Jacobs and van Lohuizen, 1999; Kuzmichev et al., 2004; Negishi et al., 
2007; Vire et al., 2006). Among Polycomb complexes, Polycomb repressive complex 2 (PRC), 
comprised of EZH2, EED, SUZ12, RbAp46/48 and AEBP2 (E(z), Esc, Su(z)12, and RbAp48 in 
Drosophila) of which EZH2 bears the enzymatic activity that trimethyates Histone H3 at Lys 27  
(H3K27me3) (Cao and Zhang, 2004a; Cao and Zhang, 2004b; Satijn et al., 2001; Sparmann and 
van Lohuizen, 2006a). Such PRC2 activity is known to associate with transcriptional repression 
by several mechanisms. PRC2 has been shown to recruit DNA methytransferases (DNMT) to the 
chromatin for repression (Vire et al., 2006). PRC2 binding has also been reported to attract 
Histone deacetylases (HDAC) to deacetylate the histone tails for gene repression (Wang et al., 
2004b). Furthermore, it has also been proposed that Polycomb complexes lead to condensed 
chromatin structure and thus physically hinder the transcription machinery (Wang et al., 2004b) 
PRC2 is also known to facilitate binding of another Polycomb complex, PRC1, which then 
contributes to the maintenance of gene repression (Cao et al., 2005; Wang et al., 2004a; Wang et 
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al., 2004b). Thus, PRC2 is thought to be involved in the initiation and PRC1 in the maintenance 
of gene repression.  
Ezh1, unlike Ezh2, is a part of a non-canaonical PRC2 and mediates methylation of H3K27 
similar to Ezh2 and functions in the maintenance of embryonic stem cell pluripotency and 
plasticity (Shen et al., 2008). Ezh1 was shown to colocalize with the H3K27 trimethylation mark 
in Ezh2 -/- cells and to preferentially preserve this mark at development-related genes. Co-
depletion of both Ezh1 and Ezh2 abolished residual methylation on H3K27 and derepressed 
H2K27-trimethylated target genes (Shen et al., 2008). Compared to Ezh2, Ezh1 has very weak 
methyltransferase activity but efficiently represses transcription and compacts chromatin 
(Margueron et al., 2008).  It is also been demonstrated that Ezh1 is expressed in non-proliferative 
cells while Ezh2 is expressed in proliferative cells which again argues for their evolution for 
different roles. 
In the current study, we investigated whether the Polycomb machinery is involved in 
transcriptional reprogramming during EMT. Since it has been shown earlier that  E-cadherin can 
be repressed by Ezh2 in the prostate cancer (Cao et al., 2008) and that low Ezh2 expression 
levels are correlated with metastasis-free survival in breast cancer (Kleer et al., 2003), we 
investigated whether Ezh2-catalyzed H3K27me3 is involved in the transcriptional modulation 
during TGF-β-induced EMT in breast carcinogenesis. Towards this, we used the normal 
mammary epithelial cells, NMuMG, which undergo progressive EMT upon TGF-β treatment 
(Supplemental figure 1a). We performed Chromatin Immunoprecipitation using H3K27me3-
specific antibody at six different morphological stages during TGF-β-induced EMT followed by 
next generation sequencing (ChIP-seq). A comparison of identified H2K27me3 enriched genes 
with global transcription profiling of the corresponding stages revealed a number of key EMT 
genes that may possibly be transcriptionally regulated by the PRC2 machinery. By carrying out 
loss of function studies, we demonstrate that double-knockdown of Ezh1 and Ezh2 not only 
prevents TGF-β-induced EMT but also blocks EMT-driven cell migration. Such depletion further 
suppresses TGF-β-induced apoptosis, arguing for a H3K27me3-mediated regulation of survival- 
associated genes. Gene ontology studies on gene regulated by Ezh1 and Ezh2 further supported 
our data for a Polycomb-mediated mechanisms regulating transcription of genes underlying 
EMT-related migration, adhesion and survival. Moreover, comprehensive MeDIP-chip analysis 
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at three different stages of TGF-β-induced EMT revealed no significant changes in DNA 
methylation. In summary, our data reveals new insights into the epigenetic reprogramming of 
key EMT genes by Polycomb-mediated mechanisms. 
 
3.3.3 Results 
 
3.3.3.1 Genome-wide analysis of H3K27me3 mark reveals widespread epigenetic 
reprogramming during TGF-β-induced EMT  
To assess the role of Polycomb group of proteins during EMT, we employed NMuMG cells 
which are untransformed normal murine mammary gland cell line and undergo progressive EMT 
in response to TGF-β (Lehembre et al., 2008; Miettinen et al., 1994; Piek et al., 1999a), 
acquiring the complete mesenchymal transition by the end of 10 days (Supplemental figure S1a). 
To illustrate the dynamics of the PRC2-mediated repressive histone modification H3K27me3 
during EMT, we performed Chromatin immunoprecipitation (ChIP) using a H3K27me3-specific 
antibody upon TGF-β treatment in NMuMG cells for 1, 4 ,7, 10 and 20 days and subjected the 
precipitated DNA to next generation sequencing (ChIP-seq). This high resolution profiling 
showed that H3K27me3 is enriched in broad domains for the Hox locus that mostly remains 
unchanged during EMT (Figure 1a). We next attempted to reveal H3K27me3 peaks associated 
with genes using a sliding window approach (see experimental Procedures). This analysis 
identified a total of 2034 genes (Figure 1b). To correlate H3K27me3 enrichment with 
transcription levels of associated genes, we compared this list with the genome wide expression 
analysis performed in the non-treated NMuMG cells as well as those treated with TGF-β for 1, 4, 
7, 10 and 20 days. Using this comparison, we sorted out 90 genes which are transcriptionally 
upregulated during EMT and lose the H3K27me3 mark and 181 genes which are 
transcriptionally downregulated during EMT and gain the H3K27me3 mark (Supplemental 
figure 1b, 1c, 1d and 1e and table 1). We further validated the ChIP-Seq data using single gene 
controls (Figure 1c). To further strengthen our data, we used the Py2T cells (Waldameier et.al, 
unpublished data) which are derived for MMTV-PyMT transgenic mice tumors and undergo 
EMT upon TGF-β treatment in a similar fashion to NMuMG cells. All tested promoters were 
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similarly enriched for H3K27me3 in Py2T cells (Figure 1d). In summary, genomewide location 
analysis identifies targets of the PRC2-associated mark H3K27me3 during EMT.  
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Figure 1: Genome-wide reprogramming of the Polycomb-associated mark H3K27me3 during TGF-β-induced EMT. 
(a) Following ChIP using H3K27me3-specific antibody in non-treated as well as TGF-β treated (1, 4, 7, 10 and 20 
days) NMuMG cells, next-generation sequencing was carried out. Genome browser view of H3K27me3 ChIP 
enrichment at the HoxD cluster for several stages of TGF-β-induced EMT. (b) Dynamics of H3K27me3 upon TGF-
β treatment for 1, 4, 7, 10 and 20 days in NMuMG cells. The numbers of genes have been counted at each stage in 
comparison with untreated NMuMG cells and having a Z-Score above 3.5. (c) & (d) ChIP-qPCR validation of 
H3K27me3 enrichment at various identified targets in NMuMG (c) and Py2T (d) cells. Statistical values were 
calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with 
(**), p-value ≤ 0.001 indicated with (***). 
 
 3.3.3.2 Polycomb targets are key EMT genes  
To gain insight into the categories of genes represented within the promoter class, we performed 
a gene ontology analysis revealing that many of the H3K27me3 targets genes have already been 
implicated in various cancers and in EMT. The EMT relevant genes include E-cadherin  (Cdh1) 
(Cavallaro, 2004; Wheelock et al., 2008), melanoma cell adhesion molecule (Mcam) (Zabouo et 
al., 2009), platelet-derived growth factor receptor beta (Pdgfrb) (van Zijl et al., 2009), Snail2 
(Snai2) (Herranz et al., 2008; Peinado et al., 2007), Integrin alpha 5 (Itga5) (Kim et al., 2010), 
Occludin (Ocln) (Ikenouchi et al., 2003), Fibroblast growth factor receptor 2 (FGFR2) (Katoh 
and Katoh, 2009) and Inhibitor of differentiation 1 (Id1) (Tobin et al., 2011). In addition, genes 
related to extracellular matrix, cell adhesion, cytoskeleton re-modeling, apoptosis, cell-cycle, cell 
signaling pathways and DNA replication were also over-represented (Table 2, Table 3 and 
Supplemental Figure S2). 
 
3.3.3.3 Ezh1 and Ezh2 both contribute to the H3K27me3-mediated repression 
It is long known that Ezh2, a catalytic subunit of the PcG complex, is a main player in setting the 
H3K27me3 mark at the promoters. There is emerging evidence that Ezh1, a member of the non-
canonical PcG complex also mediates transcriptional repression via H3K27me3 (Ezhkova et al., 
2011; Margueron et al., 2008; Shen et al., 2008; Stojic et al., 2011).  To dissect the contribution 
of the two enzymes of the PRC complex in our system, we depleted Ezh1 and Ezh2 expression 
individually as well as together by using pools of two or three siRNAs, respectively.  RT-qPCRs  
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Table 1: Genes that are transcriptionally downregulated and gain the H3K27me3 mark during EMT (a) and vice 
versa (b). 
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Table 2: Gene-Ontology analysis revealed crucial EMT relevant pathways under regulation by Polycomb. GeneGo 
software was used to categorize the genes into functional groups. Gene ontology on the genes that lose the 
H3K27me3 mark and are transcriptionally up-regulated (a) during EMT and vice-versa (b). 
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Table 3:  Function analysis of regulated genes. David software was used to group genes into functional categories. 
(a) Genes that lose the H3K27me3 during EMT have a role in extra-cellular matrix organization, cell adhesion, 
cytoskeleton organization, neuronal differentiation, angiogenesis, cell projection formation, cell proliferation, 
apoptosis/survival and cancers. (b) GenesA  that gain the H3K27me3 mark are necessary for cytoskeleton 
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organization, angiogenesis, apoptosis/survival and cancer. Furthermore, they are also required for cell-cycle, 
replication, and morphogenesis of organs and cell-cell integrity.  
confirmed efficient depletion of Ezh1 and Ezh2 expression (Figure 2a-d). Immunoblot analysis 
suggested that Ezh2, to the large extent, contributed to the overall H3K27me3 levels in NMuMG 
cells (Figure 2e). To assess whether reduction of Ezh1 and Ezh2 (Ezh1/2) provide an additive 
effect, we tested transfected cells with pooled Ezh1 and Ezh2-specific siRNAs. Immunoblot 
analysis revealed that double-knockdown provides a more efficient reduction in global 
H3K27me3 levels (Figure 2e). We further determined the H3K27me3 levels in Py2T cells upon 
depletion of Ezh1, Ezh2 as well as double-knockdown of Ezh1and Ezh2. This experiment 
revealed a reduction in global H3K27me3 levels even after Ezh1 knockdown and the depletion 
efficiency is higher after double knockdown of Ezh1 and Ezh2 (Figure 2f). Together, these 
results suggest that Ezh1 and Ezh2 together contribute to the H3K27me3 levels in NMuMG and 
Py2T cells. 
3.3.3.4 Co-depletion of Ezh1 and Ezh2 blocks epithelial differentiation 
We next employed loss of function studies for studying the impact of Ezh1/2 on EMT. 
Interestingly, Ezh1/2-ablated cells retained their epithelial phenotype and were not able to 
undergo EMT upon TGF-β treatment (Figure 3a). This further accompanied the retention of the 
epithelial marker E-cadherin at the same time decrease in the levels of mesenchymal markers 
such as N-cadherin and fibronectin (Figure 3b; Supplemental figure S3a-c). Immunofluorescence 
studies showed that Ezh1/2 knockdown cells were able to maintain the adherent junction protein 
E-cadherin and tight junction protein ZO-1 at their membranes, while the mesenchymal marker 
N-cadherin remained unchanged to the control cells after 7 days of TGF-β treatment (Figure 3c). 
Moreover, TGF-β-mediated cytoskeleton re-modeling was also prevented and stress fibers were 
reduced in cells depleted of Ezh1/2 compared to control cells. Fibronectin and paxillin staining 
showed almost no focal adhesions after Ezh1/2 reduction (Figure 3c). Similar to NMuMG cells, 
a lentiviral-mediated stable knockdown of Ezh1/2 in Py2T cells resulted in failure to undergo 
EMT and also retained epithelial markers such as E-cadherin and showed a decrease in 
mesenchymal markers such as N-cadherin and fibronectin (Supplemental figure S3d-f). 
Together, these results strongly argue that Ezh1/2 is required for EMT. 
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Figure 2: Ezh1 and Ezh2 together contribute to the overall levels of H3K27me3 in NMuMG cells. (a-d) Realtime 
RT-PCR was carried out to test the knockdown efficiency following siRNA-mediated single knockdowns of Ezh1 
(a) or Ezh2 (b) in NMuMG cells during TGF-β-mediated EMT. Ezh1(c) and Ezh2 (d) transcript levels were further 
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measured upon depletion of Ezh1 and Ezh2 together. Cells were treated with TGF-β for 0, 1, 4, 7 and 10 days. (e-f) 
Total histones were isolated from Ezh1 and Ezh2 depleted or Ezh1/Ezh2 co-depleted NMuMG (e) and Py2T (f) 
cells. Total H3K27me3 levels were detected using specific antibodies by immunoblotting. Depletion of both Ezh1 
and Ezh2 leads to a highly efficient reduction in H3K27me3. Total H3 was used as loading control. Statistical values 
were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated 
with (**), p-value ≤ 0.001 indicated with (***). 
 
3.3.3.5 Ezh1 and Ezh2 ablation together prevent cell migration but does not provides a 
survival advantage to the cells during EMT  
Cell migration and invasion are critical parameters in the metastatic dissemination of cancer cells 
and the formation of metastasis, the major cause of death in cancer patients (Brabletz et al., 
2005; Christofori, 2006; Grunert et al., 2003; Huber et al., 2005; Thiery and Sleeman, 2006; 
Yilmaz and Christofori, 2010). Since migration has an important role in forming metastasis via 
EMT, we assessed the migratory capacity of Ezh1/2 knockdown cells. Transwell migration 
assays revealed a significantly lower chemo-tactic migration of Ezh1/2 knockdown cells 
compared to control cells in the absence of TGF-β (Figure 4a). These findings were further 
confirmed in Py2T cells (Supplemental Figure S3a). 
Ezh1 was shown to be expressed in non-proliferative cells while Ezh2 is known to be expressed 
in proliferative cells. Ezh2 depletion was shown to result in slower proliferation of prostate 
cancer (Varambally et al., 2002). Thus, we next investigated whether Ezh1/2 depletion can affect 
the proliferation and survival during TGF-β-induced EMT in NMuMG cells. Surprisingly, loss 
of Ezh1/2 led to an increase in proliferation of NMuMG cells upon TGF-β treatment (Figure 4b). 
No obvious changes were detectable upon Ezh1/2 knockdown in the absence of TGF-β. To 
determine whether this effect was due to alterations in proliferation or changes in apoptosis rates, 
we analyzed cell-cycle as well as the rates of apoptosis. Compared to control siRNA-treated 
cells, no difference was observed in cell-cycle profile upon Ezh1/2 depletion in the absence as 
well as in the presence of TGF-β for 2 and 4 days (Figure 4c). On the other hand, Annexin V 
staining showed a clear reduction in the fraction of apoptotic cells, arguing for a pro-survival  
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Figure 3: Ezh1/2 depletion prevents epithelial differentiation. (a) Cells were treated with TGF-β for 0, 1, 4, 7 and 10 
days and evaluated by phase contrast microscopy.  Cells retained epithelial morphology upon Ezh1/2 depletion, 
while control cells progressed to EMT during TGF-β treatment. Original magnification was 10x. (b) Immunoblot 
analysis for the epithelial marker E-cadherin and the mesenchymal markers N-cadherin and fibronectin during TGF-
β-induced EMT in NMuMG cells after depletion of Ezh1/2. Actin was used as a loading control. Cells were treated 
with TGF-β for the indicated time-periods. (c) Immunofluorescence studies showing localization and expression 
levels of the adherent junction proteins E-cadherin and N-cadherin and the tight junction protein ZO-1 after 7 days 
of TGF-β treatment in NMuMG cells depleted of Ezh1/2. Focal adhesions were visualized by fibronectin and 
paxillin staining and cytoskeleton-remodeling by phalloidin staining. Original magnification was 40x. 
 
effect due to attenuation of TGF-β-induced apoptosis (Figure 4d). We further extended our 
studies in Py2T cells and found that unlike NMuMG cells, these cells do not undergo apoptosis 
during TGF-β treatment suggesting that apoptotic phenotype is biased toward untransformed 
cells. However, we did observe a significant increase in proliferation after Ezh1/2 knockdown in 
Py2T cells (Supplemental Figure S4b). Furthermore, we could not notice any significant 
differences in the cell cycle profiles upon Ezh1/2 depletion during the TGF-β time-course 
(Supplemental Figure S4c). 
3.3.3.6 Dual role of Ezh1/2 during Polycomb-mediated regulation of EMT 
Our ChIP-seq analysis suggested a Polycomb-mediated regulation of many key EMT genes. We 
next attempted to assay whether the transcription of these genes was affected upon Ezh1/2 
depletion. The promoters of Mcam and Pdgfrβ are highly enriched with H3K27me3 mark in 
untreated NMuMG cells while Cdx2 and Ocln gain this mark during TGF-β-induced EMT. 
Ezh1/2 depletion led to the loss of H3K27me3 at the promoter of Mcam and Pdgfrb (Fig 5a and 
5b) with a concomitant increase in their expression (Figure 5a-b). Along with this function, once 
the mark is removed from the genes which are already methylated, Ezh1/2 starts blocking the 
EMT process and leads to reduction in their expression levels. A similar loss of H3K27me3 mark 
was observed at the promoters of Cdx2 and Ocln (Fig 5e) that resulted in their de-repression 
upon depletion of Ezh1/2 in TGF-β-treated cells. (Figure 5c-d). In addition, Ezh1/2 reduction 
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Figure 4: Ezh1/2 depletion prevents TGF-β-induced apoptosis and migration. (a) Ezh1/2 depleted NMuMG cells 
were subjected to a Boyden chamber migration assay for 20 hours. 20% FBS was used as a chemoattractant. (b) 
Proliferation assays were performed after siRNA-mediated knockdown of Ezh1/2 during TGF-β time-course. Cells 
were counted using a Neubauer counting chamber. (c) Cell cycle analysis was done after transient knockdown of 
Ezh1/2 during EMT for 0, 1 and 4 days. Propidium Iodide (PI) was used for the staining. (d) Annexin V staining 
was performed to quantify cell death in Ezh1/2 knockdown NMuMG cells during TGF-β-induced EMT for 0, 1, 4, 7 
and 10 days. Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.001 indicated with 
(***). 
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Figure 5: Depletion of Ezh1/2 results in transcriptional deregulation of H3K27me3-target genes (a-d) Realtime RT-
PCR was performed to assess the expression levels of Mcam (a) and Pdgfrb (b), which are already enriched with 
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H3K27me3 in untreated NMuMG cells and Cdx2 (c) and Ocln (d), which gain this mark upon TGF-β treatment for 
1, 4, 7 and 10 days. (e-f) Following chromatin immunoprecipitation using H3K27me3-specific antibody, in 
NMuMG (e) and Py2T (f) cells after Ezh1/2 depletion, qPCRs was performed using promoter-specific primers. 
Depletion of Ezh1/2 leads to a significant reduction in H3K27me3 enrichment at target gene promoters. Statistical 
values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 
indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
removed H3K27me3 marks from the targeted promoters in NMuMG and Py2T cells and 
activated the genes (Fig. 5e and 5f).  
3.3.3.7 MeDIP analysis shows no significant difference in methylation pattern 
Since, it has been shown before that premalignant cells can acquire de novo DNA methylation at 
biologically relevant sites early in the carcinogenic process in a deterministic manner (Dumont et 
al., 2008; Ruike et al., 2010), we investigated whether similar modes also operated in our model 
system of TGF-β-induced EMT in NMuMG cells.  
We profiled DNA methylation using the MeDIP technique (Weber et al., 2005) in NMuMG cells 
untreated as well as treated with TGF-β for 10 and 20 days followed by detection using custom 
tiling arrays that cover 10% of the mouse genome including all well annotated promoters, several 
large multi-gene loci and the complete chromosome 19 (Nimblegen HD 2.1 arrays). Comparison 
of promoter methylation levels revealed no promoters with significant differences at day 10 and 
day 20 of TGF-β treated cells compared to control cells (Supplemental Figure S5a-c). However, 
given previous evidences of silencing of Cdh1 by DNA methylation, we performed bisulfite 
sequencing of DNA derived from control cells as well as those treated with TGF-β for 10 and 20 
days. Analysis of the Cdh1 promoter also indicated only a very marginal increase in promoter 
CpG methylation in day 20 samples (data not shown). Overall, these data suggest that TGF-β-
induced EMT does not involve any reprogramming of promoter DNA methylation. 
 
3.3.4 Discussion 
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Epithelial-to-mesenchymal transition (EMT) underlies crucial steps in many developmental and 
disease events including cancer.  Both genetic and epigenetic pathways have been implicated in 
EMT gene regulation. Polycomb Group of proteins have been implicated in cancers of various 
subtypes (Mills, 2010; Sauvageau and Sauvageau, 2010; Sparmann and van Lohuizen, 2006b), 
but no comprehensive studies have been performed in models of EMT to reveal their role in 
transcriptional regulation of EMT genes. In the current study, by performing ChIP-seq analysis 
for H3K27me3 for several stages of EMT progression, we reveal targets of epigenetic 
reprogramming during this process. These genes include a number of key EMT genes normally 
repressed in epithelial cells, such as Mcam, Pdgfrb and Itga5. These cells lose this mark and get 
activated upon treatment with TGF-β that follows EMT.  On the other hand, another set of genes 
that define epithelial identity, such as Cdh1, Ocln and Cdx2, gain this mark and become 
repressed during TGF-β-induced EMT. We functionally show that both Ezh1 and Ezh2 
contribute to the H3K27me3 levels in these cells as upon knockdown of these enzymes, both 
global as well as promoter-specific H3K27me3 levels drop significantly, which further 
accompanies transcriptional activation of associated genes. These changes further result in the 
blockage of EMT. Our date argue for a model where, in normal epithelial cells, the Polycomb 
machinery is involved in repressing transcription of genes, the activation of which would 
otherwise result in loss of epithelial identity. Upon induction of EMT with TGF-β leading to 
EMT, genomewide remodeling in H3K27me3 levels occurs and the function of Polycomb 
switches to repressing epithelial cell-type-specific genes and mesenchymal genes get de-
repressed. These data provide convincing evidence that Polycomb-mediated transcriptional 
regulatory mechanisms underlie phenotypic changes during EMT. 
Ezh2 was shown to directly repress the transcription of KLF2 in cancer cells (Taniguchi et al., 
2011). Expression of a non-coding RNA, HOTAIR, was implicated in reprogramming of PRC2 
function in metastatic progression including in breast cancer (Kogo et al., 2011). Another study 
showed that Ezh2 may further regulate cancer cell growth and invasiveness by regulating 
miRNAs (Cao et al., 2011). An important marker of epithelial cell identity, Cdh1, was shown to 
be silenced by the Polycomb machinery by a Snail-dependent recruitment of Ezh2 to the Cdh1 
promoter during EMT (Cao et al., 2008)  In line with these observations, our data identified 
Cdh1 among the targets that gain H3K27me3 mark during TGF-β-induced EMT. Cdh1 was also 
                                                                                 Polycomb-dependent mechanisms regulate Epithelial to 
                                                                                                                        Mesenchymal transition 
 
 139  
 
shown to be silenced by DNA methylation in a variety of human cancers (Esteller, 2007; 
Esteller, 2008b; Graff et al., 1995; Yoshiura et al., 1995). Genomewide analysis of DNA 
methylation did not reveal any promoters that exhibit reprogramming of DNA methylation 
during EMT. However, bisulfite sequencing discovered a mild, but detectable, increase in 
promoter CpG methylation at Cdh1 promoters at day 20 of TGF-β-induced EMT. 
These observations demarcate the dynamics of the Polycomb-associated mark and its role in an 
experimental model of EMT.  Such reprogramming seems crucial for proper EMT progression, 
as knockdown of this mark had substantial effects on cell migration and proliferation. It has been 
recently shown that  EMT accompanies a global reduction in the heterochromatin mark H3 Lys9 
dimethylation (H3K9Me2), an increase in the euchromatin mark H3 Lys4 trimethylation 
(H3K4Me3) and an increase in the transcriptional mark H3 Lys36 trimethylation (H3K36Me3) 
(McDonald et al., 2011b). Thus it is very likely that other chromatin modifications not examined 
so far are also reprogrammed during EMT. However, given a number of previous studies that 
linked Polycomb-mediated mechanisms with carcinogenesis (Mills, 2010; Sauvageau and 
Sauvageau, 2010; Sparmann and van Lohuizen, 2006b), our study is of utmost relevance to the 
field where we outline genomewide targets of the Polycomb machinery for transcriptional 
modulation during several stages of EMT. Our findings may reflect a general mechanism for 
cell-fate transitions including other cases of EMT such as development. It will be further 
interesting to explore epigenetic events in the reverse process, mesenchymal-to-epithelial 
transition (MET), such as those involved in normal development or disease as well as in vitro 
induced pluripotent stem cells (iPSCs) generation.  It is important to note that the epigenetic 
reprogramming of the Polycomb-associated H3K27me3 mark during TGF-β-induced EMT very 
closely resembles stem cell differentiation (Mohn et al 2008). However, in contrast to stem cell 
differentiation, DNA methylation patterns remain unchanged during EMT. Taken together, our 
data reveal strong evidence that Polycomb machinery-mediated epigenetic mechanisms underlie 
transcriptional changes that are crucial for epithelial to mesenchymal transition. It will be further 
exciting to investigate whether similar epigenetic reprogramming occurs in other cases of EMT 
and in experimental systems where in cell-fate transitions are observed. 
3.3.5 Supplemental data 
                                                                                 Polycomb-dependent mechanisms regulate Epithelial to 
                                                                                                                        Mesenchymal transition 
 
 140  
 
 
Figure S1: Dynamics of PcG mark H3K27me3 during EMT in NMuMG cells. (a) Morphological changes are 
observed after TGF-β treatment of NMuMG cells for 0, 1, 4, 7, 10 and 20 days by using a phase-contrast 
microscopy, reflecting epithelial to mesenchymal transition. Original magnification was 10x. (b-c) Venn-Diagram 
showing the overlap between genes that lose the H3K27me3 mark during TGF-β-induced EMT and those that are 
transcriptionally induced upon TGF-β treatment (b) and vice-versa (c). (d-e) Systemic comparison of genes gaining 
                                                                                 Polycomb-dependent mechanisms regulate Epithelial to 
                                                                                                                        Mesenchymal transition 
 
 141  
 
(c) or losing (d) H3K27me3 mark during EMT with genes that are transcriptionally downregulated or upregulated 
during TGF-β-induced EMT. 
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Figure S2: H3K27me3 is enriched at the promoters of key EMT genes. Genome browser view of H3K27me3 ChIP 
enrichment at the Mcam, Pdgfrb, Snai1, Sgsh1, Cdh1 and Ocln gene loci during TGF-β-induced EMT in NMuMG 
cells. Promoter regions are marked by the rectangular boxes. 
5 
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Figure S3: Ezh1/2 depletion prevents EMT. (a-f) Realtime RT-PCR was carried out to quantify the expression 
levels of EMT markers E-cadherin (a and d), N-cadherin (b and e) and fibronectin (c and f) in NMuMG (a, b and c) 
and Py2T cells (d, e and f) during TGF-β mediated EMT.  NMuMG cells were treated with TGF-β for 0, 1, 4, 7 and 
10 days while Py2T cells were treated for 0, 1, 4 and 7days. Py2T cells were stably transfected with Ezh1/2 shRNA. 
Statistical values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 
0.01 indicated with (**), p-value ≤ 0.001 indicated with (***). 
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Figure S4: Ezh1/2 are required for cell migration but not for survival. (a) Boyden-chamber migration assays were 
performed to assess the migratory capacity of stably transfected Ezh1/2 depleted Py2T cells treated with TGF-β for 
15 days. The assays were carried out for 20 hours and 20% FBS was used as a chemo-attractant. (b) Proliferation 
assays were done to assess the proliferation rate after Ezh1/2 ablation in Py2T cells. Neubauer counting chambers 
were used for the counting. (c) Cell cycle analysis was done in the absence as well as in the presence of TGF-β (2 
and 4 days) after Ezh1/2 reduction in Py2T cells. PI staining was used to distinguish the cell cycle phases. Statistical 
values were calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 
indicated with (**), p-value ≤ 0.001 indicated with (***). 
 
 
 
 
Figure S5: DNA methylation pattern remain unchanged during TGF-β-mediated EMT in NMuMG cells. (a-b) 
Scatter plot comparing averaged DNA methylation values from replicate microarrays for all mouse promoters from 
nontreated NMuMG cells versus NMuMG cells treated with TGF-β for 10 days (a) and 20 days (b). 
 
4.1.6 Methods and Materials 
Reagents and antibodies 
Reagents: TGF-β (240-B, R&D systems). DMEM (D5671, Sigma-Aldrich), PBS (D8537, 
Sigma-Aldrich), trypsin (T4174, Sigma-Aldrich), Opti-MEM (11058, Gibco), FBS (F7524, 
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Sigma-Aldrich), Glutamine (G7513, Sigma-Aldrich), Pencillin/streptomycin (P4333, Sigma-
Aldrich), Lipofectamine RNAiMax (11668-019, Invitrogen), Alexa Fluor-488, 568, 633 
(Invitrogen),  Polybrene (AL-118, Sigma-Aldrich), Puromycin (P7255, Sigma-Aldrich), Fugene 
HD ( 12998300, Roche), Trizol (T9424, Sigma-Aldrich), M-MLV reverse transcriptase (M314C 
28692233, Promega),  SYBR-green PCR MasterMix (Eurogentec) and  Bradford reagent (500-
0006, Biorad), Protease inhibitor cocktail (P2714, Sigma-Aldrich). Antibodies: Western Blot: 
E-Cadherin (610182, Transduction Laboratories), N-Cadherin (M142, Takara), ZO-1 (617300, 
Zymed), Fibronectin (F-3648, Sigma-Aldrich), Actin (SC-1616, Sanata Cruz Biotechnology). 
Immunofluorescence: E-Cadherin (13-1900, Zymed), N-Cadherin (610921, Transduction 
Laboratories), ZO-1 (617300, Zymed), Phalloidin (A12380, Invitrogen) and Paxillin (13520, 
Transduction Laboratories. Chromatin Immunoprecipitation: H3K27me3 (abcam) Apoptosis 
and Cell cycle: Annexin-V (559934, BD Biosciences) and PI (P4170, Sigma-Aldrich). Small 
interfering RNAs:  siControl (Stealth RNAi™ siRNA Negative Controls, 12935-100, 
Invitrogen), siEzh1 (SASI_Mm01_00114972 and SASI_Mm01_00114974, Sigma-Aldrich) and 
siEzh2 (SASI_Mm01_00061987 & SASI_Mm01_00061988, Sigma-Aldrich). Small hairpin 
RNA: shControl (Mission Non-target shRNA control vector, SHC002) and shEzh1/2 
(SHCLNG-NM_007971 Mouse, TRCN0000039041).  
Cell lines and cell culture 
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has been 
previously described (Jechlinger et al., 2002). MCF7 shControl and MCF7-shEcad have been 
described before (Lehembre et al., 2008). Py2T cells were derived from Polyoma middle T 
breast cancer tumor model (unpublished data, Waldmeier et.al). NMuMG, MCF7shControl, 
MCF7-shEcad, Py2T, 293T and PLAT-E cells were cultured in DMEM supplemented with 10% 
FBS, 2mM glutamine, 100U penicillin and 0.2mg/ml streptomycin. All the cells were cultured at 
370c with 5% CO2 in humid incubator. For TGF-β time-course experiments, cells were treated 
with 2ng/ml TGF-β for indicated time point and it was replaced every 2 days. For siRNA 
transfections, Lipofectamine RNAiMax was used according to the manufacturer's instructions.  
Microarray processing and data analysis 
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RNA was isolated from NMuMG cells transfected with NMuMG cells treated with TGF-β for 0, 
1, 4, 7 and 10 days by RNAeasy Mini kit (Sigma-Aldrich). Non-treated cells are used as a 
control. RNA quality and quantity was evaluated using an Agilent 2100 Bioanalyzer (Agilent 
Technologies). The manufacturer’s protocols for the GeneChip platform by Affimetrix were 
followed. Methods included synthesis of the first- and second-strand cDNA followed by 
synthesis of cRNA by in vitro transcription, subsequent synthesis of single-stranded cDNA, 
biotin labeling and fragmentation of cDNA and hybridization with the microarray slide 
(GeneChip® Mouse Gene 430 2.0 array), post-hybridization washings and detection of the 
hybridized cDNAs using a streptavidin-coupled fluorescent dye. Hybridized Affimetrix 
GeneChips were scanned using an Affimetrix GeneChip 3000 scanner. Image generation and 
feature extraction were performed using Affimetrix GCOS Software and quality control was 
performed using Affimetrix Expression Console Software. Raw microarray data were 
normalized with Robust Multi-Array (RMA) and analyzed using Partek® Genomics Suite 
Software (Partek Inc.). One-way analysis of variance (ANOVA) and asymptotic analysis were 
used to identify significantly differentially expressed genes. The gene ontology (GO) tools from 
Metacore Software as well as the David gene ontology software were used for further analysis 
 
Chromatin Immunoprecipitation 
ChIP experiments were performed as previously described (Weber et al, 2007). In brief, 
crosslinked chromatin was sonicated to achieve an average fragment size of 500 bp. Starting 
with 100 μg of chromatin and 5 μg of anti-H3K27me3 antibody, 1 μl of ChIP material and 1 μl 
of input material were used for quantitative real-time PCR using specific primers covering the 
1000 bp promoter region form the transcription start site. Primers covering an intergenic region 
are used as a control. The efficiencies of PCR amplification were normalized for between the 
primer pairs. Following primers were used for ChIP –PCR. Relative positions from the 
transcription start site are also mentioned. 
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Name Sequences 
Mcam FP ggtccccgctagtagtggacaaa 
Mcam RP ggttgaaggagcaatgacaggtg 
Pdgfrb FP gaaaacagacacacgcgtccac 
Pdgfrb RP caccacacactttgggggaaag 
Itga5 FP cccagaggtgattcctttcctca 
Itga5 RP cctccccctcctttccagatgta 
Col1a1 FP tggactcctttcccttcctttcc 
Col1a1 RP atcttgatggagagctgggagga 
St3gal5 FP ccacctacttctcggctggagtt 
St3gal5 RP cgtcacgaggataagggagacca 
Stmn4 FP tcatctttcactccccagccttc 
Stmn4 RP gcttggcaattggacagtctcct 
Gapdh FP ctctgctcctccctgttcc 
Gapdh RP tccctagacccgtacagtgc 
 
Next Generation Sequencing and Analysis  
The ChIP libraries were prepared with the Illumina ChIP-Seq DNA Sample Prep Kit (Cat# IP-
102-1001) according to Illumina’s instructions and sequenced on the Genome Analyzer 2 
following the manufacturer’s protocols. 
Genomic coordinates 
The July 2007 M. musculus genome assembly (NCBI37/mm9) provided by NCBI 
(http://www.ncbi.nlm.nih.gov/genome/guide/mouse/) and the Mouse Genome Sequencing 
Consortium (http://www.sanger.ac.uk/Projects/M_musculus/) was used as a basis for all 
analyses. Annotation of known RefSeq transcripts was obtained from UCSC 
(http://hgdownload.cse.ucsc.edu/goldenPath/mm9/database/refGene.txt.gz from Oct 18, 2009).  
Read filtering, alignment and weighting 
Low-complexity reads were filtered out based on their dinucleotide entropy (removing <1% of 
the reads). Alignments to the mouse genome were performed by the software bowtie (version 
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0.9.9.1) (Niessen et al., 2008) with parameters -v 2 -a -m 100, tracking up to 100 best alignment 
positions per query and allowing at most two mismatches. To track genomically untemplated hits 
(e.g., exon-exon junctions or missing parts in the current assembly), the reads were also mapped 
to an annotation database containing known mouse sequences (miRNA from 
ftp://ftp.sanger.ac.uk/pub/mirbase/sequences/13.0, rRNA,snRNA, snoRNA and RefSeq mRNA 
from GenBank http://www.ncbi.nlm.nih.gov/sites/entrez, downloaded on July 16, 2009, tRNA 
from http://lowelab.ucsc.edu/GtRNAdb/ and piRNA from NCBI (accessions DQ539889 to 
DQ569912). In that case, all best hits with at most two mismatches were tracked. Each alignment 
was weighted by the inverse of the number of hits. In the cases where a read had more hits to an 
individual sequence from the annotation database than to the whole genome, the former number 
of hits was selected to ensure that the total weight of a read did not exceed one. All 
quantifications were based on weighted alignments. 
Peak finding 
Genomic regions of increased ChIP-seq read alignment densities were identified using macs 
(version 1.3.7.1) (Shi and Massague, 2003), using a pool of read alignments from all biological 
replicates and cellular stages (weights rounded to integers) as input, parameters --mfold=8 --
gsize=2700000000 --tsize=36 and default values for all other parameters. IP enrichments (see 
below) of resulting peak candidates were calculated and peak candidates with enrichments lower 
than 2-fold above background (combining biological replicates) were removed. 
Calculation of peak enrichments in genomic regions 
Enrichment of peaks in genomic regions (see above for definition) were calculated as the ratio of 
observed over expected number of peaks in a region, where the observed number is the count of 
all peaks overlapping a region by more than half of their length, and the expected number is the 
fraction of genomic bases in that region type, multiplied with the total number of peaks. 
Calculation of IP enrichments 
IP enrichments of a genomic region (TSS windows or peak region) were calculated as e = log2( 
(n_fg /N_fg *min(N_fg,N_bg) + p) / (n_bg /N_bg *min(N_fg,N_bg) + p) ), where n_fg and n_bg 
are the summed weights of overlapping foreground and background (input chromatin) read 
alignments, respectively. N_fg and N_bg are the total number of aligned reads in foreground and 
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background samples, and p is a pseudocount constant (p=16) used to regularize enrichments 
based on low counts that would otherwise be dominated by sampling noise. 
MeDIP-chip data analysis 
Nimblegen array intensity files were read and log2 enrichments (log2 bound/input ratios) for 
each individual probe were calculated using the R package Ringo. Probe-level as well as 
promoter level log2 enrichments showed good reproducibility between the two replicates.  
Quantitative RT-PCR 
Total RNA was prepared by using a Tri Reagent according to the manufacturer’s instructions. 
RNA was further reverse transcribed with ImProm-II Reverse Transcriptase, and transcripts were 
quantified by PCR using SYBR-green PCR Mastermix in a real time PCR system (Step One 
Plus, Applied Biosystems). Human or mouse ribosomal L19 primers were used for 
normalization. PCR assays were performed in duplicates, and fold induction was calculated 
against control-treated cell lines using the comparative Ct method (ΔΔ Ct). Following primers 
were used:  
Primer name Sequences 
mRpl19 Forward primer ctcgttgccggaaaaaca 
mRpl19 Reverse primer tcatccaggtcaccttctca 
mEzh2 Forward primer caggctggggcatctttatc 
mEzh2 Reverse primer acgaattttgttgccctttc 
mE-cadherin Forward primer cgaccctgcctctgaatcc 
mE-cadherin Reverse primer tacacgctgggaaacatgagc 
mN-Cadherin Forward primer caatgacgtccaccctgttct 
mN-Cadherin Reverse primer ctgccatgactttctacggaga 
mFibronectin1 Forward primer cccagacttatggtggcaatt 
mFibronectin1 Reverse primer atattccgactcgagtctga 
mMcam Forward primer actggtgtgcgtcttcttgttcg 
mMcam Reverse primer gcttttcctctcctggcacacc 
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mPdgfrb Forward primer acctgcagagacctcaaaaggtg 
mPdgfrb Reverse primer ctgatcttcctcccagaaagtcaca 
mCdx2 Forward primer catcaccatcaggaggaaaagtga 
 
Immunoblot 
Cells were lysed for 1 hour on ice in RIPA-Plus buffer (50mM Tris-HCl, pH8.0), 150mM NaCl, 
10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 2mM 
CaCl2, 1mM dithiothreitol, 1mM sodium fluoride, 0.2mM sodium orthovanadate, 1x protease 
inhibitor cocktail and further quantified by using Bradford reagent. 50 μg of cleared protein 
lysates were separated by SDS-PAGE and electroblotted on PDVF membranes, and proteins 
were visualized with the appropriate primary and secondary antibodies and ECL on superRX 
films. Depending on the species origin of antibodies, immunoblots were either probed 
sequentially or on multiple membranes. Adobe Photoshop has been used to excise the relevant 
portion of the immunoblots from the original scans of X-ray films exposed to 
chemoluminescence visualization of specific proteins. 
Immunofluorescence 
siControl and siEzh1/2 cells were plated on coverslips and treated with TGF-β for mentioned 
time. The cells were fixed with 4% paraformaldehyde in HBSS and further permeablized with 
0.2% Triton for 5 minutes at room temperature. These cells were blocked by using 3.5% goat 
serum for 15 minutes and incubated with primary antibodies against E-cadherin, N-cadherin, 
fibronectin, ZO-1, vimentin, paxillin and phalloidin for 1 hour and then incubated with 
flurochrome-labeled secondary antibody for 1 hour at room temperature. The coverslips were 
counterstained with DAPI and imaged with a confocal laser-scanning microscope. Data were 
processed with Adobe Photoshop 7.0 software. 
Production of lentivirus for in-vivo and in-vito knockdown studies  
Murine Ezh1/2 shRNAs and control shRNA were purchased from Sigma-Aldrich as described 
above. For lenti-virus production, 293T cells were transfected with the shRNA expressing lenti-
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viral vector in combination with the packaging vectors including envelope protein; HDM-
pVSV/G,  codon-optimized HIV gag-pol; HDM-Hpgm2, transactivator of transcription; HDM-
Tat1b and  pRC-CMV-RaII by Fugene HD. After 48 hours of transfection, viral supernatant was 
harvested, filtered (0.46 µm), supplemented with polybrene (8ng/ml) and used to infect target 
cells. Infections were performed once a day for two consecutive days. Infected cells were 
positively selected using Puromycin (5ug/ml). 
Migration assay 
Cell migration was assessed by transwell migration assay (pore size: 8 μm; Falcon BD). 104 cells 
were seeded in 2% FBS/DMEM (Sigma) in the upper chamber and the lower chamber was filled 
with 20% FBS/DMEM. After 20 hours of incubation at 37°C, cells in the upper chamber were 
carefully removed with a cotton swap and the cells that had traversed the membrane were fixed 
in 4% paraformaldehyde/PBS, stained with DAPI. Pictures of the membrane were taken at a 10x 
magnification using a fluorescent microscope (Nikon Diaphot 300). Quantification was done 
using the software ImageJ. 
Apoptosis assay (Annexin assay) 
Cells were washed twice with cold PBS and resuspended in 1X Annexin V binding buffer at a 
concentration of 1 x 106 cells/ml. 5 µl of Cy5 Annexin V was added to the 100 µl of cells (1 x 
105) and incubated for 15 min on ice in the dark. Stained cells were filtered with a 40um mesh 
and analyzed on a FACSCanto II using DIVA software. 
Cell growth curve 
1x104 cells were seeded in each well of 24-well plate and cell numbers were assessed for 
mentioned days by using a Neubauer counting chamber. 
PI Staining 
Cells were trypsinized and fixed in 70% ice-cold Ethanol for overnight.  Washed twice with PBS 
and resuspended in sodium citrate buffer with 5μg/ml PI for overnight. Stained cells were 
analyzed by FACSCanto II using DIVA software. 
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Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad 
Software Inc, San Diego, CA). All statistical analysis was done by unpaired, two-sided t-test. 
Normality testing was performed using the Kolmogorov-Smirnov test with Dallal-Wilkinson-
Lillie for p-values. All the data are shown as mean ± SD and are representative of at least three 
independent experiments. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), 
p-value ≤ 0.001 indicated with (***) in whole paper. 
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Technical Assistant November 2004 to September 2005 
 
5.2.2 Education 
Department of Biochemistry,                                                                                    Faizabad, India                                
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Dr. R.M.L. Avadh University  
MSc (Masters of Science) 2002-2004 
 
 
K.S. Saket PG College,                                                                                             Faizabad, India                                        
Dr. R.M.L. Avadh University  
BSc (Bachelors of Science) 1999-2002 
 
 
Central School,                                                                                                       New Delhi, India                                                    
Central Board of Secondary Education  
Pre-degree 1997-1999 
 
Central School,                                                                                                       New Delhi, India                                                                   
Central Board of Secondary Education  
SSC (High School) 1995-1997 
 
5.3  Workshops, Courses and Conferences 
5.3.1 Workshops  
• "2009 EMBO Molecular Medicine workshop-Invasive Growth: a Genetic Programme for 
Stem cells and Cancer"- Congress Center, Torino, Italy 
• SGV Meeting for mouse Experiments, University of Basel, Switzerland 
• Workshop on “Parallel Sequencing", D-BSSE, Basel, Switzerland 
• LTK module 1 for animal experiment, Friedrich Miescher Institute, Basel, 
Switzerland 
• Workshop on "preparation of cDNA library from single cells"- Cambridge University, 
UK 
• Workshop on “Introduction to Cell Culture”- Johns Hopkins University, USA 
• Workshop on “Introduction to Protein Expression”-Johns Hopkins University, USA 
• Workshop on "Advanced lab techniques", Cytogenetics Laboratory, Banaras Hindu 
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University, India 
• Workshop on “National Young Scientist Workshop on Environmental Microbiology and 
Parasitology”- Allahabad University, India 
 
5.3.2 Courses  
• English: Academic Writing workshop at University of Basel, Basel, Switzerland, Jun 
2011 
• R Course at Friedrich Miescher Institute, Basel, Switzerland, Feb 2011 
• Genetic approaches in biomedical research at University of Basel, Basel, Switzerland, 
Jan 2010  
• Translation control and Post-translation protein modification at University of Basel, 
Basel, Switzerland, Jan 2010  
• Cell interactions in Development and Disease at University of Basel, Basel, 
Switzerland, Jan 2009 
• Structure, Processing and Function of RNA at University of Basel, Basel, Switzerland, 
Mar 2009 
• Bio-informatics course at Friedrich Miescher Institute, Basel, Switzerland, May 2009 
• Experimentelle Krebsforschung I: Biologie und Molekularbiologie at University of 
Basel, Basel, Switzerland, Aug 2008 
• Transcription, Regulation and Gene expression in Eukaryotes at University of Basel, 
Basel, Switzerland, Jun 2008 
• Research Compliance Training Courses (includes Human Subjects Research, Animal 
Care and Use, Conflict of Interest and Commitment), at Johns Hopkins University, 
Baltimore, USA, Dec 2006 
• HIPAA Compliance Training Course at Johns Hopkins University, Baltimore, USA, 
Dec 2006 
• Blood Borne Pathogen Course at Johns Hopkins University School of Medicine, 
Baltimore, USA, Dec 2006 
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5.3.2 Conferences  
• "1st International SystemsX.ch Conference on Systems Biology ", Congress Center, 
Basel, Switzerland, Oct 2011 
• "Biovalley life Science day" and "Miptec", Congress Center, Basel, Switzerland, Sep 
2011 
• EuCC (European Cancer Center) Symposium, Restaurant Seegarten, Basel, 
Switzerland, May 2011 
• "Biovalley life Science day" and "Miptec", Congress Center, Basel, Switzerland, Sep 
2010 
•  “Swiss Stem Cell Network Meeting”, Biocenter, Basel, Switzerland, Feb 2010 
•  “Multiple Sclerosis Meeting”, ZLF, Basel, Switzerland, Nov 2009 
• "Biovalley life Science day" and "Miptec", Congress Center, Basel, Switzerland, Oct 
2009 
• "MicroEnviMet symposium"- Univeristy of Torino, Torino, Italy, Sep 2009 
• “D-BSSE System Biology symposium, Basel, Switzerland, Apr 2009 
• TUMIC (An integrated concept of tumor metastasis) symposium- Univeristy of Basel, 
Basel, Switzerland, Jan 2009 
• "Biovalley life Science day" and "Miptec", Congress Center, Basel, Switzerland, Oct 
2008 
• EuCC (European Cancer Center) Symposium, Hotel Dorint, Basel, Switzerland, May 
2008 
 
5.4  Achievements 
• Poster presentation on Biovalley life Science day 2011. The title of the poster was “Sox4: 
a key modulator of EMT”. 
Neha Tiwari, Erik van Nimwegen and Gerhard Christofori 
• Poster presentation on Biovalley life Science day 2009. The title of the poster was “KLF4 
and SOX4 as regulator of EMT". 
Neha Tiwari, Mahmut yilmaz, Lorenz Waldeimer, Dorothea Maass, Chantal 
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Achermann, Lukas Manhart, Phil Arnold, Eric Van Nimwegen and Gerhard Christofori 
(Best poster award) 
• Poster presentation in EMBO Molecular Medicine Meeting 2009. The title of the poster 
was “KLF4 and SOX4 as regulator of EMT". 
Neha Tiwari, Mahmut yilmaz, Lorenz Waldeimer, Dorothea Maass, Chantal 
Achermann, Lukas Manhart, Phil Arnold, Eric Van Nimwegen and Gerhard Christofori 
• Poster presentation in IMPaCT (Innovation Minds in Prostate Cancer) Meeting 2007. The 
title of the poster was "Consequences of the inhibiton of CDK5 in Prostate cancer Cells". 
Barry D Nelkin. Christopher J. Strock, Neha Tiwari and Micheal J. Ochs. 
 
5.5 Publications 
• Sprouty 4 expression prevents angiogenesis in Rip-Tag mouse model 
Tiwari N, Jaggi F, Antoniadis H, Christofori G (In Process). 
• Polycomb-dependent Mechanisms Regulate Epithelial to Mesenchymal  Transition 
            Tiwari N #, Tiwari VK#, Arnold P, Balweirz P, Nimwegen E, Schübeler D, Christofori                    
            (In Process) 
            #-Authors contributed equally 
• KLF4 directly regulates transcription of genes crucial for Epithelial to Mesenchymal 
Transition  
             Tiwari N, Arnold P, Nimwegen E, Christofori G (In Process). 
• Sox4 regulates epithelial to mesenchymal transition by directly controlling transcription 
of underlying master genes 
            Tiwari N, Arnold P, Mikhail P, Schaller N, Christofori G (Submitted). 
• Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis 
Yilmaz M#, Maaß D#, Tiwari N, Waldmeier L, Schmidt P, Lehembre F, Christofori G   
EMBO J. 2011 
#-Authors contributed equally        
• A single-nucleotide deletion in the POMP 5' UTR causes a transcriptional switch and 
altered epidermal proteasome distribution in KLICK genodermatosis. 
Dahlqvist J, Klar J, Tiwari N, Schuster J, Törmä H, Badhai J, Pujol R, van Steensel MA,            
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Brinkhuizen T, Gijezen L, Chaves A, Tadini G, Vahlquist A, Dahl N. 
Am J Hum Genet. 2010  
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